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ABSTRACT 
Chinedu Anthony Anene 
Platelet micro-particles induce angiogenesis through the delivery of the micro-
RNA Let-7a into endothelial cells. 
Keywords: Cardiovascular Diseases, microRNA, Angiogenesis, Endothelial 
cells, Let-7a, Micro-Particles, Platelet Activation, Molecular Mechanisms. 
 
Cardiovascular disease is a major cause of morbidity and mortality around the 
globe, which is linked to athero-thrombosis. The risk factors for athero-
thrombosis, thus cardiovascular disease is impaired anti-thrombotic and anti-
inflammatory functions of the endothelium. Thrombosis is a hallmark of 
cardiovascular disease/complications characterised by increased platelet 
activation and increased secretion of platelet micro-particles that induce 
angiogenesis. This study determined the role of platelet micro-particles derived 
microRNA in the regulation of angiogenesis and migration, with a focus on the 
regulation of thrombospondin-1 release by platelet micro-particles delivered Let-
7a. The role of thrombospondin-1 receptors (integrin beta-1 and integrin 
associated protein) and downstream caspase-3 activation were explored by Let-
7a inhibition prior to PMP treatment. MicroRNA dependent modulation of pro-
angiogenic proteins including monocyte chemoattractant protein-1 and placental 
growth factor, and recruitment of activating transcription factor-4 protein to their 
promoter regions were explored. Main findings are: 1. Platelet micro-particles 
induce angiogenesis, migration, and release of novel cytokine subsets specific 
to platelet micro-particle’s RNA content. 2. The targeting of thrombospondin-1 
mRNA by platelet micro-particles’ transferred Let-7a chiefly modulate the 
angiogenic effect on endothelial cells. 3. The inhibition of thrombospondin-1 
translation enable platelet micro-particles to increase angiogenesis and 
migration in the presence of functional integrin beta-1 and integrin associated 
protein, and reduced cleaving of caspase-3. 4. Platelet micro-particle modulate 
the transcription of monocyte chemoattractant protein-1 and placental growth 
factor in a Let-7a dependent manner. 5. Let-7a induce angiogenesis 
 ii 
independent of other platelet micro-particle’s microRNAs. Platelet micro-particle 
derived Let-7a is a master regulator of endothelial cell function in this model, 
which presents an opportunity for the development of new biomarkers and 
therapeutic approaches in the management of cardiovascular disease. Future 
studies should aim to confirm these findings in-vivo. 
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Thrombospodin-1                                                                                             THBS-1 
Transmembrane   semaphorin   protein                                                            Sema 
Vascular cell adhesion molecule                                                                      VCAM 
Vascular endothelial growth factor                                                                   VEGF 
Vesicle transport through interaction with t-SNAREs homolog 1A                    VTI1A 
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CHAPTER 1: INTRODUCTION 
1.1 General Introduction 
Cardiovascular disease (CVD) is a broad term for vascular conditions including 
coronary heart disease, strokes, peripheral heart disease and aortic disease. 
CVD is now at epidemic proportions; in 2016 there were an estimated 5.9 million 
CVD suffers in England (Bhatnagar et al. 2016). The heightened prevalence of 
CVD is largely driven by an increase in modifiable risk factors such as smoking, 
high blood pressure, high blood cholesterol, physical inactivity and diabetes 
mellitus (Delamater et al. 2015). Classical non-modifiable risk factors such as 
age, sex and family history of vascular complications also contribute in the 
development of CVD. CVD causes more than 26 percent of all deaths in the UK; 
approximately 160,000 deaths per-annum – an average of 435 people each day 
or one death every three minutes (Bhatnagar et al. 2016). The majority of these 
cases are thought to be preventable if CVD risk factors were more tightly 
controlled (Townsend et al. 2014).  
 
CVD is characterised by a haemostatic imbalance caused by dysfunctional 
endothelium and evidenced by a reduction in the release of vasodilators such as 
nitric oxide (NO) and dysregulation in angiogenesis, proliferation and cell-
cell/cell-matrix interactions through increased pro-angiogenic and inflammatory 
cytokines (Jay Widmer and Lerman 2014). Mechanistically, CVD is associated 
with a range of  metabolic complications, which promote oxidative stress and 
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chronic inflammation, leading to endothelial cell (EC) dysregulation (Delamater 
et al. 2015). This dysregulation is associated with a switch from a quiescent 
phenotype to active defence response phenotype (Vanhoutte and Boulanger 
1999), which is a key initiating event in the development of atherosclerosis and 
subsequent CVD.  
 
Atherosclerosis is the build-up of fatty plaques in the arteries that is strongly 
linked to the development of CVD. Moreover, the pathogenic changes to ECs 
caused by haemostatic imbalance help drive platelet activation and subsequent 
thrombosis (Ouviña et al. 2001). Under physiological conditions, platelets 
circulate in a non-active state, but quickly switch to an adhesive phenotype upon 
vascular injury to promote clot formation and to stop bleeding (Ouviña et al. 
2001). Increased platelet activation, in part a symptom of haemostatic 
imbalance, is a hallmark of most CVD, accounting for elevated inflammation and 
thrombotic risk (Creager et al. 2003, Malerba et al. 2016, Vital et al. 2016, Zeller 
et al. 2005). It is now apparent that hyper-activated platelets enhance 
haemostatic imbalance in the vasculature and contribute in the development of 
atherosclerotic plaque, creating a potent amplification loop (Paneni et al. 2013). 
However, the full mechanisms involved in this complex process remains elusive 
and need to be investigated.  
 
Upon activation platelets release micro-particles (PMPs); small membrane 
bound vesicles which contain an array of proteins, RNA and lipid molecules 
(Furman et al. 2001, Leppanen et al. 1999, X. Zhang et al. 2014). PMP release 
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is enhanced in patients with CVD and in individuals with CVD risk factors 
(Furman et al. 2001, Leppanen et al. 1999, X. Zhang et al. 2014). PMPs  induce 
ECs activation and promote the development of CVD (Morel et al. 2006), 
potentially through inducing angiogenesis (Brill et al. 2005, Janowska-Wieczorek 
et al. 2005, Kim et al. 2004, Leroyer et al. 2008, Tushuizen et al. 2011). 
Angiogenesis, the formation of new blood vessels, may help destabilise 
atherosclerotic plaques, hence promoting thrombosis.  
 
The mechanisms involved in PMP regulation of ECs are yet to be fully 
characterised. Recent evidence shows that PMPs contain several microRNAs 
(miRNA), which they transfer to recipient cells to elicit phenotypic changes 
(Andaloussi et al. 2013, Laffont et al. 2013). miRNAs are a class of small non 
coding RNAs that bind to messenger (mRNA) with complementary sequences, 
to elicit post-transcriptional regulation of gene expression (He and Hannon 
2004).  Delivery of miRNA by PMPs may therefore underpin the athero-
thrombotic effects of PMPs (Koganti et al. 2016). Therefore, determining the 
extent to which PMP delivered miRNAs regulate EC function is key to further the 
understanding of CVD progression. This will help in the development of new 
biomarkers/therapeutic targets to enable future stratification of aggressive CVD 
risk and treatment.  
 
1.2 The Endothelium  
ECs lining blood vessels create a distinct interface between the underlying 
tissues and the blood (Mombouli 1997). The endothelium is physiologically in a 
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neutral state that favours dilation over constriction, but responds to various 
stimuli including shear stress, temperature, inflammation, injury and other 
factors, reviewed extensively by (Verma and Anderson 2002). In response to 
these stimuli, ECs synthesise and release several regulatory agents such as 
growth factors, cytokines and nitric oxide (NO) that play an important role in 
controlling vascular tone (Moncada et al. 1988), thrombosis (Moncada et al. 
1977), immune responses (Szekanecz and Koch 2004) and angiogenic 
pathways (Saba and Saba 2014, Stern et al. 1988, Thompson and Salem 1986). 
However, at sites of disrupted blood flow and around atherosclerotic plaques, 
ECs lose cardio-protective signalling and produce thrombogenic factors that 
promote platelet activation and facilitate the process of clot formation 
(summarised in Figure 1.1). Indeed, dysfunctions associated with the synthesis, 
release and signalling of ECs derived factors are the key pathogenic mechanism 
regulating CVD through reduced vasodilation, a pro-inflammatory state, and pro-
thrombotic activity (Rajendran et al. 2013). Molecular processes mediated 
through mechanical and biochemical stimuli contribute to the development of EC 
dysregulation leading to CVD (Deanfield et al. 2007). However, the emerging 
role of non-coding RNAs such as microRNAs (miRNA) in the progression from 
EC dysfunction to CVD is a growing area of investigation. 
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Figure 1.1: Normal Endothelial Function. The endothelium controls several 
physiological functions including; regulation of vascular tone through balanced 
production of vasodilators and vasoconstrictors such angiotensin II, 
prostaglandins, endothelin-1, endothelial hyperpolarizing factor. The 
endothelium also controls blood fluidity and coagulation through production of 
factors that regulate platelet activity, including tissue plasminogen, plasminogen 
activator inhibitor-1, thrombomodulin, von Willebrand Factor (vWF), the clotting 
cascade, and the fibrinolytic system. The regulation of inflammatory processes 
through expression of cytokines and adhesion molecules such as TNF and IL-6 
(Arrebola-Moreno et al. 2012, Rajendran et al. 2013). 
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1.3 Atherosclerosis and thrombosis  
Atherosclerosis is a serious inflammatory condition contributing to the high 
mortality rate associated with CVD because of the high risk of thrombosis 
(Armstrong et al. 2011, Glass and Witztum 2001, Järvilehto and Tuohimaa 
2009). The development of atherosclerotic plaques starts as a fatty streak in the 
endothelium of artery wells. These fatty streaks are common in large carotid and 
coronary arteries and the accumulation of fat results in dysfunction of the 
endothelium, as well as further increase in lipid and cholesterol accumulation. 
The next phase is marked by larger infiltration of the plaque by inflammatory 
cells. Atherosclerotic plaque formation progresses with time, moving from intimal 
thickening, fatty streaks, and foam cell formation, to lipid and cholesterol rich 
plaques (Armstrong et al. 2011, Glass and Witztum 2001, Järvilehto and 
Tuohimaa 2009). This stage is marked by narrowing and blockade of the arterial 
lumen, resulting in reduced blood flow (Armstrong et al. 2011, Glass and 
Witztum 2001, Järvilehto and Tuohimaa 2009). The instability of the 
atherosclerotic plaque characterised by increased inflammatory cell content, and 
enlarged necrotic core has been linked to angiogenesis within the plaques 
(summarised in Figure 1.2). Moreover, progression results in the 
compartmentalisation of the media and sub-intimal space between the layers of 
the blood vessel to narrow the lumen (Figure 1.2). Subsequent angiogenic 
stimulation and sprouting from the adventitia results in new blood vessels 
growing into the atherosclerotic plaque (Herrmann et al. 2001, Khurana et al. 
2005). This physiological process increases the supply of oxygen, nutrients and 
inflammatory cells that destabilise the plaque (Herrmann et al. 2006). The 
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number of intimal micro-vessels correlates with intimal thickening (Van der 
Veken et al. 2016). This correlation suggest that angiogenesis plays an 
important role in plaque progression and instability (Higashida et al. 2008, 
Ribatti et al. 2008).  
 
 
 
 
Figure 1.2: The progression of an atherosclerotic lesion; from a normal 
blood vessel (left) to a vessel with an atherosclerotic plaque and superimposed 
thrombus (right). Atherosclerotic lesion progress through endothelial cell 
dysregulation, inflammation, angiogenesis and thrombus formation to cause 
several diseases, adapted from (Sanz and Fayad 2008). 
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1.4 MicroRNAs: Insight into Lethal-7 (Let-7) 
miRNAs are small non-coding RNA of about 22 nucleotides that inhibit the 
translation of mRNAs to proteins, leading to silencing and post-transcriptional 
modulation of gene expression (Yang et al. 2005). miRNA mediated regulation 
of gene expression contributes to many normal and pathogenic processes, 
through modulation of signalling pathways and associated cellular processes 
(Yang et al. 2005). Several biological functions in humans, including stem-cell 
differentiation, cell proliferation and tumour suppression have been attributed to 
miRNA regulation of their target genes (Büssing et al. 2008, Johnson et al. 
2007, Peter 2009). Sequence complementarity between mature miRNA and 
untranslated regions (UTR) of mRNA result in its degradation or reduced 
stability. Moreover, multiple genomic locations produce miRNAs with similar 
sequence, which allows cells to regulate the miRNA more tightly for targeting of 
the same mRNA UTR or differentially regulate gene expression if one genomic 
region is targeted by another molecular mechanism. Therefore, differential 
transcription of different subtypes of the same mature miRNA allows for tight 
regulation of cellular processes (Büssing et al. 2008, Johnson et al. 2007, Peter 
2009).  
 
Recent computer based prediction algorithms like TargetScan have revealed 
more than 25000 human miRNAs  (Chiang et al. 2010, Griffiths-Jones et al. 
2008, Kozomara and Griffiths-Jones 2014), most of which remain to be 
functionally characterised. The importance of miRNAs in normal physiology is 
highlighted by the observation that approximately 200 miRNAs are evolutionally 
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conserved in mammals (Chiang et al. 2010, Wheeler et al. 2009). While the list 
of confirmed human miRNAs continues to grow, the Lethal-7 (Let-7) miRNAs 
were some of the initial miRNAs identified in developmental timing of 
Caenorhabditis elegans (Reinhart et al. 2000, Sulston and Horvitz 1977). 
Currently, genes encoding microRNA subtypes are denoted with alphabetical 
suffixes (Figure 1.3c), with the addition of numeric identifiers if the mature 
miRNA is transcribed from multiple loci (Figure 1.3a). There are ten members of 
the human Let family of miRNA including Let-7a-g, Let-7i, miR-98 and miR-202, 
reviewed in (Roush and Slack 2008). Currently, three genomic loci encode the 
human let-7a miRNAs (Figure 1.3a), which are distinguished by numbers (Let-
7a-1, Let-7a-2 and Let-7a-3) for different isoforms (Pasquinelli et al. 2000) and 
differ by one or two bases and by genomic location (Figure 1.3c).  
 
Let-7 subgroup is perhaps the most investigated member of the Let family to 
date (Roush and Slack 2008). Several studies have shown that this conserved 
miRNA can target a range of human genes including transcription factor MYC, 
integrin Beta3 and THBS-1 (Dogar et al. 2014, Müller and Bosserhoff 2008, Park 
et al. 2007, Peter 2009, Sampson et al. 2007), hence regulating apoptosis, cell 
migration and proliferation. However, Let-7f is the only member of this family 
that has been linked to the induction of angiogenesis in breast cancer, but the 
mechanisms of its pro-angiogenic effect are yet to be described (Yan et al. 
2008). Physiologically, each miRNA genomic locus results in two mature 
sequences originating from the 5’ and 3’ ends of the precursor miRNA (pre-
miRNA) (such as the Let-7a-3p and Let-7-5p used in this study) (Figure 1.3c.) 
 10 
Though empirical studies are required to determine the most abundant 
sequence, it is thought that one end (the passenger strand) guides the action of 
the other (the alternative strand), which results in more abundance and 
biological activity. Because of the novel approach and cost limitations of this 
study, both strands of the Let-7a miRNA were targeted.  
Figure 1.3a: Genomic location of the human Let-7 members. + or – 
chromosome strand, locations: including intergenic and intronic clusters. Key: 
Red, black and blue hairpins represents miR-100 or miR-99, let-7 and miR-125, 
respectively. The distances between miRNAs or close protein-coding genes are 
given (Lodish et al. 2008, Roush and Slack 2008). 
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Figure 1.3b: Regulation of Let-7 transcription. Representative regualtion at 
transcription and post-transcription levels (Lodish et al. 2008, Roush and Slack 
2008). T.F: trancription factor, m7G: 7-methylguanosine (m(7)G)-capped (5’). 
AAAA: adenine tail. 
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Figure 1.3c: Molecular and structural characteristics of Let-7 family. 
Sequence alignment of mature human let-7 members, with near identical mature 
miRNAs, but variable precursor and primary structures, (Lodish et al. 2008, 
Roush and Slack 2008). 
 
		Mature	Let-7 	Precursor	Let-7 
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1.4.1 Regulation of miRNA transcription  
Transcription of human miRNA occurs mainly by RNA polymerase II (RNA Pol 
II), which generates a long primary microRNA (pri-miRNA) that contains a 
hairpin structure (Figure 1.3-1.4). In line with the evidence that most miRNAs are 
produced from RNA Pol II transcription of their host genes, initial transcription 
can be regulated by transcription factors associated with this polymerase (Figure 
1.3b) (Kim et al. 2009, Krol et al. 2010). Several epigenetic factors including 
DNA methylation and histone modifications have also been shown to regulate 
miRNA transcription (Davis-Dusenbery and Hata 2010). Moreover, some 
miRNAs can regulate the transcription of other miRNAs through targeting of 
transcription factors, or other transcription mechanisms (Figure 1.3b) (Newman 
et al. 2008).   
 
Gene duplication, the occurrence of identical gene coding DNA sequences at 
multiple genomic locations increases the abundance of similar miRNA 
sequences by multiple loci transcription (Berezikov 2011, Ho et al. 2011). 
Though most of the identified miRNAs are transcribed from different genomic 
regions, most of the human miRNAs are introngenic i.e. non-coding DNA 
sequence located between genes (Figure 1.3a). Indeed, most human miRNAs 
are transcribed from non-coding regions between genes, including protein 
coding and non-coding genes, and exonic regions coding for genes (Figure 
1.3a). Another important aspect of miRNA production is the co-transcription of 
closely arranged microRNA loci (polycisctronic) (Lee et al. 2002). However, 
though these clustered miRNAs are transcribed together, differential regulation 
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post-transcription allows tight regulation of gene expression and function (Figure 
1.3a). For instance, among the members of the mir-100: let-7: mir-125 clusters, 
let-7a is post-transcriptionally suppressed in embryonic stem cells but not the 
mir-100 or mir-125 members of the cluster (Roush and Slack 2008). The actual 
promoter regions of most miRNAs remain to be identified, but the advances in 
sequencing technology and results of recent studies suggest that miRNAs 
transcribed from introns of protein coding genes can share promoter regions of 
their host gene (Ozsolak et al. 2008). However, the functional importance of 
these shared promoter regions remains to be fully characterised because 
miRNAs often have several transcriptions start sites (Ozsolak et al. 2008), and 
sometimes intronic miRNAs also have different promoters from the same host 
gene (Monteys et al. 2010).  
1.4.2 Nuclear processing  
Following the tightly regulated transcription of pri-miRNA is the complex process 
of maturation to produce precursor-miR (pre-miR) that contain a hairpin 
structure (Lee et al. 2002). The maturation process relies on the activity of 
RNase-cofactor activity, and nuclear to cytoplasm transport mechanisms. The 
basic pri-miRNA sequence consists of a stem (<35 bp), terminal loop and 
double side (5p and 3p) RNA segments of ~ 22 nucleotides (Figure 1.4). In the 
nuclear compartment, pri-miRNA is initially processed by the nuclear RNAse 
Drosha, a specific double strand RNA nuclease that produce a 70 nucleotide 
pre-miR (Figure 1.4). To function, Drosha forms a complex with its co-factor 
DGCR8 (microprocessor complex), which is a double stranded RNA binding 
protein (Denli et al. 2004, Gregory et al. 2004, Han et al. 2004, Landthaler et al. 
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2004). In this complex, the role of DGCR8 is majorly to recognise the pri-miRNA 
(Han et al. 2006), and to promote the activity of Drosha through its haem-binding 
domain (Friedman et al. 2009, Weitz et al. 2014). The double stranded RNA 
activity of Drosha then mediates the cleavage of both the 3’ and 5’ ends of the 
stem pri-miRNA through its RNAse III domains RIIDa and RIIDb specific activity 
of the microprocessor complex (Blaszczyk et al. 2001, Zhang et al. 2004) to 
create the pre-miR.  
1.4.3 Nuclear export and silencing complex  
The microRNA biogenesis and directional movement before regulation of gene 
expression is summarised in (Figure 1.4). After the nuclear processing, a 
transport complex involving exportin 5, Ran-GTP-binding protein, a 
nucleocytoplasmic transport GTPase and pre-miRNA is assembled. This 
complex transports the pre-miR from the nucleus to the cytoplasm for further 
processing and incorporation into the RNA-silencing complex (Yi et al. 2003). In 
the cytoplasm, Dicer, an endonuclease that cleaves the pre-miR at the terminal 
loop releases the small RNA duplex (Bernstein et al. 2001, Grishok et al. 2001, 
Hutvágner et al. 2001). These final RNA species are then loaded onto argonaute 
(AGO) RNA binding protein to form the effector complex called the RNA-induced 
silencing complex (RISC) that guides the miRNA to the target mRNA. Upon 
binding, the RISC complex guides the gene regulation function of miRNAs 
(summarised in Figure 1.4). The AGO proteins including (1-4) contain Piwi-
Argonaute-Zwille domains that form a binding pocket for the 3’ of the 
incorporated microRNA (Jinek and Doudna 2009). The catalytic activity of RISC 
resides in the AGO proteins, but in humans only the AGO2 protein has been 
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shown to cleave target RNA’s phosphodiester bonds to inhibit translation (Liu et 
al. 2004, Meister et al. 2004). In the context of this thesis, the process of miRNA 
biogenesis predominantly occurs in megakaryocytes (Figure 1.3b), the parent 
cells of platelets, rather than in platelets themselves (Landry et al. 2009). 
However, some processing stages, like the incorporation of miRNA to RISC 
complex, may happen in platelets, as they have been shown to contain AGO 
and Dicer (Landry et al. 2009). This aspect of platelets and corresponding 
transfer to micro-particles are discussed under the sections on platelets, below. 
 
 
Figure 1.4 miRNA biogenesis. In the canonical pathway. miRNAs are 
processed by the Drosha–DGCR8 (DiGeorge syndrome critical region 8) 
complex to generate precursor miRNAs (pre-miRNAs) which are transported by 
exportin 5 into the cytoplasm. In the cytoplasm, Dicer–TRBP (TAR RNA-binding 
protein 2) process the miRNA before loading into AGO2/RISCs to target mRNA. 
miRNAs are also produced though non-canonical pathways, like spliceosome-
dependent mechanisms, from (Li and Rana 2014). 
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1.5 Angiogenesis  
Angiogenesis is the formation of new blood vessels and capillaries from existing 
vessels (Risau 1997). It is a critical process in normal growth, but physiologically 
only occurs in adult humans during wound healing/tissue repair (Risau 1997), 
hair cycle (Yano et al. 2001), and in distinct phases of the female reproductive 
cycle (Risau 1997). Pathologically, angiogenesis supports cancer growth 
(Folkman 2002) and various types of CVD such as the proliferative phase of 
diabetic induced retinopathy (Crawford et al. 2009) and may help 
atherosclerosis development (Carmeliet 2003, Khurana et al. 2005). 
Angiogenesis sequentially entails EC-mediated degradation of the extracellular 
matrix, migration of EC to the peri vascular space followed by proliferation, 
which consequently results in endothelial cell sprouting and tube formation 
(Risau 1997, Vandekeere et al. 2015). The survival of ECs and completion of 
this complex process depends on cell-cell  and cell-extracellular matrix 
interactions (Vandekeere et al. 2015), primarily mediated by integrin receptors 
on the ECs (Strieter et al. 1999). Moreover, this complex and tightly regulated 
process is modulated by several growth factors and cytokines, which are 
produced and released by ECs, platelets, and other vascular cells (Risau 1997).  
 
1.5.1 Cell-matrix interaction in angiogenesis 
Two central aspects of angiogenesis are EC-extracellular matrix binding and 
remodelling, which facilitates EC migration and tube formation (Herbert and 
Stainier 2011). The complex cell-cell and cell-matrix interactions needed for 
angiogenesis are modulated primarily by integrins, although adhesion molecules 
like members of the immunoglobulins family (VCAM-1 and ICAM), selectins and 
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cadherins contribute in this complex interaction (Carmeliet 2000, Lamalice et al. 
2007). Integrins are small heterodimeric proteins that are composed of non-
covalently bound α and β subunits (Humphries 1999). The identified 18 α and 8 
β subunits have been shown to interact with each other in several combinations 
to form 24 individual heterodimers (Giancotti and Ruoslahti 1999). Though many 
cells express these proteins, ECs particularly express β1, β3, β4, α1, α2, α3, α5, 
α6, αvβ3 and αvβ5 integrins (Hynes 1999, Hynes 2002). For instance, αvβ3 
integrin expression is dependent on ECs activation (Bello et al. 2001, Brooks et 
al. 1994) and once expressed, αvβ3 stimulate the production and activation of 
matrix metalloproteinase (MMP) -2 and inhibition of the intracellular transcription 
factor NF kB during the initiation of angiogenesis (Brooks et al. 1996, Leavesley 
et al. 1993, Scatena et al. 1998). MMP is a zinc containing protease that 
functions through calcium-depend endopeptidase activity and NF kB is a family 
of transcription factors that bind to kappaB sites of regulated genes. Increased 
MMP-2 and reduced NF kB facilitate EC migration through the degradation of 
extracellular matrix and promote cell survival through the inhibition of apoptosis, 
respectively (Silletti et al. 2001). Indeed, inhibition of αvβ3 integrin binding and 
subsequent inhibition of MMP-2 activation potently suppresses angiogenesis 
(Boger et al. 2001). Integrin αvβ3 can also directly stimulate EC proliferation and 
growth through the activation of the MAP kinase family member of extracellular 
signal regulated kinase (ERK) (Strömblad et al. 1996), inhibition of the activity of 
p53 transcription factor (Strömblad et al. 1996), and interaction with vascular 
endothelial growth factor receptor –2 (VEGF-R2) (Soldi et al. 1999). Other 
integrins like β1 and α5β1 expressed in both active and quiescent endothelium 
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have been associated with EC adhesion and migration (Languino et al. 1989, 
Taverna and Hynes 2001). 
 
In addition to extra cellular matrix remodelling, ECs need adequate cell-cell 
contact to form capillary networks (Bach et al. 1998). This contact and 
interaction is mediated by the upregulation of the surface receptors platelet 
endothelial cell adhesion molecule-1 (PECAM-1), endothelial cadherins and 
selectins (Newman et al. 1990). PECAM-1 is a member of the immunoglobulin 
superfamily, highly expressed in the vasculature (Newman et al. 1990). The 
ligands that bind to this receptor include the integrin αvβ3 (Piali et al. 1995), 
cyclic ADP ribose hydrolase (CD38) (Muller et al. 1992), and glycosaminoglycan 
(Horenstein et al. 1998). PECAM-1 can also influence cell adhesion by 
interacting with itself on the surface of adjacent ECs (Newton et al. 1997). 
Cadherins are transmembrane proteins that form calcium dependent 
interactions with each other on the surface of cells (Dejana 1996, Feng et al. 
2015) and cadherin link to the actin cytoskeleton resulting in firm attachment of 
ECs once engaged (Dejana 1996). Because they are highly expressed at cell 
junctions, cadherins play crucial role in angiogenesis through the modulation of 
contact inhibition, cell polarity and EC interaction with other vascular cells 
(smooth muscles cells, pericytes), reviewed extensively by (Dejana et al. 2009, 
Feng et al. 2015, Giannotta et al. 2013).  
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1.5.2 Role of Growth Factors in angiogenesis  
The best studied mediators of angiogenesis are the growth factors like vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF) and 
angiopoietins (AGIO) (Yancopoulos et al. 2000). These growth factors are either 
stored within the extracellular matrix or storage granules of platelets and ECs  to 
ensure a prompt release (Yancopoulos et al. 2000). VEGF-A, the archetypal 
angiogenic mediator, potently increases EC migration, mitogenesis and 
angiogenesis (Takahashi and Shibuya 2005). Angiogenic sprouting is quickly 
observed after increased expression of VEGF-A and its receptor (Gerhardt et al. 
2003). However, a splice variant of this growth factor called VEGF-165b can 
inhibit angiogenesis potentially through the inhibition of VEGF-A mediated 
angiogenesis (Woolard et al. 2004). VEGFR-2 induces the phosphorylation of 
phospholipase C gamma (PLCg), which in turn activates protein Kinase C and 
Sphingosine kinase (SPK) to induce signal transduction through the mitogen-
activated protein kinases (MAPK)/ extracellular signal-regulated kinases (ERK) 
pathway (Koch et al. 2011). VEGF-A also increase the release of other 
angiogenic factors from ECs, including von-Willebrand factor, and urokinase 
plasminogen activator (Sahni and Francis 2000), strengthening the angiogenic 
response.  
 
FGF produce a potent angiogenic response through the activation of protein 
kinase C and phospholipase upon receptor ligation, leading to MAPK/ERK 
mediated transduction of FGF signal (Kanda et al. 1996, Kent et al. 1995, Sa et 
al. 1995). Additionally, FGF may promote the production of VEGF (Seghezzi et 
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al. 1998). FGF also plays an important role in the remodelling of the extracellular 
matrix through the induction of matrix proteins like urokinase receptors, 
collagen, fibronectin, and proteoglycans (Lu et al. 2011). Thus, optimum 
angiogenesis depend on a multiple cross-talk between several growth factors 
(Yancopoulos et al. 2000).  
 
The complexity in the regulation of angiogenesis is further increased as some 
mediators are context specific. For instance, the angiopoietins (AGIO), which 
are growth factors that bind to EC-specific Tie receptor kinases can antagonise 
each other to induce context dependent angiogenic effect  (Maisonpierre et al. 
1997, Suri et al. 1996). AGIO-1 binding to the receptor Tie-2 results in the 
phosphorylation and activation of the protein kinase B/ark/FOX01 pathway (Gale 
and Yancopoulos 1999), promoting EC survival. This AGIO-1 binding also 
inhibits the binding of pro-angiogenic AGIO-2 (Asahara et al. 1998), while the 
expression of AGIO-2 and its interaction with Tie-2 receptor cause EC activation 
and initiation of angiogenesis. The binding of AGIO-2 inhibits AGO-1 mediated 
phosphorylation of Tie-2 receptor to promote survival, sprouting and tube 
formation (Maisonpierre et al. 1997, Scharpfenecker et al. 2005). Interestingly, 
exposure of ECs to angiogenic stimuli is associated with increased expression 
of AGIO-2 (Pichiule and LaManna 2002, Ray et al. 2000). Moreover, EC derived 
AGIO-2 in extracellular bodies can also promote angiogenesis through autocrine 
promotion of VEGF activity. Though the full role of angiopoietins in angiogenesis 
remains controversial, their context dependent function relative to other growth 
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factors and pathophysiologic states play an important role in the complex 
regulation of angiogenesis by growth factors.  
 
1.5.2 Endogenous inhibitors of angiogenesis  
In addition to positive regulation, angiogenesis is controlled by the release and 
production of potent angiogenesis inhibitors within the vasculature. Important 
endogenous inhibitors measured in this study include platelet factor 4 (PF4), 
tissue inhibitors of metalloproteinases (TIMPs), endogenous inhibitors of MMPs 
and thrombospondin-1 (THBS-1). PF4 is a chemotactic CXC chemokine 
produced by megakaryocytes and platelets, released in alpha granules as a 
homotetramer. PF4 is thought to exhibit anti-angiogenic properties due to its 
ability to neutralise heparin in a charge mediated mechanism (Bikfalvi 2004). 
The in-vitro treatment of EC with recombinant PF4 inhibit both proliferation and 
migration (Maione et al. 1990). However, its ability to modulate EC activity 
remains poorly described due to lack of a defined chemokine receptor for PF4 
(Lambert et al. 2009). TIMPs (1-4) are broad-spectrum, natural inhibitors of 
MMPs that inhibits their ability to degrade extracellular matrix and subsequent 
induction of anti-angiogenic or pro-angiogenic effects (Sang 1998). Moreover, 
TIMP-1 and TIMP-3 may directly inhibit EC motility and proliferation to inhibit 
angiogenesis. By contrast, TIMP1-4 inhibits anti-angiogenic MMPs-2, -7, -9 and 
-12, which may allow them to elicit pro-angiogenic effects (Johnson et al. 1994, 
Sang 1998). Therefore, the effects of TMPs on angiogenesis requires a careful 
consideration of the context and complex interactions they have with MMPs. 
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Figure 1.5: The structure of THBS-1 protein. Domain dependent binding to 
Ligands and receptors mediate cellular processess including angiogensis 
(Isenberg et al. 2009). 
 
The THBS family contain five members, that together have been associated with 
a wide range of developmental processes and disease pathogenesis (Figure 
1.5) (Bornstein 2001). THBS-1 is the most studied member of this family, largely 
because it can be purified readily. THBS-1 is a high molecular weight multi-
domain glycoprotein that plays an important role in cell to cell, and cell to matrix 
interactions (Figure 1.5) (Armstrong and Bornstein 2003). THBS-1 is a trimer of 
identical polypeptides linked by disulphide bonds, with each polypeptide 
containing one amino-terminal domain, three repeated domains (including type-
1, type-2 and type-3) and the carboxyl-terminal domain, which are independently 
implicated in different cellular functions of THBS-1 (Esemuede et al. 2004). The 
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N-terminal domain of the protein binds to heparin sulphate proteoglycans, which 
facilitates its cellular uptake and clearance from extracellular space (Adams 
1997). The amino acid residues in this domain bind to a3b1, a laminin integrin 
(Chandrasekaran et al. 1999), inhabiting EC migration, chemotaxis and 
angiogenesis (Figure 1.5) (Esemuede et al. 2004).  
 
The THBS-1 procollagen domain mediates trimer formation, and inhibits 
angiogenesis by binding to transforming growth factor β (TGFβ) (Tolsma et al. 
1993). Moreover, the other functional domains of THBS-1 can bind to β1 
integrins, and the platelet glycoprotein 4 (CD36) and integrin associated protein 
(CD47) receptors (Figure 1.5) (Kazerounian et al. 2008). Though the full 
functional mechanism underlying the anti-angiogenic and anti-proliferative 
effects of THBS-1continues to be studied, it is thought that different regions of 
the THBS-1 protein interact with different proteins to induce conformational 
changes or block growth factor binding (Murphy-Ullrich and Poczatek 2000, 
Schultz-Cherry et al. 1995).  
 
The complex cell to cell, and cell-matrix interactions explained above have been 
studied in the context of angiogenesis. Indeed, the regulation of angiogenesis by 
THBS-1 can occur through the direct effect on ECs or indirect effect on 
inflammatory cells (BenEzra et al. 1993, Nicosia and Tuszynski 1994). Indirectly, 
THBS-1 can activate and induce migration of polymorphonuclear cells and 
myofibroblasts to induce angiogenesis (Nicosia and Tuszynski 1994). The pro-
angiogenic response of THBS-1 is consistent with the increase in smooth 
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muscle cell migration (Armstrong and Bornstein 2003). By contrast, direct 
targeting of ECs by THBS-1 inhibit angiogenesis. However, the opposing 
evidence on THBS-1 is not contradictory, as they are context and cell type 
dependent. The direct effect of THBS-1 on ECs results includes apoptosis, 
which is mediated through TSRs binding to CD36, CD47 and Integrin beta-1 
(CD29) (Dawson et al. 1999, Iruela-Arispe et al. 1999, Tolsma et al. 1993). 
Moreover, Src family kinase Fyn and JNK-1/MAP kinase downstream of CD36, 
are important in the inhibition of angiogenesis by THBS-1 (Jiménez et al. 2000, 
Jimenez et al. 2001).  
 
In-vitro and in-vivo experiments have shown that synthetic peptides containing 
the THBS-1 type 1 repeats (TSRs) can inhibit migration. However, there is 
evidence that THBS-1 still inhibit migration in the absence of CD36, which 
suggests that other mechanisms might play a role in its modulation of ECs 
function (Iruela-Arispe et al. 1999). Multiple inhibitory sites in the TSRs act 
through different mechanisms to modulate angiogenesis. For instance, TSRs 
bind to EC’s surface proteoglycans to act as co-receptors for growth factors 
(Iruela-Arispe et al. 1999). This co-receptor activity can effectively inhibit key 
steps in angiogenesis. Conversely, the induction of apoptosis also involves 
p38MAPK and caspase 3 (Jiménez et al. 2000, Nör et al. 2000). Treatment of 
ECs with high glucose concentration (25mmol/L) causes phosphorylation of 
P38MAPK, and inhibition of caspase 3 blocks phosphorylation of P38MAPK. In 
addition to apoptosis induction, THBS-1 reduces the expression of survival 
pathways (Nör et al. 2000). Thus, THSB-1 inhibits angiogenesis through several 
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mechanisms including induction of apoptosis, inhibition of survival, reduced 
mobilisation of growth factors and reduced receptor binding of angiogenic 
inducers, which is summarised in Figure 1.6. In summary, several endogenous 
angiogenic inhibitors including THBS-1 play a role in maintaining angiogenic 
balance. Depending on the physiological or pathological conditions, changes 
can influence EC’s angiogenic potential.  
 
1.5.3 Role of microRNAs in angiogenesis  
miRNAs are becoming recognised as major regulators of both normal vascular 
physiology and pathogenesis of vascular diseases (Urbich et al. 2008). The 
early indications of the role of miRNAs in vascular physiology were provided by 
a study that studied mouse models with mutated genes in the Dicer machinery 
(Yang et al. 2005). The data from this study showed that the presence of a 
hypomorphic dicer allele, a mutation that cause partial loss of function, results in 
prenatal death of mice due to immature and leaky blood vessels and late 
induction of embryonic EC markers including VEGF-A, VEGFR-1 and Tie-1 
receptor (Yang et al. 2005).  Correspondingly, silencing of Dicer expression 
using siRNA in mature ECs was shown to elicit anti-angiogenic phenotypes 
through altered microRNA profile (Suárez et al. 2007), providing further 
evidence that miRNAs are important in angiogenesis. Some of the characterised 
miRNAs involved in angiogenesis are summarised in Table 1.  
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Table 1.1: The identified miRNAs modulating angiogenic process  
miRNA Target Genes 
Angiogenic 
Activity  References 
miR-126 SPRED1/PIK3R2  Pro 
(Fish et al. 2008, 
Wang et al. 2008) 
miR 17 – 92 
Cluster THBS-1 Pro (Gupta et al. 2014) 
 miR-132 pl20RasGAP Pro (Anand et al. 2010) 
 miR-210 EFNA3 Pro (Fasanaro et al. 2008). 
 miR-296 HGF Pro (Chen and Gorski 2008) 
miR-23 Sprouty 2/SEMA6A Pro (Bang et al. 2012) 
 miR-378 SUFU/FUS-1  Pro (Lee et al. 2007) 
 miR-15a VEGF-A/FGF2 Anti (Suzuki et al. 2015) 
 miR-16 VEGF-R2/FGFR1 Anti (Kane et al. 2014) 
 miR-24 GATA2/PAK4/NOS3 Anti (Kane et al. 2014) 
 miR-
34a/b/c 
SIRT1/VEGF/ 
NOTCH1/SEMA4B Anti (Kane et al. 2014) 
 miR-92a ITGB5 Anti (Kane et al. 2014) 
 miR-100 mTOR Anti (Kane et al. 2014) 
 miR-503 CCNE1/cdc25A Anti (Kane et al. 2014) 
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The miRNA profile of ECs has been established primarily in human umbilical 
vein endothelial cells (HUVECs) using qRT-PCR and microarray techniques 
(Wang et al. 2008, Wang and Olson 2009). ECs have high expression of specific 
miRNA clusters including miR-17-92, miR- 23-24, Let family of miRNAs and 
individual miRNAs including miR-221/222, miR-126 and miR-21, extensively 
reviewed in (Wang and Olson 2009). Though partial functional characterisation 
of the above miRNA clusters has been conducted (Wang and Olson 2009), the 
full extent of their role in angiogenesis and EC activity remains to be identified. 
Subsequently, RNA-sequencing techniques revealed differential expression of 
400 characterised (annotated) and some novel miRNAs between HUVECs 
grown in basal conditions and those grown under hypoxia induced angiogenic 
conditions (Voellenkle et al. 2012). Voellenkle revealed that miR-21 and miR-
126 account for 40% of all the miRNAs detected in HUVECs (Voellenkle et al. 
2012). miR-126 play a principal role in sustaining angiogenesis through the 
inhibition of sprouty related EVH1 domain containing 1 (SPRED1), a negative 
regulator of growth factor-induced activation of MAP kinase pathway, (Fish et al. 
2008) and through targeting of the phosphatidylinositol 3-Kinase (PI3K) 
regulatory subunit beta PIK3R2, a regulator of growth signalling pathways 
through additional phosphorylation of phospholipids  (Wang et al. 2008). Both 
SPRED1 and PIK3R2 inhibit VEGF signalling (Fish et al. 2008, Wang et al. 
2008), which reduces angiogenesis, thus their inhibition allows the growth of 
new vessels. In addition, EC sprouting, an important stage of angiogenesis, 
relies on the zinc finger transcription factor KLF2a, which induce EC-specific 
miR-126 that can inhibit SPRED1 and PIK3R2.  
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Whilst one of the most studied, miR-126 is not the only regulator of 
angiogenesis. EC stimulation with VEGF induces the expression of miR-130a 
and miR-296 (Chen and Gorski 2008, Würdinger et al. 2008), that promote 
angiogenesis through the inhibition of negative regulators of angiogenesis 
including homobox genes like homobox-2 (GAX) (Chen and Gorski 2008), and 
hepatocyte growth factor (HGF)- regulated tyrosine kinase (Würdinger et al. 
2008), respectively.  VEGF-A and bFGF also result in miR-132 transcription in 
EC, which has been shown to facilitate proliferation and sprouting by the 
inhibition of p/20RasGAP an important GTPase-activating protein (Anand et al. 
2010), which normally regulate cell cycling in G-protein dependent manner.  
 
In-vitro overexpression of miR-210 in HUVECs increases cell migration and 
sprouting through reduced release of tyrosine kinase ligand, ephrin A3 
(Fasanaro et al. 2008). Ephrin A3 elicit negative regulation of angiogenic 
remodelling and EC activity (Kuijper et al. 2007). Furthermore, miR-424 
inhibition of culin 2 (CUL2) and downstream upregulation of HIF-α promotes 
angiogenesis (Ghosh et al. 2010). Among the members of the miR-17-92 
cluster, miR-18a and miR-19a can inhibit several proteins that contain 
thrombospondin type 1 repeats (Dews et al. 2006, Suárez et al. 2007) like 
THBS-1 to promote angiogenesis. miR-17-5p can inhibit TIMP1 (Otsuka et al. 
2008) to induce EC migration and proliferation. Furthermore, miR-23 and miR-
27 elicit their pro-angiogenic effect by inhibiting Sprouty2 and Sema6A (Zhou et 
al. 2011), both of which are known anti-angiogenic proteins. Finally, inhibition of 
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tumour suppressors, Fus-1 and SUFU by miR-378 indirectly upregulate VEGF 
and angiopoietin-1/2 (Lee et al. 2007) to promote angiogenesis. 
 
In addition to the pro-angiogenic role of EC derived miRNAs, some of the 
identified miRNAs have anti-angiogenic effects (Poliseno et al. 2006) as 
summarised in Table 1. For instance, overexpression of miR-221/222 in EC 
inhibits the stem cell factor (SCF) receptor C-kit (Poliseno et al. 2006), as such 
inhibit the angiogenic effect of SCF (Poliseno et al. 2006). Among the miR-17-92 
cluster, miR-20a and miR-92a negatively modulate angiogenesis, by inhibiting 
the transcription of VEGF-A and integrin β5, respectively (Bonauer et al. 2009, 
Hua et al. 2006). Finally, miR-503 inhibits cdc25A and cyclin E1 (Caporali et al. 
2011), resulting in reduced proliferation, sprouting and migration (Caporali et al. 
2011).  
 
1.5.4 Angiogenesis in cardiovascular diseases  
The contribution of angiogenesis in the development of atherosclerosis and 
associated CVD is a somewhat controversial issue in vascular biology (Khurana 
et al. 2005). On the one hand angiogenesis is targeted for the treatment of 
diseases associated with impaired vascular function, while on the other, 
increased angiogenesis can destabilise the plaques leading to rupture (Khurana 
et al. 2005). However, angiogenesis is increasingly recognised to be one 
underlying mechanism in the progression of arthritis, thrombosis and ocular 
diseases (Armstrong et al. 2011, Glass and Witztum 2001, Järvilehto and 
Tuohimaa 2009), which is supported by the numerous trials targeting 
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angiogenesis in the treatment of these conditions (Carmeliet and Jain 2000). 
However, emerging evidence have only begun to establish the role of intra-
lesion angiogenesis in the plaque instability, potentially enabling thrombosis and 
cardiovascular complications (Khurana et al. 2005, Layne et al. 2015, Slevin et 
al. 2008, Yao et al. 2013).  
 
Bleeding in the plaque is a marker of instability because they may weaken 
plaque, enabling rupture which is driven by immature neo-blood vessel 
formation (Jain et al. 2007). This suggest that bleeding plays an important role  
in plaque destabilisation, however bleeding is not the only factor in this 
pathological process (Jain et al. 2007). Correspondingly, new blood vessels in 
plaque are fragile and prone to haemorrhage, compared to normal blood 
vessels. One critical aspect to this association is the fact that such vessels are 
single layer and lack smooth muscles cells. Immature vessels are significantly 
increased in patients with unstable atherosclerotic plaques, and leaky vessels 
are associated with the infiltration of inflammatory cells and an increased risk of 
bleeding (Jain et al. 2007). Moreover, bleeding is associated with increased 
release of lipids from lysed red blood cells, which can indirectly increase plaque 
volume and cause instability. Red blood cell lysis can also activate 
macrophages through the release of iron, which in turn increases the 
progression and development of angiogenesis (Jain et al. 2007).  Moreover, 
leaky blood vessels provide an entry route for platelets and PMPs to the plaque, 
allowing for further inflammation and progression (Li and Cong 2009). Platelets 
provide a pro-thrombotic interface in plaques, leading to thrombus growth and 
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narrowing of the blood vessels (Li and Cong 2009). The subsequent narrowing 
mediated increase in shear stress promotes activation of more platelets and 
shedding of PMP within the plaque environment that cause further increase in 
plaque destabilisation and rupture (Li and Cong 2009). 
 
The increase in plaque’s necrotic core is associated with instability and rupture. 
Disrupted blood flow due to vessel occlusion or narrowing can prevent the 
clearance of inflammatory cells in the necrotic core, and has increased risk of 
rupture when combined with the increased supply of nutrients and cells by neo-
vessels. In addition to cells, haemorrhage and fatty deposits, the activity of 
angiogenic proteins can also contribute to rupture. For instance, the activity of 
MMPs which are central to migration and sprouting of EC may also contribute in 
this process. Thus, platelet induced release of pro-angiogenic proteins can 
contribute to plaque rupture independent of blood vessel formation. Mechanical 
factors such as strain and stress is increased by angiogenesis to increase the 
risk of rupture  (Jain et al. 2007). Despite the evidence that angiogenesis is 
important in plaque destabilisation and rupture, the mechanisms driving the 
initiation of angiogenesis remains to be characterised. The role of platelets in 
this process is emerging as an important factor, and will be discussed below.  
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1.6 Platelet structure and biology  
Platelets are anucleate cells, 2-4μm in diameter, which circulate in the blood at 
approximately 3 x 108 cells/ml. Platelets are produced in the bone marrow at 
4000 cells per megakaryocyte (Niswander et al. 2016). As megakaryocytes 
develop into giant cells they undergo cytoplasmic fragmentation. The fragments 
(platelets) circulate in the vasculature for approximately 10 days before spleen 
elimination. The structure of a resting platelet is divided into four zones, 
including; membrane, organelle, structural and peripheral zones (Figure 1.6).  
 
Figure 1.6: Platelet structure and biomolecules. Each of the zones, 
membrane, organelle, structural and peripheral contain unique biomolecules that 
influnce cellular processes (primary hemostasis). 
Surrounding the platelet surface is the glycocalyx, a region rich in adhesion 
receptors required for the recognition and binding to exposed proteins in blood 
vessels following damage (Phillips et al. 1988). The key receptors are integrin 
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a2b, GPIb/IX/V and GPIIb/IIIa, which promote activation through binding of 
collagen, vWF and fibrinogen, respectively (Saboor et al. 2013). Following 
activation, platelets also express phospholipid phosphatidylserine (PS) on the 
unit membrane, which interact with the Na/K-ATPase to form a negatively 
charged surface that initiates and localises the tissue coagulation cascade 
(Thiagarajan and Tait 1990). The coagulation cascade converts pro-thrombin to 
thrombin, which induces clot formation through the conversion of fibrinogen to 
fibrin (Hemker et al. 2006). Invaginations of the membrane system form the 
open canalicular network for the absorption of clothing factors (factors I, II, V, V 
+ VIII, VII, X, XI, or XIII) and activation of the coagulation process (Van Creveld 
et al. 1951). Additionally, the actin filaments contained in the sub-membrane 
region that surrounds the peripheral zone play important role in maintaining the 
shape of platelets. These actin filaments also promote activation induced 
spreading and degranulation of platelets.  
Platelets contain three types of granules, the contents of which are released 
following activation. These granule types include alpha granules, dense 
granules, and lysosomes (Rendu and Brohard-Bohn 2001). The alpha granules 
contain adhesive proteins like vWF and fibrinogen as well as pro-inflammatory 
mediators and growth factors like THBS-1, PDGF and cytokines (Rendu and 
Brohard-Bohn 2001). The dense granules contain platelet agonists such as 
ADP, Ca2+ and serotonin, which act in coordination to enhance platelet 
activation following vascular injury (Rendu and Brohard-Bohn 2001). Finally, the 
lysosomes contain hydrolytic enzymes that also play an important role in platelet 
function, summarised in Figure 1.7.  
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Under physiological conditions, platelets circulate in the blood without 
interactions with the vessel wall, other platelets, or ECs (Turitto and Hall 1998). 
However, following vascular damage caused by injury or plaque rupture, several 
biochemical processes are activated that facilitate the formation of a platelet- 
rich plug (Turitto and Hall 1998). The biochemical and cellular processes 
involved in this blood clot formation can be divided into platelet adhesion, 
activation, secretion and aggregation, as shown in Figure 1.8 (Harrison 2005, 
Monagle 2015, Weiss 1975). 
 
 
Figure 1.7: Platelet activation in blood clothing. Platelets adhere to a matrix 
proteins, get activated, secrete granular contents, aggregate via integrins, 
produce thrombin and form a fibrin cloth (Versteeg et al. 2013). 
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1.6.1 Platelet Micro-particles  
Micro-particles (MPs) are cell membrane vesicles ranging in size from 0.2 – 1.0 
um (Piccin et al. 2007), produced from activated and apoptotic cells (Piccin et al. 
2007). The formation of MP requires calcium mediated plasma membrane 
budding, which is characterised by changes in lipid asymmetry and protein 
reorganisation (Coleman et al. 2001, Zwaal and Schroit 1997). Formation of MP 
causes the loss of plasma membrane asymmetry leading to exposure of 
phosphatidylserine (Daleke 2003, Hamon et al. 2000, Zwaal and Schroit 1997). 
This reorganisation is partly linked to the inhibition of translocase/flippase 
activity and induction of scramblase/floppase/ABC1 activity by calcium (Daleke 
2003, Hamon et al. 2000, Zwaal and Schroit 1997). In platelets, calcium 
mediated activation of calpain, a protease involved in cytoskeleton 
reorganisation seems to play an important role in MP release (Zwaal and Schroit 
1997). Calpain seems to function by the activation of receptors and pro-
enzymes (Zwaal and Schroit 1997).  
 
The most abundant MPs in the circulation are from platelets (PMPs). PMPs 
have been extensively studied in relation to their pro-coagulant activity; platelet 
coagulation activity is an important step in thrombus formation, a key feature in 
cardiovascular complications (VanWijk et al. 2003). It has been demonstrated 
that 25% of the platelet associated pro-coagulant activity in-vitro is linked to 
PMP release and activity (Sinauridze et al. 2007, Tans et al. 1991). PMPs 
promote sustained platelet binding to sub-endothelial matrix at sites of injury 
(Merten et al. 1999) through the stimulation of fibrin-fibril formation (Siljander et 
 37 
al. 1996). Studies on mouse models of venous thrombosis showed that PMP 
injection significantly increased the level of thrombosis (Ramacciotti et al. 2009). 
Importantly, PMP levels are significantly elevated in patients with a pulmonary 
embolism and valvular atrial fibrillation, which are both associated with 
heightened risk of thrombosis (Azzam and Zagloul 2009, Bal et al. 2010).  
 
MP express surface markers specific to their cells of origin and to a lesser 
extent, surface markers that represent the activation process of the MP 
formation. PMPs express platelet adhesion molecules including CD42b (GpIba), 
integrin αIIbß3 (Schwarz et al. 2004), PECAM-1 (Losy et al. 1999) and P-selectin 
(George et al. 1986b), (Flaumenhaft et al. 2009, Scharf et al. 1992). MPs 
interact with recipient cells through these adhesion receptors, eliciting 
phenotypic responses (Ratajczak et al. 2006). This is thought to occur through 
several mechanisms including: the transport of active biomolecules between 
platelets and other cells (Mause and Weber 2010), communication through 
receptor-cell ligation (Théry et al. 2002) and through the transfer of miRNAs 
(Diehl et al. 2012a). It is becoming apparent that these mechanisms play a role 
in the pathophysiology of vascular diseases (Diamant et al. 2004). PMPs can 
activate the production and expression of EC MPs and adhesion molecules, 
respectively (Barry et al. 1998), induce endothelial progenitor cell apoptosis 
(Gambim et al. 2007) and facilitate in-vitro neutrophil aggregation (Jy et al. 
1995). PMPs have been shown to release arachidonic acid that can activate the 
expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-
selectin on ECs and monocytes (Abrams et al. 1990, Barry and FitzGerald 1999, 
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Barry et al. 1998, George et al. 1986a, Wencel-Drake et al. 1993). Moreover, 
PMPs amplify leukocyte-induced inflammatory and thrombotic disorders (Forlow 
et al. 2000, Jy et al. 1995). In the context of the current study, PMPs are 
significantly elevated in patients presenting with risk factors for cardiovascular 
complications, including hypertension, obesity and diabetes, which promote the 
production of more PMPs and consequent amplification of their biological 
functions (Casey et al. 2004, Goichot et al. 2006, Nomura et al. 2009, Nomura et 
al. 1993, Preston et al. 2003).  
1.6.2 Platelet and PMP-miRNA  
Although platelets are anucleate, they have the cell machinery necessary for 
translation (Zimmerman and Weyrich 2008). The ability of platelets to carry out 
mRNA translation to produce proteins has generated significant interest in 
characterising their messenger RNA and miRNAs profiles (Gidlof et al. 2013, 
Laffont et al. 2013, Risitano et al. 2012). Platelets are now known to contain 
hundreds of miRNAs (Nagalla et al. 2011), which regulate platelet functions, but 
importantly they release these miRNAs in PMPs upon activation (Nagalla et al. 
2011). ECs, monocytes, lymphocytes, and dendritic cells have been 
demonstrated to be viable recipients of PMP mediated miRNA transfer (Aatonen 
et al. 2012, Baj-Krzyworzeka et al. 2006, Montecalvo et al. 2012, Valadi et al. 
2007, Wahlgren et al. 2012). Once released, PMPs are able to bind to target 
cells and alter their function (VanWijk et al. 2003). Particularly, the transfer of 
miRNA to ECs by PMPs has been quantified using flow cytometry and 
fluorescence techniques (Gidlof et al. 2013, Laffont et al. 2013, Risitano et al. 
2012). Laffont et al., (2013), reported increased levels of miR-223 on ECs 
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following incubation with PMPs, which can regulate endogenous gene 
expression of onco-suppressor (FBXW7) and glycosylphosphatidyl inositol-
anchored receptor tyrosine kinase ligand (EFNA1) at both mRNA and protein 
levels, but the functional importance of these target genes remains to be 
identified. PMPs act as an intracellular carrier for the Ago2-microRNA complex, 
which initiates heterotrophic gene regulation in circulatory cells, most especially 
EC (Laffont et al. 2013). The sequence of events follows the dicer III production 
of miRNA, which is integrated with Ago2-complexes. The miRNA translational 
repression and/or destabilization of mRNA transcripts is known to occur through 
miRNA modulation of effector complexes that contain Ago proteins and Dicer 
(Bartel 2009, Meister et al. 2004).  
 
Activated platelets release most of their miRNAs packaged in the MPs, while a 
negligible amount is released to the supernatant (Diehl et al. 2012a, Laffont et 
al. 2013). Thrombin activation of platelets transfected with fluorescent 
exogenous synthetic miRNA demonstrated the enrichment of synthetic miRNA 
in PMPs (Gidlof et al. 2013). Functional analysis of activated platelet miRNA 
profiles demonstrated that platelet miR-223 levels are significantly increased 
following thrombin activation (Laffont et al. 2013), which induced about 60-fold 
increase in miR-223 levels in ECs. Using RNA-induced silencing complex 
(RISC) assay (Laffont et al. 2013) demonstrated that MP transfer of miR-223 
and activity occurs through complex formation with Ago2 protein (Laffont et al. 
2013). The importance of platelet miRNA in regulating the functions of recipient 
cells lies on the sustained function of transferred miRNA. Indeed, platelet 
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miRNA – Ago2 complex remains functional in ECs after thrombin activation 
(Laffont et al. 2013).  
 
Moreover, immuno-precipitation, qRT-PCR and RNA-induced silencing of 
platelets miR-223 showed that Ago2 forms complexes with miR-223 and 
possibly other functional microRNAs. Interestingly, co-incubation of fluorescently 
labelled PMPs with HUVEC was demonstrated by confocal microscopy to be 
internalised by EC and deliver functional Ago2-miR-223 complex (Gildof et al., 
2013). In addition, incubation of human embryonic cell lines (HEK293) with 
platelets possessing 3’ – UTRs luciferase reporter gene labelled miR-22, miR-
185, miR-320b and miR-423-5p (Gidlof et al. 2013), demonstrated that thrombin 
activated platelets inhibited ICAM-1 reporter signal compared to control of 
scrambled pre-mRNA. This supports the notion that functional miR-22 and miR-
320b can be transferred from platelets to ECs. Though miRNA may be 
transferred to recipient cells through fusion or internalisation, the available 
evidence seems to support transfer by internalisation rather than fusion. 
 
1.6.3 Platelet microRNA in cardiovascular complications 
Microarray and sequencing analysis of isolated RNA from individuals suffering 
from cardiovascular complications including atherosclerosis and ischaemic heart 
conditions have identified several correlations between disease phenotypes and 
differentially expressed RNA transcripts. These include links between 
inflammation related RNA transcript levels and body weight (Freedman et al. 
2010). PMPs have been linked to atherosclerosis (Boilard et al. 2010b, Rautou 
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et al. 2011) through enhanced vascular permeability (Cloutier et al. 2012) and 
coagulation (Owens and Mackman 2011). PMPs induced vascular permeability 
and platelet coagulation functions promote inflammation, which subsequently 
increase the risk of developing atherosclerosis (Boilard et al. 2010b, Cloutier et 
al. 2013).  
 
The role of platelet miRNAs was first investigated by (Gidlof et al. 2013) in 
myocardial infarction patients. Gidlof proposed that platelet miRNA is important 
in the progression of myocardial injury, potentially through the repression of anti-
inflammatory gene expression. Initial miRNA profiling suggests that patients with 
myocardial infarction have a unique miRNA profile compared to healthy 
individuals (Gidlof et al. 2013). Consistent with the above, it is proven that eight 
miRNAs including (miR- 22, miR- 127-3P, miR- 139-3p, miR- 185, miR- 320b, 
miR- 423-5p, miR- 1250 and miR- 1307) were down regulated in myocardial 
infarction patients, while miR–320a was up regulated compared to controls. The 
study demonstrated that most of the miRNAs differentially expressed in the 
circulation of myocardial infarction patients are depleted in their platelets. It was 
thought that they are decreased because of miRNA transfer to endothelium 
induced by activation of platelets (Gidlof et al. 2013). 
 
1.7 Aims 
Several lines of evidence suggest that specific miRNAs are preferentially 
packaged by platelets into PMPs, and these can be released and transferred to 
EC to induce angiogenesis. It is now established that PMP plays an important 
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role in CVD, cancer and wound healing, but the mechanisms remain poorly 
described. The role of PMPs in CVD correlates with the ability to induce 
angiogenesis, which could be mediated through PMP derived miRNAs. 
However, the molecular mechanisms underlying PMP-miRNA in pro-angiogenic 
response associated with PMPs remains to be investigated. Based on the 
emerging role of miRNA in angiogenesis, we hypothesised that PMPs induced 
angiogenesis leading to CVD is driven by miRNA regulation of EC function. 
 
1.6.1 Objectives 
To achieve these aims we investigated these specific objectives: 
i. Determine the angiogenic potential of ECs treated with PMPs.  
ii. Determine the profile of angiogenic proteins released by ECs treated with 
PMPs.  
iii. Quantify other cellular functions modulated by PMPs treatment of ECs. 
iv. Determine whether PMPs effect on angiogenesis was mediated by 
miRNA. 
v. Identify specific miRNAs and its molecular function controlling the effect 
of PMPs on angiogenesis. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Chemicals and Kits 
All cell culture reagents used were of cell culture grade, and reagents were of 
experimental grade and stored as directed by the manufacturer’s description. 
The name and identification details of key reagents and assays kits are 
described in Tables 2.1 – 2.4. 
Table 2.1: List of chemicals, suppliers and identification numbers. 
Chemical Supplier Catalogue Number 
L-Glutamine Life Technologies 25030081  
Dulbecco modified Eagle 
medium (DMEM) Life Technologies 31885-023 
Penicillin/streptomycin Life Technologies 15140122 
Medium 200  Life Technologies M-200-500 
Endothelial growth 
medium PromoCell 
C-22010/ C-22210 
 
Endothelial growth 
medium supplement PromoCell 
C-39215 
 
Low serum growth 
supplement (LSGS) kit Life Technologies S-003-K 
Fast SYBR® Green 
Master Mix  Life Technologies 4385610/4385612 
Lipofectamine® 3000 
Reagent Life Technologies L3000001 
FuGENE® HD 
Transfection Reagent Activemotif 32042 
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Table 2.2: List of antibodies and proteins, suppliers and identification 
numbers. 
Antibodies/Proteins Supplier 
Catalogue 
Number 
APC mouse anti-human 
CD41a – platelet 
glycoprotein IIb (clone: 
HIP8) 
BD Biosciences 561852 
APC mouse IgG1, k Isotype 
control (Clone: MOPC-21) BD Biosciences 555751 
FITC Annexin V BD Biosciences  
Thrombin Sigma-Aldrich T7009 
Ribonuclease A (RNAse A) Sigma-Aldrich R6513 
Prostaglandin E1 Sigma-Aldrich P7527 
Polyclonal Sheep IgG anti-
human CD47 R&D Systems AF4670 
Monoclonal mouse IgG1 
anti-human Integrin 
b1/CD29 (Clone: P5D2) 
R&D Systems MAB17781 
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Table 2.3: List of assay kits, suppliers and identification numbers. 
Assay Kits Supplier 
Catalogue 
Number 
Quick start Bradford protein assay 
kit Bio-Rad 5000201 
Human angiogenesis antibody array R&D Systems 893313 
CellTiter-Glo Luminescent Cell 
Viability Assay Promega G7570/ G9241 
Aurum™ Total RNA Mini Kit Bio-Rad 732-6820 
SimpleChIP® Plus Kit (Magnetic 
Beads) Cell Signalling  38191 
Endothelial Tube Formation Assay Cell BioLabs CBA-200 
iScript ™ cDNA Synthesis Kit  Bio-Rad 170-8890 
iScript ™ Select cDNA Synthesis Kit  Bio-Rad 170-8896 
Human Thrombospondin-1 
Quantikine ELISA Kit R&D Systems DTSP10 
Human CCL2 (MCP-1) ELISA 
Ready-SET-Go® 
Affymetrix 
ebioscience 88-7399-88 
MISSION® LightSwitch Luciferase 
Assay Reagent™ Sigma-Aldrich MLS0001-1KT 
QIAprep Spin Miniprep Kit Qiagen 27104 
 
 
 46 
2.2 Platelet and PMP isolation and characterization  
2.2.1 Isolation of platelets   
Platelets were harvested from whole blood using prostaglandin E1 as described 
previously by (Gidlof et al. 2013). The method uses prostaglandin E1 to inhibit 
platelet activation and ensure that platelet response to agonist stimulation is 
maintained during the process.  Venous blood was collected from healthy 
volunteers into a plastic syringe containing citrate-dextrose solution (ACD) 
(113mM glucose, 30mM Tri-sodium citrate, 73mM NaCl, 3mM citric acid, pH 6.4) 
as anticoagulant. ACD inhibits the coagulation cascade through chelating 
calcium and lowering the pH to 6.4. Platelet rich plasma (PRP) was prepared by 
centrifugation at 1000g for 25 min at room temperature and supernatant 
collected. PRP was centrifuged at 2500g for 12 minutes with the addition of 
50ng/ml prostaglandin, which inhibit platelet aggregation through cAMP 
elevation and subsequent inhibition of calcium mobilization.  Following 
centrifugation, the platelet pellet was re-suspended in 2.6 ml Hepes-Tyrode 
buffer (150mM NACL, 5mM HEPES, 0.55mM NaH2PO4, 7mM NAHCO3, 2.7mM 
KCL, 0.5mM MgCL2, 5.6mM glucose, pH 7.4). Resuspension in 2.6 ml Hepes-
Tyrode ensured optimal platelet number for the activation stage. Platelet yield 
was determined with haemocytometer by counting 10 small squares within the 
middle square of the haemocytometer and the sum multiplied by the volume of 
each small square (0.004) and the dilution factor. Platelets were used for PMP 
isolation after 60 minutes recovery from prostaglandin treatment. 
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Equation 1  
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2.2.2 Isolation of platelet micro-particles 
Platelets micro-particles (PMPs) were isolated as previously described by 
(Gidlof et al. 2013). Washed platelet suspensions were activated with the 
agonist thrombin (0.1U/ml) for 60 minutes at 37oC with gentle agitation. 
Thrombin cleave protease-activated receptors to initiate coagulation signalling 
and activate platelets (Brass 2003). To ensure effective pelleting of platelets and 
removal of supernatant containing PMPs without cell contamination, platelet 
activation was stopped with the addition of EDTA (20mM) to a final volume of 3 
ml. EDTA act by chelating extracellular calcium required for integrin αIIb/β3 
activation. The mixture of platelet suspension and EDTA was centrifuged with 
50ng prostaglandin at 3200g for 10 minutes to prepare a platelet free releasate. 
The resulting supernatant was split into equal 1ml volumes that can fit in a sticky 
1.5ml Eppendorf tube, and PMPs isolated by centrifugation at 18,000g for 90 
minutes at 18oC. The PMP pellet was then resuspended in 1ml of Hepes-Tyrode 
buffer. For experiments needing stained PMPs, washed platelets were 
incubated with 0.2μM 3,3'-Dihexyloxacarbocyanine Iodide (DiOC6) for 25 
minutes before thrombin activation and isolation of PMP as described above. 
DiOC6 is a permanent fluorescent dye that bind to cell’s vesicle membranes 
through its hydrophilic groups (Fath and Burgess 1993). The PMP sample was 
snap frozen and stored in -80oC for use in experiments. The protein content was 
measured using Bradford assay and cell origin quantified using flow cytometry 
as described below (Sections 2.2.3-2.2.4). 
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2.2.3 Flow cytometry to confirm cell origin of PMP 
The flow cytometry analysis was performed in the centre for skin sciences by Dr 
Andrei Mardaryev. The size and proportion of platelets and PMP in the samples 
were quantified by flow cytometry. Platelets or PMPs (1ml) were diluted in 100 
ml PBS and incubated in the presence of APC-conjugated mouse IgG (isotope), 
Allophycocyanin (APC)-conjugated anti-human CD41a (BD Biosciences) or 
Fluorescein (FITC)-Annexin-V and CD31-anti-FITC for 30 minutes, which binds 
to CD41a, phosphatidylserine, and CD31, respectively. Anti- CD41a bind to the 
calcium-dependent GPIIb/IIIa (Von dem Borne et al. 1989) found on platelet 
precursors and platelets where it mediate platelet adhesion and aggregation 
(Hogg 1997). Phosphatidylserine and platelet endothelial cell adhesion 
molecular (CD31) are surface markers for MP (Marguet et al. 1999, Nomura et 
al. 2001). Following incubation, the samples were diluted to a final volume of 
500mL in PBS and analysed cytometricaly using a forward-scattered light and 
side-scattered light (BD Biosciences) mounted on CyAn ADP analyzer flow 
cytometer (Beckman Coulter). The cytometer was calibrated and gated by size 
before   all   data   acquisition. Forward scatter is proportional to the diameter of 
the PMPs or platelets and side scatter equates to the granularity of the platelets 
or PMPs (Huh et al. 2005).  
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2.3 Cell culture  
Human umbilical vein endothelial cells (HUVEC) and human endothelial cell line 
EAhy926 cells were obtained from the ethical tissue bank (University of 
Bradford). Human embryonic kidney cells 293T (HEK 293) cell line was obtained 
from the centre for skin sciences (University of Bradford). For HUVEC, the 
cobblestone morphology of endothelial cells was observed (Figure 2.1), and 
cells were used below passage 8. 
 
 
Figure 2.1: Representative morphology of HUVEC. (A) Phase contrast 
microscope of confluent HUVEC (magnification of x40), (B) Fluorescent image 
of HUVEC stained with 1uM Calcein AM (magnification of x100). 
 
The functional characteristics of EAhy926 cell line, including morphology and 
genetic features are well described (Edgell et al., 1990; Gifford et al., 2004; 
Unger et al., 2002). Moreover, the genetic and functional characteristics of HEK 
293T are well characterised (Shaw et al. 2002). During normal culture periods, 
cells were incubated at 37°C in a humidified 5% CO2 enriched atmosphere 
(SANYO cell culture incubator).  
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HUVEC were cultured as a monolayer in 75-cm2 flasks (Corning) in Medium 200 
(Life Technologies) supplemented with Low Serum Growth Supplement (LSGS) 
kit (2% v/v foetal bovine serum, (1µg/ml) hydrocortisone, 10ng/ml human 
epidermal growth factor, 3ng/ml basic fibroblast growth factor, 10µg/ml heparin, 
and 50-units/ml penicillin:50-ug/ml streptomycin or Endothelial cell growth 
medium (PromoCell) supplemented with endothelial cell growth supplement kit 
(2% v/v fetal calf serum, 0.4% endothelial cell growth supplement, 1µg/ml 
hydrocortisone, 0.1ng/ml human epidermal growth factor, 1ng/ml basic fibroblast 
growth factor, 90µg/ml heparin, and 50-units/ml penicillin:50-ug/ml streptomycin. 
EAhy926 and HEK 293T cells were cultured as a monolayer in 75-cm2 flasks 
(Corning) in DMEM (Life Technologies) supplemented with 10% foetal bovine 
serum (FBS) (Life Technologies), 50-units/ml penicillin, 50-ug/ml streptomycin 
(Life Technologies) and 200mM L- glutamine (Life Technologies). Cells were 
observed three to four times weekly and at every media change (every 2-3 
days), for normal growth by phase contrast microscopy. For confluent HUVEC 
and EAhy926 cells, medium was aspirated and cells washed twice with 
phosphate buffered saline (PBS) (mmol/L: 137 NaCL, 2.7 KCl, 10 Na2HPO4, 1.8 
KH2PO4), thereafter cells were trypsinised and passaged into a 1:4 dilutions in 
the appropriate medium. For confluent HEK 293T cells, medium was aspirated 
and flask agitated by gentle hitting, thereafter cells were resuspended and 
passaged into 1:3. Cell counts were determined following using the 
haemocytometer.  
 
 51 
For experiments requiring low supplements, culture media was removed and the 
cells were washed in phosphate-buffered saline (PBS) and bathed in either 
Medium 200 with 2% v/v foetal bovine serum (HUVEC experiment medium); or 
DMEM without serum (EAhy926 experiment medium) (Life Technologies). Cells 
were cultured in a humidified 5% CO2-enriched atmosphere (SANYO) for 24 
hours prior to experimentation. In experiments with HUVEC or requiring 
transfection, cells were bathed in experiment medium and incubated for 3 hours 
prior to experimentation.  
2.3.1 Cell transfection for loss or gain of function analysis  
The loss of function effect of miRNA was investigated by transfecting inhibitors 
using Lipofectamine 3000 reagent (Life Technologies). Transfection using 
Lipofectamine 3000 is based on the cationic lipid delivery of nucleic acid into 
eukaryotic cells (Chesnoy and Huang, 2000; Hirko et al., 2003; Liu et al., 2003). 
The cationic lipids are designed to have a positive charged head group and 
hydrocarbon chain, where the charged group interacts with the phosphate 
backbone of nucleic acid and the negative charge on the cell membrane to elicit 
endocytosis. In this biological process, the siRNA/liposome or DNA/liposome 
complex is deposited into the cells through a membrane bound/intracellular 
vesicle. On the transfection day, Let-7a inhibitor (ActiveMotif) or non-targeting 
inhibitor (ActiveMotif) were diluted in Opti-MEM media. For 6 well culture plates 
(5x105 cells/well), 90pmol each of combined Let-7a-3p and Let-7a-5p inhibitor or 
120pmol of non-targeting inhibitor were prepared in Opti-MEM. Lipofectamine 
3000 Reagent was diluted to 1:50 in Opti-MEM media and mixed with the diluted 
miRNA inhibitors at 1:1 ratio. The mixture was incubated for 15 minutes at room 
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temperature and added to HUVEC cells at a final concentration of 90pmol. 
miRNA inhibitors contains chemically modified, single strand RNA sequence that 
recognise and bind to the sequence of a mature miRNAs to inhibit their function, 
based on the sequence complementarity with the target mRNA. Chemical 
modification of either the sugar or the linkages of the nucleotide improve binding 
affinity and reduce degradation by endogenous nuclease.  
 
Transfected cells were cultured in normal conditions, as described in section 
2.3.1 for 24 hours before removing the transfection media. Cells were starved 
for 3 hours in experimental medium before trypsinisation and treatment with 
1µg/µl PMP. For receptor inhibition experiments, trypsinised cells were held in 
suspension in experimental growth medium in the presence of antibodies; 
2µg/ml CD47, 2µg/ml CD29, or combined 2µg/ml each of CD47 and CD29 for 1 
hour at 37°C in a humidified 5% CO2-enriched atmosphere. The effect of Let-7a 
inhibition on THBS-1 and MCP-1 prior to PMP treatment was determined by 
performing ELISA on the transfection media collected after 24 hours. 
 
The effect of overexpressing Let-7a miRNA (gain of function) was investigated 
by transfecting pmiR expression plasmid with Lipofectamine 3000 reagent (Life 
Technologies). On the transfection day, Let-7a expression plasmid or empty 
expression plasmid were diluted in Opti-MEM media and P3000 reagent. For 24 
well culture plates, 1µg of Let-7a expression plasmid or empty expression 
plasmid were prepared in Opti-MEM and 2µl P3000 reagent to a final volume of 
25 µl. Lipofectamine 3000 Reagent was diluted to 0.75:250 in Opti-MEM media 
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and mixed with the diluted expression plasmids at 1:1 ratio. The mixture was 
incubated for 5 minutes at room temperature and added to HUVEC cells at 75 – 
85% confluence. The sequence of the transfected inhibitors are presented in 
Figure 2.4. Expression plasmids are independent, circular and self-replicating 
DNA molecule that produces the mRNA product of the inserted gene. 
Incorporation of sequence for a fluorescent protein provides a quantifiable 
measure of gene expression and activity. Transfected cells were cultured in 
normal conditions, as described in section 2.3.1 for 24 hours before removing 
the transfection media. Cells were starved for 4 hours in experimental medium 
before trypsinisation and culture on well plates coated with Matrigel. The effect 
of Let-7a inhibition on MCP-1 treatment was determined by performing ELISA 
on the transfection media collected after 24 hours. 
 
Table 2.4: List of microRNA inhibitors and sequence.  
Inhibitor  Supplier  Catalogue  Sequence 
Non-
Targeting 
miRNA 
Inhibitor V2 
Active 
Motif  INH9002 5’ UUGUACUACACAAAAGUACUG 3’ 
Hsa-let-7a-
3p Inhibitor  
Active 
Motif  INH0002 5’ CUAUACAAUCUACUGUCUUUC 3’ 
Hsa-let-7a-
5p Inhibitor  
Active 
Motif  INH0002 
5’ UGAGGUAGUAGGUUGUAUAGUU 
3’ 
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2.3.2 Cell transfection to measure reporter gene signal 
The effect of Let-7 miRNA on reporter of THBS-1 3’UTR was investigated by co-
transfecting 3’UTR, miRNA expression vector and inhibitors using FuGENE HD 
reagent (ActiveMotif) and Lipofectamine 3000 reagent (Life Technologies), 
details of the expression plasmids are presented in section 2.6.2. Transfection 
using FuGENE HD is based on a non-liposomal proprietary reagent that directly 
deliver reagent/DNA complex into cells. On the transfection day, 3’UTR (30µg/µl 
stock), expression vector (20µg/µl stock) or Let-7a inhibitor or non-targeting 
inhibitor (5nmol stock) were diluted in reduced serum Opti-MEM media as 
described in cell culture section. For 96 well culture plates, 600µg of plasmid 
DNA 3’UTR, 200µg of miRNA expression plasmid or 800µg combined 3’UTR 
and miRNA expression vector plasmids (3:1 ratio of 3’UTR to miRNA expression 
vector) were diluted in 97µl of Opti-MEM and mixed with 3µl of FuGENE HD 
reagent. The mixture was incubated for 10-minutes at room temperature and 
added to HEK 293T cells at 75 – 85% confluence. Transfected cells were 
cultured in normal conditions, as described in section 2.3.1 for 12 hours before 
the transfection of Let-7a inhibitor or non-targeting inhibitor as described before 
2.3.1. Cells were cultured for additional 2 hours before treatment with 100µg/ml 
PMP and cultured for 15 hours in normal culture conditions. The culture media 
was removed and plates frozen for at least 6 hours to improve cell lysis before 
reporter assay experiments. 
2.3.3 Immunocytochemistry analysis of PMP internalisation 
The internalisation of PMP by endothelial cells was investigated by treating 
HUVEC cells with DioC6 stained PMP before visualisation using a fluorescent 
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microscope. HUVEC cells (1 x 105 cells per well) seeded on a cover slip in 
normal endothelial growth medium were treated with 100μg/ml of DiOC6 stained 
PMPs for 6, 12 or 18 hours. Cells were washed with PBS, fixed with 4% 
paraformaldehyde for 10 minutes, stained with 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) and imagined with a fluorescent microscope. DAPI 
produces strong blue fluorescent staining of the nucleus because of its ability to 
pass through an intact cell membrane and bind to A-T rich regions of the DNA 
(Kapuscinski 1995). 
 
2.4 Endothelial Cell Functional assays 
2.4.1 Endothelial Cell Tube Formation Assay  
The Endothelial Tube Formation Assay Kit (Cell Biolabs) or Geltrex 
(ThermoFisher) were used to quantify angiogenic tube formation and vessel 
sprouting based on the principle of proteolysis of the extracellular matrix 
(Goodwin 2007). The degradation of extracellular matrix promote the activation 
of angiogenic proteins, release of growth factors and subsequent angiogenesis, 
summarised in Figure 2.2 (Goodwin 2007). The extracellular matrix gel (ECM 
gel) was thawed at 4oC overnight to avoid rapid polymerisation and degradation 
of growth factors contained in the gel. Sterile 96-well cell culture plates were 
coated with a thin layer of ECM gel (50μL/well) and left to polymerize at 37oC for 
60 minutes. HUVEC or EAhy926 cells (2 x 104 cells/mL) in experiment medium 
were added to each ECM coated well and were treated with 100μl PMPs diluted 
in the appropriate experiment medium. Cells in 10% serum supplemented 
DMEM (EAhy926), untreated cells or transfected untreated cells were setup as 
positive and two negative controls, respectively. For Let-7a expression 
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experiment, 2 x 104/mL untransfected HUVEC, HUVEC transfected with Let-7a 
expression plasmid or empty expression plasmid in experiment medium were 
added to ECM coated well. The plates were incubated at 37oC, for 18 hours and 
tube formation was observed with Evos fluorescent microscope (Life 
Technologies) after staining with 1μM Calcein AM (Cell Biolabs). Four 
microscope fields were selected at random and photographed. Total tube length 
and the number of individual branch points per field under x40 magnification was 
used to quantify tube-forming ability. The quantification was performed with 
AngioTool software (National Cancer Institute, United States). The length of tube 
and branch points was expressed in micrometre and arbitrary numbers, 
respectively. 
 
Figure 2.2: Principle of in-vitro angiogenesis. PMP mediate endothelial cell 
release of cytokines and enzymes that cause the breakdown of the Matrigel, 
sprouting of cells, migration and reorganisation to form capillary like structures.  
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2.4.2 Proliferation assay with CellTiter-Glo  
The CellTiter-Glo luminescent Cell Viability Assay kit or CellTiter-Glo 2.0 kit 
(Promega) was used to measure EC proliferation. This assay is based on the 
reaction of thermostable luciferase with ATP, which generates a stable glow-
type luminescent signal (Crouch et al. 1993). The CellTiter-Glo reagent can be 
added directly to cultured cells and the luminescent signal can be measured with 
a plate reader. The resulting luminescent signal is proportional to ATP present in 
the medium and represents metabolically active cells. HUVEC or EAhy926 cells, 
suspended in 100μl medium were seeded into black or white 96-well plates at 
2000 cells per well in triplicate. Cells were then treated with 100μg/ml of PMPs 
diluted in 100μl experiment medium, then cells were incubated at 37oC in a 
humidified 5% CO2 atmosphere for up to 72 hours. After 0, 24, 48 or 72-hours 
incubation, 200μl of CellTiter-Glo reagent was added to the wells and incubated 
for 30 minutes at room temperature. Thereafter, the resulting luminescent signal 
was measured with a plate reader (Promega-GloMax). The Luminescence 
readings of the blank wells were subtracted from the luminescence of all 
treatment well, giving a relative proliferation rate for every treatment group.  
2.4.3 Luciferase assay to measure reporter gene signal 
The LightSwitch Luciferase Assay Reagents (ActiveMotif) was used to measure 
Renilla luminescent reporter gene (RenSP) signal. This assay is based on the 
oxidation of coelenterazine substrate by RenSP to generate light at 480nm (Hori 
et al. 1973). The Luciferase reagent can be added directly to the cultured cells 
and luminescent signal measured with a plate reader. The resulting luminescent 
signal is proportional to the products of the expression plasmid. HEK 293T cells 
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suspended in 100μl medium were seeded into black or white 96-well plates at 
15000 cells per well in replicates. Cells were transfected with plasmids as 
described above in section 2.3.2 and incubated at 37oC in a humidified 5% CO2 
atmosphere for 30 hours. After freezing, 100μl of luciferase reagent diluted to 
1:1 ratio in PBS was added to the wells and incubated for 30 minutes at room 
temperature. Thereafter, the resulting luminescent signal was measured with a 
plate reader (Promega-GloMax). The luminescence readings of the targeting 
transfection were normalised to the respective non-targeting controls, giving a 
percentage ratio of targeting to non-targeting signal (Equation 2).  
Equation 2  
Luminescence	signal = Specific	signalnon − specific	signal 
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2.5 Protein analysis 
2.5.1 Protein quantification assay with Bio-Rad Bradford assay 
Following PMP isolation from venous blood, frozen PMP suspensions were 
thawed at room temperature and the concentration of solubilized protein in the 
sample measured by Bio- Rad Bradford assay kit following the manufacturer’s 
instructions. Moreover, all protein concentration measurements including whole 
cell extract and cell culture supernatant were measured as described below. The 
Bradford protein quantification assay is based on colorimetric change caused by 
binding of Coomassie Brilliant Blue G-250 dye to proteins (Bradford, 1976). The 
unbound dye is in the protonated red cationic form, which changes to 
unprotonated blue form when bound to proteins. Briefly, PMP suspensions were 
further homogenized by repeated aspiration through a sterile pipette tip (200ul). 
Four dilutions (1mg/ml, 0.5mg/ml, 0.25mg/ml and 0.125mg/ml) of BSA in PBS 
were prepared as standards. 5μl of each standard and sample suspension were 
pipetted into separate wells of 96-well plates in triplicate and 250μl of diluted 
Bio-Rad dye reagent (dye, phosphoric acid and methanol; Bio-Rad Laboratories) 
added to each well. The mixtures were incubated at room temperature for 5 
minutes and absorbance measured spectrophotometrically at wavelength 
595nm with microplate reader (Promega-GloMax). The resulting absorbance 
value was used to generate a protein standard curve and quantify PMP 
concentrations.  
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2.5.2 Protein array of angiogenesis related proteins 
To determine the level of angiogenic factors released by EC treated with PMP or 
cytokines bound to PMP surface, the antibody array method by R&D systems 
using the Human Angiogenesis Antibody Array and Cytokine panel A. The 
analysis helped to characterise the angiogeneic factors modulated by PMP or 
bound to PMP surface. The assay is based on a protein array technique where 
support surface of nitrocellulose membrane coated with purified antibodies and 
fluorescent-labelled proteins from samples are added to the membrane, 
summarised in Figure 2.3 (Kane et al. 2010). Physical interaction between the 
capture protein and sample proteins emit luminescent signals that are visualized 
using X-ray film or automated documentation machine. This membrane contains 
positive controls (3 x 2 spots), negative controls (1 x 2 spots) and 55 x 2 spots 
for determining known angiogenic proteins, see (table 2.1).  
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Figure 2.3: Protein array method. Interaction between capture and sample 
proteins produce light signal, (adapted from product insert). 
Table 2.5: List of Proteins probed. The actual protein sequence probed are 
described in the product information sheet. 
Activin A FGF-7/KGF PD-ECGF 
ADAMTS-1 GDNF PDGF-AA 
Angiogenin GM-CSF PDGF-AB/PDGF-BB 
Angiopoietin-1 HB-EGF Persephin 
Angiopoietin-2 HGF CXCL4/PF4 
Angiostatin/Plasminogen IGFBP-1 PIGF 
Amphiregulin IGFBP-2 Prolactin 
Artemin IGFBP-3 Serpin B5/Maspin 
Tissue Factor/Factor III IL-1 beta Serpin E1/PAI-1 
CXCL16 CXCL8/IL-8 Serpin F1/PEDF 
DPPIV/CD26 LAP (TGF-beta 1) TIMP-1 
EGF Leptin TIMP-4 
EG-VEGF CCL2/MCP-1 Thrombospondin-1 
Endoglin/CD105 CCL3/MIP-1 alpha Thrombospondin-2 
Endostatin/Collagen XVIII MMP-8 uPA 
Endothelin-1 MMP-9 Vasohibin 
FGF acidic NRG1-beta 1 VEGF 
FGF basic Pentraxin 3 VEGF-C 
FGF-4   
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The detection of the above proteins (Table 2.5) were carried out according to the 
User Manual, R&D Systems, human angiogenesis Antibody Array. The antibody 
immuno complexes that were formed on the appropriate spots with different 
intensities were visualized by peroxidase-conjugated streptavidin and substrate 
(ECL1: luminol, P- coumaric and 1M Tris base pH 8.5, ECL2: 30% hydrogen 
peroxide 1 M pH 8.5). The resultant membrane with visible spots of variable 
intensity was captured using G-Box (Gel documentation and analysis, Syngene) 
using the ECL settings and analysed densitometrically. The quantification was 
carried out using the Gel plugin on Image J v1.49 software (National Institutes of 
Health, United States). Additional comparative analysis was performed with 
ImageStudioLite software (LI-COR Biosciences). The level of individual protein 
was expressed as pixel density and analysed statistically.  
 
2.5.3 Enzyme-linked Immunosorbent Assays (ELISA) 
ELISA is invaluable in proteomics, where the specificity of antibodies is 
incorporated with the sensitivity of enzyme activity to quantify absolute amount 
of proteins. The assay is based on coupling easily assayed enzymes to 
antibodies or antigens to detect measurable signals. Normal HUVEC, cells 
transfected with Let-7a inhibitor or transfected with non-targeting inhibitor 
sequence (2x104 cells/well) were treated with 100μg/ml of PMP or left untreated 
for 24 hours. The medium was collected and stored at -20oC till further use. 
Medium from different functional assays were collected, pooled into three sets 
and analysed. 
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2.5.3.1 ELISA for THBS-1 
The concentration of THBS-1 was analysed using the Human Thrombospondin-
1 Quantikine ELISA Kit (R&D Systems). Prior to assay procedure, samples were 
diluted to 2-fold using the calibrator diluent. Likewise, 7 standard concentrations 
(ng/ml: 500, 250, 125, 62.5, 31.3, 15.6, 7.81) were prepared with the calibrator 
diluent. All reagents and samples were brought to room temperature, before 
sequential addition of 100µL of assay diluent and 50µL of standard, control, or 
sample to each well. Plate were sealed and incubated at room temperature for 
2-hours with shaking. The wells were aspirated and washed four times with 
wash buffer. Thereafter, wells were incubated with 200µL of conjugate at room 
temperature for 2-hours on the shaker, then aspirated and washed four times 
with wash buffer. Finally, wells were incubated with 200µL substrate solution in 
the dark at room temperature for 30 minutes, and reaction stopped with 50µL of 
stop solution. For both ELISA procedures, fluorescence signal was measured at 
450nm and corrected with measurement at 570nm (Tecan). The standard curve 
was plotted and protein concentration determined using excel spread sheet. 
 
2.5.3.2 ELISA for MCP-1 
MCP-1 levels were assessed with the Human CCL2 (MCP-1) ELISA Ready-
SET-Go® (eBiosciences). Nunc Maxisorp® ELISA plate was coated with 100μL 
of capture antibody diluted in 1X coating buffer, sealed and incubated overnight 
at 2-8°C. Prior to assay procedure, samples were diluted to a 2-fold and 7 
standard concentrations (pg/ml: 25, 50, 100, 200, 400, 600, 1200) were 
prepared with the 1X ELISA/ELISPOT diluent. The wells were aspirated and 
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washed three times with wash buffer. Then, wells were blocked with 200μL of 
1X ELISA/ELISPOT at room temperature for 1-hour, aspirated and washed once 
with Wash Buffer. 100µL of standard, control, or sample was added to each 
well, sealed and incubated at room temperature for 2 hours with shaking. The 
wells were aspirated and washed five times with wash buffer, before the addition 
of 100μL of detection antibody diluted in 1X ELISA/ELISPOT diluent. Thereafter, 
wells were aspirated ad washed as described above. Incubated with 100µL of 
Avidin-HRP diluted in 1X ELISA/ELISPOT Diluent at room temperature for 30 
minutes on the shaker, then aspirated and washed seven times. Finally, wells 
were incubated with 100μl of 1X TMB solution in the dark at room temperature 
for 15 minutes, and reaction stopped with 50µL of stop solution.  
 
 2.5.4 SDS-PAGE and Western blot analysis  
The effect of PMP treatment on ATF-4, Histone-3 and caspase-3 levels in EC 
was investigated by immunoblotting. HUVEC transfected with Let-7a inhibitor or 
non-targeting inhibitor sequence (2x105 cells/well) were treated with 100ug/ml of 
PMP or buffer control for 24 hours. Cells were lysed on ice in 300μl lysis buffer 
(0.25M Tris-HCl, pH 6.8, 3.75mM sodium pyrophosphate, 32mM EDTA, 5% w/v 
SDS and 15ul β-mercaptoethanol), and the proteins were degraded by boiling at 
100oC for 5 minutes in the presence of β-mercaptoethanol. β-mercaptoethanol 
cleave disulphide bonds between cysteine residues to disrupt the quaternary 
and tertiary structure of the proteins, which allows the migration by size. The 
addition of protease inhibitor cocktail reduces the degradation by endogenous 
proteases released by lysed cells. Approximately, 30μg in 30μl per lane, with 
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0.01% bromophenol blue or 10μl of pre-stained protein ladder (Cell signalling) 
were separated by 10% sodium dodecyl sulphate- polyacrylamide gel 
electrophoresis (SDS-PAGE). The electrophoresed protein was transferred to a 
PVDF membrane (pores size 0.2µm, Bio-Rad, United Kingdom), for 90 minutes 
at 100 volts on ice. Then, non-specific binding was blocked with 5% BSA in 
TBS-T (mM: 150 NaCl, 20 Tris, pH 7.6, and 0.1% Tween 20) for 1-hour at room 
temperature with gentle shaking. The membrane was washed for 5 minutes with 
TBS-T with gentle shaking, before incubation with the appropriate primary anti-
body in 5% BSA (Sigma-Aldrich) in TBS-T (Table 2.6) overnight at 4oC. 
Immediately, the membrane was washed thrice (5 minutes per wash) with TBS-
T (in mM: 150 NaCl, 20 Tris, pH 7.6, and 0.1% Tween 20). The washed 
membrane was incubated with the appropriate horseradish peroxidase 
conjugated secondary antibody (table 1) in 5% non-fat milk (diluted in TBS-T) for 
1-hour at room temperature. Following three additional 5-minutes washes with 
TBS-T, the immune-reactive bands were visualized using the enhanced 
chemiluminescent (ECI) substrate (ECL1: luminol, P-coumaric and 1M Tris base 
pH 8.5, ECL2: 30% hydrogen peroxide 1M pH 8.5). The addition of this 
peroxide-based reagent facilitates oxidation of luminol resulting in the emission 
of light, which was captured with an imaging system (G:Box, Gel documentation 
and analysis, Syngene) or x-ray film. The densitometry of the bands was 
quantified using the ImageStudioLite (LI-COR Biosciences).  
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Table 2.6: Details of primary and secondary antibodies and dilution 
factors. 
Antibody Host Dilution Manufacturer 
ATF-4 Rabbit 1:500 Cell Signalling 
Histone H3 Rabbit 1:1000 Cell Signalling 
Caspases 3 Rabbit 1:1000 SIGMA 
Anti-Rabbit IgG Goat 1:2000 SIGMA 
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2.6 Manipulation of Nucleic acids 
2.6.1 RNA degradation experiments with RNAse Treatment 
To investigate the effectiveness of RNA degradation process used for functional 
assays, PMPs were treated with RNAse A (1U/ml) in 37oC for 60 minutes and 
reaction stopped by RNAse inhibitor (10 U/ml) for 5 minutes (Gidlof et al. 2013).  
2.6.1.1 RNA Isolation for degradation analysis  
Total RNA was isolated from PMPs treated with RNAse or non-treated control 
PMP using Trizol reagent (Invitrogen) according to manufacturer’s instructions. 
Initially, 750μl of Trizol reagent was added to 250μl of PMP sample and lysed by 
brief vortex. The homogenized PMPs and Trizol reagent mixture were incubated 
at room temperature for 5-minutes to allow complete dissociation of protein 
complexes. After incubation, 150μl of lysed PMP sample were added and 
incubated for 3 minutes at room temperature. Then, the mixture was centrifuged 
for 15 minutes at 12,000g at 4oC. Following centrifugation, the colourless 
aqueous phase was transferred to a new tube and incubated at room 
temperature for 10 minutes in the presence of 375 μl isopropanol (100%). The 
mixture was then centrifuged at 12,000g for 10 minutes at 4oC. Then, the 
supernatant was discarded and the RNA pellet washed in 1000μl of 75% 
ethanol. The RNA pellet was vortexed and centrifuged at 7500g for 5 minutes at 
4oC. The ethanol was discarded and RNA pellet was air-dried for 5-10 minutes. 
Finally, the washed RNA pellet was resuspended in 20-50μl of nuclease free 
water and incubated for 15 minutes at 60oC.  
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2.6.2 Bacterial culture for plasmid preparation 
To investigate the effect of Let-7a expression on reporter THBS-1 3’UTR and 
angiogenic response. Precursor Let-7a expression plasmid was prepared from 
glycerol stock purchased from (Vigene biosciences) cloned and empty plasmid 
maps are shown in Figure 2.4. The THBS-1 3’UTR vector was purchased ready 
to transfect from Activemotif, and the vector map is shown in Figure 2.5 and the 
cloned sequence of THBS-1 3’UTR shown in the appendix.  
 
 
Figure 2.4: Schematic representation of Human let-7a-2 in pMIR Plasmid 
Vector and empty expression plasmid (provided by the supplier, Vigene 
biosciences). 
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Figure 2.5: Schematic representation of the human THBS-1 3’UTR vector. 
Full inserted sequence is shown in the appendix (provided by the supplier, 
Activemotif). 
 
2.6.2.1 Bacterial culture for Plasmid DNA isolation with Qiagen miniprep 
For the precursor Let-7a expression plasmid, the bacterial stock was grown 
Luria-Bertani (LB) agar plate containing 40ug/ml kanamycin (Sigma-Aldrich). 
The expression plasmid has kanamycin resistant gene to facilitate selective 
culture. Bacteria streaked agar plate was incubated overnight at 37oC before 
transferring a single bacteria colony to a 15ml Falcon tube containing 2ml LB 
broth with 40ug/ml kanamycin. The tube was then incubated overnight at 37oC 
and 250 revolution per minutes (rpm). Thereafter, the LB broth culture was 
centrifuged at 13000g for 10-minutes at 4oC and bacteria pellet re-suspended in 
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buffer P1 (Qiagen), with RNAse A. Bacteria was lysed with buffer P2 for 5 
minutes and precipitated with cold buffer P3 at room temperature for 15 minutes. 
Precipitated lysate was centrifuged at 20000g for 30minutes at 4oC before 
removing the supernatant containing plasmid DNA. Additional centrifugation of 
the supernatant at 20000g for 15minutes at 4oC was performed to clarify the 
plasmid DNA before passing the sample through buffer QC equilibrated Qiagen 
tip. Plasmid DNA was eluted with buffer QF and precipitated with 0.7 volumes of 
isopropanol at room temperature. Thereafter, the mixture was centrifuged at 
13000g for 30minutes at 4oC and supernatant discarded. Plasmid DNA pellet 
was washed with 70% ethanol, centrifuged at 15000g for 10minutes at 4oC. 
Supernatant was discarded without disturbing the pellet and air-dried for 
10minutes in a culture hood to avoid contamination. The dried plasmid DNA was 
suspended in filter sterilised TE buffer (pH 8.0) and stored at -80oC till further 
use. DNA concentration and quality was determined by spectrophotometer and 
agarose gel electrophoresis as described before.  
 
2.7 Gene expression analysis  
The effect of PMP treatment on Let-7a expression and role of Let-7a PMP 
mediated changes in gene expression was investigated by quantitative reverse 
transcriptase real-time PCR (qRT-PCR).  
2.7.1 Total RNA extraction  
Total RNA used for cDNA preparation or cDNA library construction was 
extracted from treated cells in 6 well plates (2x105) or from platelets from 30mls 
venous blood (~2x109 cells/ml), respectively. The Aurum total RNA Mini kit (BIO-
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RAD) was used for both samples, based on RNA binding to solid phase silica 
under optimal pH and slat concentration. HUVEC, cells transfected with Let-7a 
inhibitor or transfected with non-targeting inhibitor sequence (2x105) were 
treated with 100ug/ml of PMP or buffer control for 24 hours. Cells were washed 
with sterile PBS and lysed in 350μl lysis buffer supplemented with 1% β-
mercaptoethanol. The addition of β-mercaptoethanol facilitates the degradation 
of intracellular RNases released during cell lysis, which promotes the recovery 
of high quality RNA sample. This reducing agent, combined with guanidinium 
isothiocyanate present in the lysis buffer denatures RNases, through the 
reduction of disulphide bonds and irreversible destruction of the functional 
conformation of RNases. Cells were homogenized by repeated pipetting (with 
1ml pipet tips) before the addition of 350μl of 70% ethanol to the lysate and 
further homogenization. The lysates were poured into an RNA binding column 
placed in a cap-less wash tube and centrifuged for 30seconds at 14000g. Flow 
through was discarded and column washed with 700μl of low stringency solution 
for 30 seconds at 14000g. Thereafter, DNA contaminates were degraded by 
treating bound nucleic acid with 80μl DNase1 (diluted to 1:15 (v/v) DNase1 
dilution solution) for 15 minutes at room temperature. DNase hydrolyses the 
phosphodiester linkages of DNA backbone that holds nucleotides together. 
Then, the column was washed consecutively with 700μl of high stringent and 
low stringent solution for 30seconds each, at 14000g. Washed column was dried 
with further 60seconds centrifugation at 14000g, and transferred to a nuclease-
free 1.5ml microfuge tube. Then, the purified RNA was incubated with 50μl of 
elution buffer for 1minute at room temperature and eluted with centrifugation for 
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2minutes at 14000g. The RNA samples were quantified as described below 
(section 2.7.2) before immediate synthesis of first strand cDNA or stem-loop 
cDNA, cDNA library construction for RNA-seq or storage at -80oC.  
2.7.2 Quantification of RNA for polymerase chain reaction and RNA sequencing  
Total RNA concentration was quantified by spectrophotometry, using the 
(NanoPhotometer P330, Implen GmbH, Munich, Germany) programmed to 
measure the concentration of RNA or DNA at 0.2mm path length. Thereafter, 
the spectrophotometer was blanked using 3.5μl of elution buffer pipetted onto 
the measuring window. Likewise, the concentration was measured at 260nm 
(RNA) and 280nm (DNA) in μg/ml. The RNA purity was considered good at 260-
nm/280 nm ratio of 1.8-2.2 (Rodrigo et al. 2002). The RNA concentration was 
determined based on the equation 2: 
 
Equation 2 
RNA	concentration	(µg/ml) 	= 	44	(µg/ml)	x	A260	x	Dilution	factor 
Where, 44 μg of RNA per ml corresponds to absorbance reading of 1 unit at 260 
nm.  
Equation 2.1 
Total	amount	of	RNA	(µg) 	= 	Concentration	(µg/ml)	x	volume	of	samples	(ml) 
2.7.3 First strand cDNA synthesis for standard polymerase chain reaction 
First strand cDNA was generated using iScript cDNA Synthesis Kit (BIO-RAD). 
In-vitro cDNA synthesis is based on RNA-dependent DNA polymerase of single 
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strand RNA molecule. Briefly, reactions were set up in a nuclease-free 200μl 
PCR tube by mixing 5x iScript reaction mix (4μl) (containing; RNase H+, RNase 
inhibitor, deoxy-thymidine nucleotides (oligo(dT)) and random hexamer primers), 
nuclease-free water (up to 20μl), RNA (400ng) and 1μl iScript reverse 
transcriptase (from Moloney murine leukemia virus). Oligo(dT) binds to the poly-
A tail to provide a 3’-OH end that is extended by the reverse transcriptase. In 
each set of samples extra tube of no reverse transcriptase negative control was 
prepared as above, where reverse transcriptase was replaced with 1μl of water. 
The reaction tubes were incubated in thermal cycler as follows;  
§ Primed with random hexamer primer and Oligo(dT) at 25 ̊C for 
5 minutes.  
§ RNA template was reverse transcribed at 42 ̊C for 30 minutes. 
§ The reverse transcriptase was inactivated at 85 ̊C for 5 
minutes. 
 The cDNA samples were stored at -80 ̊C till use in downstream application. 
2.7.4 Stem loop cDNA synthesis for miRNA polymerase chain reaction 
Stem loop cDNA was generated using iScript Select cDNA Synthesis Kit (BIO-
RAD). Stem loop cDNA synthesis mitigates the challenge of transcribing short 
miRNA sequence of 17 – 24 nucleotides (nt) in length. The RT-primer contains a 
highly stable stem-loop structure that lengthens the target cDNA, and promote 
specific and efficient amplification of target sequence. Briefly, reactions were set 
up in a nuclease-free 200μl PCR tube by mixing 5x iScript reaction mix (4μl) 
(containing; RNase H+, RNase inhibitor and deoxynucleotide (dNTPs)), let-7a, 
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miR-221 and U6S stem loop primers at a concentration of (400nM) each, gene 
specific primer enhancer solution (2μl), nuclease-free water (up to 20μl), RNA 
(400ng) and 1μl iScript reverse transcriptase (from Moloney murine leukemia 
virus). The proprietary gene specific enhancer solution improves cDNA yield and 
detection in downstream applications. Moreover, additional tube of no reverse 
transcriptase negative control was prepared as above, where reverse 
transcriptase was replaced with 1μl of water. The reaction tubes were incubated 
in thermal cycler as follows;  
§ RNA template was reverse transcribed at 42 ̊C for 30 minutes. 
§ The reverse transcriptase was inactivated at 85 ̊C for 5 
minutes (see Appendix for summary).  
The stem loop cDNA samples were stored at -80 ̊C till use in downstream 
application.
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2.7.5 Quantitative Real Time PCR (qPCR)  
SYBR Green dye was utilised in the quantification of primer amplification of both 
gene and miRNA analysis. SYBR Green is a fluorogenic dye that emits a strong 
fluorescent signal upon binding to double-stranded DNA, as opposed to low 
fluorescence in solution. The dye form complex with DNA through intercalation 
and external binding, which is supported by the biphasic dependence of 
increasing guanidinium hydrochloride on observed fluorescence intensities 
(Zipper et al. 2004). The qPCR assays were set up for first strand cDNA and 
stem loop cDNA as described below.  
 
2.7.5.1 qRT-PCR analysis of target miRNA (stem Loop) 
qRT-PCR reactions were set up for detection of Let-7a and miRNA-221 
expression using iQ SYBR® green supermix, as described by (Yoon et al. 
2011). The primer set are summarised in Table 2.8 and derived from (Yoon et 
al. 2011). The design of the primers involved the addition of extra nucleotides to 
the mature microRNA sequence. This serves to optimise the melting 
temperature and increase assay specificity. The universal reverse primer 
disrupts the stem loop formed during the cDNA synthesis. The qPCR master 
mixes were prepared by mixing 2x iQ SYBR® green supermix (10μl), Let-7a, 
U6S or miRNA-221 forward primers (400nM), universal reverse primer (400nM), 
nuclease-free water (to a final volume of 20μl). Thereafter, 5μl of stem loop 
cDNA was added to 15μl of Master mix described above in each well of Clear 
96-well PCR plate, briefly mixed and centrifuged using a benchtop plate 
centrifuge. Each reaction mix was set up in triplicate, on ice and assay 
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performed as described below in Step-one Real-Time PCR Detection System 
(Applied Biosystems):  
§ One cycle of initial denaturation and polymerase activation at 
95°C for 30 seconds.  
§ 40 cycles of denaturation at 95°C for 15 seconds followed by 
annealing and extension at 60°C for 30 seconds, with plate 
read. 
§ Final melt curve analysis from 65-95°C (+1°C increments, 5 
seconds/increment) with plate read. 
2.7.5.2 qRT-PCR analysis of target gene mRNA transcripts 
qPCR reactions were set up for expression analysis of THBS-1, PIGF, ATF-4, 
MCP-1 and GAPDH using Fast SYBR® Green Master Mix (Applied 
Biosystems), primer sets are summarised in Table 2.7, with sources of primer 
sequence. For primers not retrieved from literature, the design process is 
presented in section 2.10. Briefly, reaction Master Mix (MM) were prepared 
according to the following scale, 2x iTaq Universal SYBR Green Supermix 
(10μl), forward and reverse primers (300nM each), nuclease-free water (up to 
20μl) and 1μl of first strand cDNA per well of a Clear 96-well PCR plate on ice. 
Reactions were briefly mixed and centrifuged using a benchtop plate centrifuge. 
Each reaction mix was set up in triplicate and assay performed as described 
below in Step-one Plus Real-Time PCR Detection System: 
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§ One cycle of initial denaturation and polymerase activation at 
95°C for 30 seconds.  
§ 40 cycles of denaturation at 95°C for 15 seconds followed by 
annealing and extension at 60°C for 30 seconds, with plate 
read. 
§ Final melt curve analysis from 65-95°C (+1°C increments, 5 
seconds/increment) with plate read. 
2.7.5.3 Comparative CT Method for the analysis of qPCR results  
The amplification plot and melt curve were viewed using the step one-plus 
software and gene expression analysed using excel template based on the 
ΔΔCT (Livak) method. The method was implemented in excel in two steps.  
Equation 3 
             ΔCT (Basal or PMP treatments) = CT (Target) – CT (Reference) 
Equation 3.1 
              ΔΔCT = ΔCT (PMP treatments) – ΔCT (Basal) 
The ΔΔCT was used for statistical analysis and represented as relative 
expression.  
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Table 2.7: List of standard primers for gene expression analysis.  
Primer Forward/Reverse primer Sequence 
THBS-1 (Cui 
et al. 2015). 
F- 5’ CCAGATCAGGCAGACACAGA 3' 
R- 5’ TCACACTGATCTCCAACCCC 3' 
PIGF F- 5’ TGATCTCCCCTCACACTTTGC 3' R- 5’ CACCTTGGCCGGAAAGAA 3' 
ATF-4 
(Nemetski and 
Gardner 
2007). 
F- 5’ GACGGAGCGCTTTCCTCTT 3' 
R- 5’ TCCACAAAATGGACGCTCACC 3' 
MCP-1 (Xu et 
al. 2016). 
F- 5’ TTGACCCGTAAATCTGAAG 
CTAAT 3' 
R- 5’ 
TCACAGTCCGAGTCACACTAGTTCAC 
3' 
GAPDH 
(Wang et al. 
2015). 
F- 5' ACAACTTTGGTATCGTGGAAGG 
3' 
R- 5’ GCCATCACGCCACAGTTTC 3' 
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Table 2.8: List of stem loop primers for miRNA expression analysis. 
Primer Sequence 
Stem Loop 221 
5’ 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCG
CACTGGATACGACGAAACC  3' 
Stem Loop U6s 
5’ 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCG
CACTGGATACGACTCACGA 3' 
Stem Loop let 7a 
5’ 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCG
CACTGGAT ACGACAACTA 3' 
Universal Reverse miR 5’ AAAAAAAAAAGTGCAGGGTCCGAGGT 3' 
Has-miR 221 F 
 
5’ 
AAAAAAAAAAGCCCGCAGCTACATTGTCTGCT
G 3' 
Has-miR U6s F 
5’ 
AAAAAAAAAAGCCCGCCTGCGCAAGGATGAC  
3' 
Has-let 7a F 
5’ 
AAAAAAAAAAGCCCGCTGAGGTAGTAGGTTGT
A 3' 
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2.8 Chromatin immunoprecipitation  
Initial search for transcription factors that are indirectly targeted by Let-7a to 
increase the release of some angiogenic proteins revealed that ATF-4 is 
predicted target that can affect some of the proteins increased by PMP. 
Therefore, binding of ATF-4 protein to the promoter regions of the increased 
protein through Let-7a mediated mechanism was explored. The simple CHIP 
immunoprecipitation assay kit (Cell signalling) was used to investigate the 
interaction between ATF-4-DNA at selected promoter regions of the increased 
proteins, stages of chromatin immunoprecipitation are summarised in Figure 2.6. 
Physiologically, gene expression involves complex spatial and temporal 
relationship between transcription factors and gene promoter regions. Initiation 
or inhibition of gene transcription proceeds through transcription factors 
mediated regulation of Polymerase activity (Levine and Tjian 2003). 
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Figure 2.6: Schematic workflow of Chromatin Immunoprecipitation. 
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2.8.1 Cross-linking of proteins to DNA in PMP treated HUVEC 
HUVEC transfected with Let-7a inhibitor or with non-targeting inhibitor sequence 
(1x106) were treated with 100μg/ml of PMP or buffer control for 24 hours. 
Chromatin was cross-linked with 1% formaldehyde for 10 minutes at room 
temperature. Formaldehyde derived methylene bridge facilitates cross-linking of 
proteins to DNA by connecting the exocyclic amino and nucleophilic nitrogen or 
sulphur that are present in nucleoside and amino acids, respectively (Lu et al. 
2010). The cross-linking was stopped by incubating the cells with 125mM 
glycine for 5minutes at room temperature. Media was removed before 
performing double washes with 20ml of ice-cold PBS. Cells were scraped into 
2ml ice-cold PBS with protease inhibitor cocktail (1x), and centrifuged at 1,500 
rpm for 5minutes at 4°C to pellet the cross-linked cells. The supernatant was 
removed and nuclei preparation was started immediately.  
 
2.8.2 Nuclei Preparation and Chromatin Digestion  
To digest the DNA to approximately 150-900bp, 0.5μl of Micrococcal nuclease 
was mixed with the samples by repeated inverting. Chromatin digestion to 150-
900bp results in effective immunoprecipitation. Then, samples were incubated 
for 20minutes at 37°C with frequent mixing every 4minutes. Micrococcal 
nuclease preferentially cleave 5’ side of Adenine or Thymine to produce 
nucleotides with 3’ phosphates. Moreover, the enzyme also cleave double 
stranded DNA and RNA. The reaction was stopped with 10μl of 0.5M EDTA and 
centrifugation at 13,000 rpm in a micro-centrifuge for 1minute at 4°C to pellet the 
nuclei. The supernatant was removed and pellet resuspended in 100μl of 1X 
ChIP buffer with protease inhibitor cocktail. The samples were incubated on ice 
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for 10minutes before sonication at 3 sets of 20-sec pulse to ensure homogenous 
digestion of chromatin (Ultra-Sonic). The samples were incubated for 30seconds 
on ice between pulses and nuclei lysis and investigated with light microscope. 
The lysed nuclei were clarified by centrifugation at 10,000rpm for 10minutes at 
4°C and cross-linked chromatin transferred to a new tube for 
immunoprecipitation using the antibodies in Table 2.9. Cross-linked chromatin 
was stored at -80°C until further use.  
 
2.8.3 Analysis of Chromatin Digestion and Concentration  
For analysis of chromatin digestion and concentration, 50μl chromatin sample 
was mixed with 100μl nuclease-free water, 6μl 5M NaCl, and 2μl RNAse A, 
vortexed and incubated for 30 minutes at 37°C. The RNAse A digested sample 
was incubated with 2μl Proteinase K at 65°C for 2hours to degrade cellular 
proteins. Thereafter, the remaining DNA was purified as described before. 
Purified DNA was assessed for fragmentation by electrophoresis on a 1% 
agarose gel with a 100bp DNA marker. Additionally, DNA concentration and 
purity was determined using Nanodrop. The concentration was measured at 
260nm (RNA) and 280nm (DNA) in μg/ml and DNA purity was considered good 
at 260-nm/280 nm ratio of ~1.8 (Rodrigo et al. 2002). The DNA concentration 
was determined based on the equation: 
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Equation 4 
WXY	Z[\Z]\^_`^a[\	(\b/cd) 	= 	ef	(\b/cd)	g	Yhif	g	Wadj^a[\	k`Z^[_ 
Where, 50ng of DNA per ml corresponds to absorbance reading of 1 unit at 260 
nm.  
2.8.4 Agarose gel electrophoresis to investigate the size of DNA  
Agarose gel electrophoresis was used to assess the quality of immuno-
precipitated chromatin DNA, plasmid DNA or qRT-PCR amplicons. This 
established procedure allows for the visualization and purification of DNA based 
on size (in base pairs). The application of electrical field to agarose gel matrix 
moves the negatively charged DNA to a positive electrode at a rate dependent 
on size. 1% agarose (Fisher Scientific) gel was mixed in 100ml of 1x Tris-borate 
EDTA (TBE) buffer (89mM Tris, 89mM boric acid, 2mM EDTA pH 7.6) and 
heated in a microwave for 2minutes. The mixture was cooled at room 
temperature for 5minutes before the addition of ethidium bromide (EtBr) to a 
final concentration of 0.5μg/ml. EtBr intercalates between the hydrophobic base 
pairs of DNA, whilst removing water molecules from ethidium cation. The 
increase in ethidium fluorescence because of this dehydrogenation process 
facilitates the visualisation of DNA under ultraviolet light. Thereafter, DNA 
samples were loaded on the casted gels and electrophoresed for 45minutes at 
120 Volts. Visual analysis of the agarose gel was performed with the gel 
documentation system (G:Box).  
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2.8.5 Chromatin Immunoprecipitation  
The digested chromatin from section 2.8.2 was diluted in immunoprecipitation 
buffer to a final volume of 500μl. 20μl of the diluted chromatin was transferred to 
a microfuge tube as the 4% input sample, and stored at -20°C until further use. 
Thereafter, 480μl of the diluted chromatin was transferred to a 1.5 ml micro-
centrifuge tube and immunoprecipitation antibodies added as shown in Table 
2.9. 
Table 2.9: Immunoprecipitation antibodies and dilution factor. 
 
 
 
 
 
 
 
Immediately after incubation, 30μl of Protein G Magnetic Beads were added to 
each immunoprecipitation (IP) reaction and incubate for 2hours at 4°C with 
rotation. In a magnetic stand, the protein G magnetic beads were pelleted and 
supernatant removed. Then, three consecutive wash with 1ml of low salt 
solution and high salt solution at 4°C for 5minutes with rotation was performed to 
remove unbound DNA fragments. Both wash was repeated twice before placing 
the tubes on a magnetic stand to pellet the beads, and supernatant removed.  
Antibody Source Dilution  Reference  
Histone H3 Rabbit  1:10 Positive control 
Normal Rabbit 
IgG 
Rabbit 1:50 Negative control 
ATF-4 Rabbit 1:50 Target 
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2.8.6 Elution of Chromatin and Reversal of Cross-links and DNA purification  
Briefly, 150μl of the 1X ChIP Elution Buffer was added to the 4% input sample 
tubes collected before in section 2.8.5 and kept at room temperature. IP sample 
was mixed with 150μl of the 1X ChIP Elution Buffer before eluting the chromatin 
from the antibody/protein G magnetic beads for 30minutes at 65°C with periodic 
mixing every 2minutes. Thereafter, the tubes were placed on magnetic stand to 
pellet the beads, and eluted chromatin supernatant collected to a new tube. The 
DNA-protein cross-link was reversed in both the 4% input sample and IP 
samples with 6μl 5M NaCl and 2μl Proteinase K for 2 hours at 65°C.  
 
Immediately after reversing the cross-links above, 750μl of DNA binding buffer 
was added to the DNA samples and the 4% input sample, vortexed and poured 
into a DNA binding column placed in a cap-less wash tube and centrifuged for 
30 seconds at 14000rpm. Flow through was discarded and column washed with 
700μl of DNA wash buffer for 30seconds at 14000g. DNA binding column was 
dried with further 30seconds centrifugation at 14000g, and transferred to a 
nuclease-free 1.5ml microfuge tube. Then, the purified DNA was incubated with 
40μl of DNA elution buffer for 1minute at room temperature and eluted with 
centrifugation for 1 minute at 14000g. The DNA samples were stored at -80 oC 
before qRT-PCR analysis.  
 
2.8.7 qRT-PCR for Chromatin Immunoprecipitation 
qRT-PCR reactions were set up for enrichment analysis of promoter regions of 
MCP-1 and PIGF using Fast SYBR® Green Master Mix (Applied Biosystems), 
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primer sets are summarised in table 2.10. Briefly, reaction master mix (MMs) 
were prepared according to the following scale, 2x Fast SYBR® Green Master 
Mix (10μl), forward and reverse primers (500nM each) in 2μl, nuclease-free 
water (up to 20μl) and 2μl of CHIP per well of a Clear 96-well PCR plate on ice. 
Reactions were briefly mixed and centrifuged using a benchtop plate centrifuge. 
Each reaction mix was set up in triplicate and assay performed as described 
below in Step-one Real-Time PCR Detection System: 
§ One cycle of initial denaturation and polymerase activation at 
95°C for 30 seconds.  
§ 40 cycles of denaturation at 95°C for 15 seconds followed by 
annealing and extension at 60°C for 60 seconds. This step 
include plate read. 
§ Final melt curve analysis from 65-95°C (+1°C increments, 5 
seconds/increment) with plate read. 
2.8.7.1 Percentage input, comparative CT method 
The CT of the input samples were normalised before evaluating the percentage 
enrichment.  
Equation 5 
              ΔCT = CT (IP) - CT (Input) - Log2 (Input Dilution Factor). 
Where, ΔCT (normalized to the input samples) for basal or PMP treatment.  
 88 
Equation 5.1 
l\mj^	Wadj^a[\	n`Z^[_	= 	n_`Z^a[\	[k	^o]	a\mj^	Zo_[c`^a\	× l\mj^	radj^a[\	k`Z^[_	s]k[_]	tuvw. 
Here, 20μl of Input chromatin and 480μl IP equates to 24 times fractions. For 
qRT-PCR runs Input was diluted 1.5 times, input dilution factor was 24 x 1.5 = 
36.  
Therefore,  
• Equation 5.2  
                ΔCT = CT (IP) - CT (Input) - Log2 (48). 
• Equation 5.3  
                Input % = 100/2 ΔCt (normalized ChIP) 
Where, Input % value represents the enrichment of each promoter per PMP 
treatment. The amplicon was collected and assed by 1% agarose gel 
electrophoresis. 
 
 
Table 2.10: List of promoter region primers.  
Primer Sequence 
MCP-1 
5' AAAACCCGAAGCATGACTGG 
3' 
5 GCCATCACGCCACAGTTTC 3' 
PIGF 5' CTAGGGGTGTGGGCATGG 3' 5' CATCCAGGAGTCCAGCGTC 3' 
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2.9 RNA sequencing  
RNA sequencing was used to explore the RNA content of PMP from healthy 
donors including miRNAs, mRNAs and long-noncoding RNAs. Total RNA was 
extracted as described before and sequenced at the Next Generation 
Sequencing facility (Leeds Institute of Molecular Medicine, Saint James’s 
University Hospital). The sequencing was and bioinformatics analysis was 
performed as summarised in Figure 2.7 by Dr Saly Harrison at the University of 
Leeds. 
 
 
Figure 2.7: RNA sequencing work flow.  
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2.9.1 Analysis of RNA sequencing data 
Initial alignment of RNA sequence shorts reads, transcript counts and 
normalisation were performed by the sequencing facility. Thereafter, the 
normalised transcript counts contained in excel was visualised using R and 
functional clustering analysis performed using David bioinformatics tools at 
https://david.ncifcrf.gov and KEGG pathway platform (through NCBI: 
Biosystems). The top highly expressed miRNAs were extracted from the 
normalised data and used to generate extensive list of predicted mRNA targets. 
The targets were analysed for functional cluster using David bioinformatics tool. 
2.10 Computational approaches 
For primer design, the target cDNA was obtained from 
https://www.ncbi.nlm.nih.gov, and exported to http://bioinfo.ut.ee/primer3/ for 
design of appropriate primer sets. For miRNA profiling and target search several 
databases were investigated including http://www.mirbase.org 
http://mirmap.ezlab.org/app/ and http://www.microrna.org. The primers used for 
the analysis of promoter region were designed as described below. First, the 
functions, genomic location, expression and profile of the genes of interest were 
investigated on  http://www.genecards.org, then the link to Ensembl: under 
External Ids was used to identify the DNA sequence. Thereafter, the whole 
promoter region including the first exon was copied to the UCSC website at 
http://genome.ucsc.edu/cgi-bin/hgBlat?command=start. From the graphical 
view, the sequence link was followed and the genomic sequence was 
investigated, with the exons in capitals and 3000 base pairs of the promoter 
sequence extracted. The promoter region was identified and filtered down to the 
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location with potential ATF-4 or CREB binding consensus before primer design 
using the primer3 website.  
2.11 Statistical Analysis  
The results are expressed as mean ± standard error of mean. Differences 
among more than two experimental groups were analysed using ANOVA 
analysis. The significance of differences between groups was assessed by 
Tukey SD post hoc test, as indicated in figure legends and variance in mean 
assessed by Independent samples Kruskal-Wallis Test. For comparisons 
between two experimental groups, the student T-test was used. Significance 
was defined for a p value of <0.05. The statistical analysis was performed using 
IBM SPSS statistics v22 software (IBM, International Business Machines Corp) 
or R programme (R Studio) and graphs plotted in GraphPad PRISM 6 
(GraphPad Software Inc, United States). 
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CHAPTER 3: PMP REGULATE ENDOTHELIAL CELL FUNCTION THROUGH 
RNA  
3. Introduction 
The central aim of this project was to investigate the role of miRNA regulated 
mechanisms in PMP stimulated angiogenesis. Angiogenesis plays an important 
role in wound healing (Zampetaki et al. 2008), while in cardiovascular diseases 
(CVD) it may destabilise atherosclerotic plaque and increases the risk of 
thrombosis (Virmani et al. 2005). A large range of miRNAs have been identified 
in PMPs (Diehl et al. 2012c), and have been shown to be delivered to 
endothelial cells (EC) (Laffont et al. 2013). Importantly, PMPs are significantly 
elevated in areas where platelets are activated, such as atherosclerotic plaques. 
Given the known regulatory functions of miRNAs in angiogenesis, we 
hypothesised that PMP delivered miRNA is a key regulator of angiogenesis.  
 
3.1 Platelet Characterisation  
In the first instance, the ability to isolate a pure platelet population using the 
method described in chapter 2 was determined. This was important as other 
blood cells can release MPs, though in much lower quantities their contribution 
in the pool of the isolated PMPs required exclusion. Following isolation of 
platelets from venous blood by differential centrifugation (Laffont et al. 2013, 
Lagarde et al. 1980), cells were incubated with an anti- CD41a (Integrin αIIb), 
CD41a is a surface marker for platelets, and were analysed by flow cytometry. 
 93 
Flow cytometry analysis showed that the platelet suspension contained single 
population of cell cluster (Figure 3.1). The analysis also showed that 
approximately 99.5% of all the events counted by the cytometer were positive 
for CD41a staining, which suggested that the isolation method yielded pure 
platelet population. The high purity (99.5%) of platelets in the samples analysed 
by flow cytometer excluded significant contamination by other cells. Therefore, 
the platelet isolation method was suitable for subsequent PMP isolation.  
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Figure 3.1: Characteristics of isolated platelets. Isolated platelets (40000 
cells in 100μl of PBS) were incubated with 20μl of APC-labelled anti-CD41a or 
IgG isotope control (20μl/ml) for 30 minutes in the dark at room temperature. 
The flow cytometer was gated for side scattering against forward scattering, and 
CD41a bound platelets. Images represents: (A) Dot plot of side scattering 
against forward scattering; Region R2 represents events used for further 
analysis and region outside R2 represents instrument noise and buffer debris. 
(B) R2 histogram of event counts against APC-labelled CD41a staining; Region 
R4 represents platelets (events positive for CD41a), accounting for 99.5% of 
total events. (C) Dot plot of IgG isotope control against forward scattering of 
platelets showing the size of platelets (D) Dot plot of APC-labelled CD41a 
against forward scattering of bound platelets showing the size of platelets. All 
data shown are Log of events counted.  
 95 
3.2 Characterisation of platelet micro-particles 
Consistent isolation of PMPs was central to this research project; hence the 
ability to isolate PMPs with similar surface markers and of the same size using 
the methods described in chapter 2 was determined. Determining the surface 
expression markers and physical characteristics of PMPs was crucial because 
platelets also release exosomes, granules and apoptotic bodies (Italiano et al. 
2008, Théry et al. 2009), which differ in size and are known to contain different 
class of biomolecules. Therefore, the inclusion of non-PMP cellular bodies could 
elicit different biological effects on EC.  
 
3.2.1 Differentiation of platelet micro-particles using surface markers 
Micro-particles (MPs) have been shown to express surface proteins inherited 
from their parent cells (Ratajczak et al., 2006, Burnier et al., 2009), which can 
act as a marker of origin. PMPs express CD31 (PECAM), a non-specific surface 
marker expressed by platelets, EC and other types of MP. They also express 
CD41a, a specific marker for PMPs and platelets that is inherited from parent 
megakaryocytes. Since the expression of both CD31 and CD41a by PMPs is 
heterogeneous, both markers were used to show that the sample contained 
PMPs. In addition, MPs from all cells expresses phosphatidylserine, which binds 
to Annexin V and differentiates debris from particles (Freyssinet, 2003). 
Phosphatidylserine is a phospholipid membrane protein that is exposed during 
MP formation. To ensure that our sample suspensions contained MPs rather 
than other vesicles, we gated for the reported size of PMPs (0.1–1.0μm) 
(Heijnen et al., 1999), then determined the expression of platelet markers.  
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The MP suspension was incubated with an anti-CD41a, Annexin V or anti-CD31 
antibodies and analysed by flow cytometry. In three independent analyses, 
22.18% of the total events were CD41a positive, highlighting the presence of the 
platelet specific marker (Figure 3.2B). The expression of platelet’s surface 
markers by PMPs is highly heterogeneous and depends on the activation 
mechanisms of platelet (Perez-Pujol et al., 2007), which is supported by the 
negative events counted. Further analysis for Annexin V and anti-CD31 binding, 
which are both ubiquitous MP markers, showed that 93% of the events captured 
by the flow cytometer were positive for Annexin V and 100% positive for CD31 
(Figure 3.3A), thus the CD41a negative events recorded in (Figure 3.2) were 
also MPs. Together, these results confirmed that platelets release a 
heterogeneous population of PMPs following thrombin activation, which is line 
with the data from other studies (Perez-Pujol et al., 2007). 
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Figure 3.2: CD41a characterisation of platelet’s micro-particles. Isolated 
PMPs (100µg/ml) were incubated with APC-labelled anti-CD41a or IgG isotope 
control (2µg/ml) for 30 minutes in the dark at room temperature. The Flow 
cytometer was first gated to PMPs specific size (0.1–1.0 μm), then gated for 
side scattering against forward scattering, and anti-CD41a binding. (A) Dot plot 
of side scattering against forward scattering; Region R2 represents events used 
for further analysis and region outside R2 represents instruments noise and 
buffer debris. (B) R2 histogram of event counts against APC-labelled CD41a; 
Regions R1 and R4 represents MPs of platelet origin, accounting for 23.18% 
and 21.33% of total events, respectively. (C) R2 dot plot of APC-labelled CD41a 
against forward scattering; Regions R3 represents MPs of platelet origin, 
accounting for 21.25% of total events. All data shown are Log of events. 
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Figure 3.3: Annexin V and CD31 characterisation of platelet micro-
particles. A. Isolated MPs were incubated with FITC-labelled Annexin V or IgG 
isotope control for 30 minutes in the dark at room temperature and analysed by 
flow cytometry. Flow cytometer was gated for side scattering against forward 
scattering, and Annexin V binding. Representative histogram of event counts 
against FITC-labelled Annexin V; Region R5 represents Annexin V negative 
events and region outside R5 (blue histogram) represents 90% of MPs. B. 
Isolated MPs were incubated with APC-labelled anti-CD41a and FITC-labelled 
anti-CD31 for 30 minutes in the dark at room temperature and analysed with 
flow cytometer. Flow cytometer was gated for side scattering against forward 
scattering and anti-CD41a binding. Dot plot of APC-labelled anti-CD41a against 
FITC-labelled anti-CD31; Regions R9 represents MPs positive for anti-CD31, 
accounting for 98.1% of total events, and region R7 represents MPs positive for 
ant-CD41a and anti-CD31, which accounts for 1.8% of all events. 
3.2.2 Protein quantification of platelet micro-particles  
The protein concentration of the PMP sample was determined by the Bradford 
protein assay using a Bio-Rad assay kit (Lan Zhang et al. 2014). Determination 
of protein concentration facilitated the use of set PMP amounts in future 
experiments. The data showed that the protein content of our PMPs 
suspensions differed, ranging from 0.24μg to 1.07mg/ml (Table 3.1). The 
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platelet counts on the samples before isolation of PMPs showed similar 
numbers of cells, which did not affect the protein concentration of PMPs (Table 
3.1 and Figure 3.4). This data would suggest that some platelet samples more 
readily produce PMPs as reported by others (Morel et al. 2011).  
 
 
 
 
 
 
 
Figure 3.4: Representative standard curve for Bradford protein 
quantification assay. OD 595 corrected to the blank absorbance. The slope 
equation was used to quantify protein concentration. Blue points represents 
absorbance for the concentration of standards. 
Table 3.1: Representative absorbance at OD 595 and protein concentration 
of PMPs samples.  
Sample ID Mean Absorbance Concentration mg/ml 
Platelet Count 
Cells/ml 
7100 0.46 0.24 9 x 106 
7103 0.794 1.07 8.7 x 106 
7101 0.574 0.52 3 x 106 
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3.3 Quantification of PMP bound cytokines  
To begin to understand the characteristics of PMPs that may influence their 
ability to regulate EC, the cytokine profile of PMPs was investigated. In addition 
to the expression of specific surface markers, several cytokines remain bound to 
the receptors on PMPs (Théry et al. 2009). The presence of 36 cytokines was 
investigated by detecting surface bound cytokines on PMP. Equal volumes of 20 
biological replicates of PMP samples were pooled to 100µg/ml and measured by 
the human cytokine array panel A kit (R&D). The results showed that 12 
different cytokines were bound to PMP (Figure 3.7) including: serpin E1, 
RANTES, CD40 Ligand, complement component 5a (C5/C5a), GROa, soluble 
intercellular adhesion molecule-1 (sICAM-1), interleukin (IL)-16, IP-10, 
macrophage migration inhibitory factor (MIF), interferon-inducible T-cell alpha 
chemoattractant (I-Tac) (.3), IL-1 receptor antagonist (rA) and IL-13 (217.8) 
(Figure 3.5). Functional analysis on Uniprot website (http://www.uniprot.org) 
revealed potential biological and molecular functions. These functions could be 
related to PMPs release and activity, including functions in cell-cell adhesion 
and signalling, platelet activation and degranulation, chemotaxis, migration and 
exocytosis, the functional effect of the top 6 protein on PMP surface are 
summarised in Table 3.2.  
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Figure 3.5: Protein array images showing binding of proteins present on 
the surface of PMPs. A) Protein array image showing proteins bound on the 
surface of PMPs. B) Quantitative data of pixel density expressed in pixels. Data 
shown are mean ± standard error of mean, n=4 technical measures of pixel 
density in each group and n=20 biological samples of healthy PMPs. The green 
highlights represent the postive control spots, while the red highlight shows the 
negative control spots.  
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Table 3.2: List of potential processes modulated by proteins bound on 
PMP surface.  
 CD40L MIF ICAM-1 RANTES C5/C5a 
Inflammatory 
response 
Y Y Y Y Y 
Cell-cell 
adhesion 
Y  Y Y  
Platelet 
activation 
Y  Y   
Migration   Y   
Chemotaxis    Y  
Viral receptor 
activity 
  Y Y  
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3.3.1 Quantification of PMP’s RNA content by Illumina RNA Sequencing 
 To further characterise the content of PMPs that could play a role in the 
regulation of EC, their RNA content was analysed using Illumina RNA 
sequencing (n=3). This analysis revealed the presence of more than 50000 RNA 
transcripts including mRNA, long non-coding RNA and miRNA. Specifically, the 
analysis revealed 836 miRNAs, with a clear high expression of Let-7 miRNA 
family members that accounted for most of the top 25 miRNAs transcripts in the 
analysed PMP (Table 3.3). Therefore, we hypothesised that at least a fraction of 
the PMPs mediated regulation of cellular process is represented by the Let-7 
miRNA members. In theory, members of the Let-7 family have the capacity to 
regulate translation of many mRNAs and indirectly regulate the functions of 
transcribed mRNAs.  
 
 
 
Table 3.3: List of Top highly expressed miRNAs in PMP. 
1st Top 10  2nd Top 
10 
3rd Top 5 
hsa-let-7f-2 hsa-mir-
3184 
hsa-mir-21 
hsa-let-7f-1 hsa-mir-
92a-1 
hsa-mir-127 
hsa-let-7i hsa-mir-
320a 
hsa-mir-222 
hsa-let-7g hsa-let-7b hsa-let-7e 
hsa-mir-486-1 hsa-mir-
92a-2 
hsa-mir-4433b 
hsa-mir-486-2 hsa-mir-
584 
 
hsa-let-7a-1 hsa-let-7d  
hsa-let-7a-3 hsa-mir-151a 
hsa-let-7a-2 hsa-mir-
744 
 
hsa-mir-423 hsa-mir-
30d 
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Next, to understand the potential functions of these highly-expressed miRNAs in 
PMP, we extracted the predicted mRNA targets for the top 25 miRNAs (Table 
3.3) using TargetScan. The strongly predicted mRNAs targets was analysed 
with DAVID bioinformatics functional analysis tool to investigate potential 
regulatory targets. The analysis revealed that functional networks with the 
highest enrichment scores were cytoplasm, nucleus, transcription and 
transcription regulation (Figure 3.6). The analysis revealed a potential 
contribution in the pathogenesis of CVD. Specifically, the results revealed the 
enrichment of metabolic, cardiovascular, neurological, and renal diseases 
related processes (Figure 3.7).  
 
 
Figure 3.6: Relative group functions of predicted mRNA targets for the top 
25 highly expressed miRNAs in PMP. The Pie chart is proportional to 
enrichment scores. 
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Figure 3.7: Relative group disease association of predicted mRNA targets 
of top 25 highly expressed miRNAs in PMP. The Pie chart is proportional to 
enrichment scores. 
 
Next, we investigated the biological, cellular and molecular functions of these 
predicted mRNA targets for the top 25 miRNAs in PMPs. The results showed 
potential regulation of several biological process including angiogenesis, 
proliferation, cell-cell adhesion and aging (Appendix: Table 3.4), which are 
linked to progression and athero-thrombosis leading to CVD, renal 
complications, neurological complications and metabolic conditions. Finally, we 
investigated the enrichment of molecular pathways and the enrichment of 
corresponding molecular functions. The results showed that pathways in cancer 
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(potentially due to the role of angiogenesis in cancer), MAPK signalling pathway, 
Ras signalling pathways cytokine-cytokine receptor pathways, and VEGF 
signalling pathways were significantly enriched. The importance of these 
pathways in angiogenesis are well described and support the role of PMP-
derived miRNA in pathologic angiogenesis. Indeed, the molecular functions 
mediating the link between these pathways and angiogenesis where significantly 
enriched including protein C activity, cytokine activity, and interestingly miRNA 
binding suggesting a potential functional loop (Appendix: Table 3.6). In 
conclusion, the RNA sequencing results show that PMP derived miRNAs might 
target key EC proteins to modulate pathways that are linked to proliferation, 
adhesion, sprouting and chemotaxis.  
 
3.4 PMP induce robust angiogenesis in EAhy926 cells 
Initially we wished to determine if PMPs induce angiogenesis and if this might 
depend on miRNA transfer. EAhy926 cells, 3 x 104 cells per well, seeded on 
Matrigel were treated with 10% serum (as a positive control), serum free media 
or 25μg/ml – 100μg/ml PMPs in serum free medium, for 18 hours. Angiogenesis 
was assessed by measuring tube length and the number of branch points (Jung 
et al. 2015, Lee et al. 2015, Wilson et al. 2015), and quantified fluorescent 
images with AngioTool software. Incubation with 25μg/ml – 100μg/ml PMPs 
caused a significant increase in angiogenesis (Figure 3.8) compared to basal 
level. The lowest concentration of PMPs (25μg/ml) significantly increased tube 
formation to 6256μm (Figure 3.8A) and branching to 11 (p<0.05) (Figure 3.4B). 
 107 
While further increase in tube length (8376μm) (Figure 3.6A) and branching (14) 
(p<0.05) (Figure 3.8B) were achieved with (100μg/ml) PMP treatment. 
 
Figure 3.8: PMP mediated tube formation and sprouting by EAhy926 in-
vitro. EAhy926 cells 3 x 104 cells per well seeded on ECM matrix were treated 
with 10% serum, serum free media or 25μg/ml – 100μg/ml PMPs in serum free 
media, for 18 hours. Angiogenesis tubes were captured with a florescent 
microscope and data quantified with AngioTool software. A) Quantitative data of 
total tube length expressed in μm and B) Quantitative data of total number of 
branching. Data shown are mean ± standard error of mean, n=3 in each group. 
*P<0.05 ANOVA, for PMP treatment compared with the basal level. (C) 
Representative photomicrographs (×40 magnification) showing extracellular 
matrix gel-based, capillary-like tube formation by human EAhy926 cells. 
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3.5 PMP induced angiogenesis in EAhy926 cells is dependent on RNA 
transfer 
Since the results from the angiogenesis experiments showed that treatment with 
PMPs increased in-vitro angiogenesis by EAhy926, we investigated the role 
played by PMPs-RNAs by RNAse treatment, which was a first step towards 
investigating the transfer of miRNAs by PMPs. 
3.5.1 RNA Degradation 
To determine if the induction of angiogenesis by PMPs were RNA dependent, 
we degraded total RNA in PMPs suspension by treating the samples with 
RNAse (Laffont et al. 2013). Before incubation of EAhy926 with RNA free PMPs, 
it was critical to investigate the potency of RNAse-A in degrading PMP’s total 
RNA. Trizol reagent was used to isolate total RNA from PMPs treated with 
RNAse and non-treated PMPs. The concentration of RNA was determined by 
spectrophotometric analysis using Nanodrop. RNAse treatment caused 
complete degradation of RNA in PMPs solution compared to untreated PMP 
(p<0.001) (Figure 3.9). 
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Figure 3.9: RNAse degradation of total RNA in PMPs. Representative RNA 
extraction result, total RNA was isolated from PMPs treated with RNAse and 
non-treated PMPs using TRIzol reagent and total RNA concentration quantified 
with spectrophotometer. Data shown are mean concentration (μg/ml) ± standard 
error of mean, n=3 in each group.  
3.5.2 Degrading PMP RNA reduces their pro-angiogenic effect on EAhy926 cells 
Next, the effect of degrading total PMP-RNA on induced angiogenesis was 
investigated as described before. EAhy926 cells 3 x 104 cells per well were 
treated with 100μg/ml PMPs treated with RNAse (1U/ml) or untreated in serum 
free media, for 18 hours and angiogenesis assessed. RNAse treatment did not 
reduce PMP stimulated tube length in EAhy926 but significantly decreased 
sprouting (Figure 3.10) compared to complete 100μg/ml of PMPs. The PMPs 
treated with RNAse increased tube formation to 7328μm (p<0.05) (Figure 3.10A) 
and reduced branching to 11 compared to untreated PMPs (p<0.05) (Figure 
3.10B). The data suggest that PMPs-RNAs is associated with sprouting but not 
tube formation in EAhy926.  
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Figure 3.10: PMP mediated EAhy926 sprouting is associated with PMP-
RNAs. EAhy926 cells (3 x 104 cells per well) seeded on ECM matrix were 
treated with 10% serum, serum free media or 100μg/ml PMPs in serum free 
media, for 18 hours. Angiogenesis was measured using an in-vitro tube 
formation assay kit and data quantified with AngioTool software. A) Quantitative 
data of total tube length expressed in μm and B) Quantitative data of total 
number of branching. Data shown are mean ± standard error of mean, n=3 in 
each group. *P<0.05 ANOVA, total tube length or branching between untreated 
PMPs and RNAse treated PMPs. (C) Representative photomicrographs (×40 
magnification) showing extracellular matrix gel-based, capillary-like tube 
formation of EAhy926 cells incubated in: EC) serum free medium (EC+) 10% 
serum (EC+PMP) in the presence of 100μg/ml of PMPs and (EC+PMP+RNAse) 
100μg/ml of PMPs with RNAse in serum free medium, respectively.  
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3.6 PMPs modulate the production of angiogenic cytokines by EAhy926 
cells 
Having demonstrated that PMPs increased angiogenesis, we began to assess 
potential mechanisms.  As a start point, we investigated the effect of PMPs on 
EAhy926 release of cytokines and growth factors known to modulate 
angiogenesis. Cytokine release was measured by the Human angiogenesis 
proteome profiler array kit (R&D) (Santhekadur et al. 2012).  
 
3.6.1 PMPs causes differential release of angiogenic cytokines by EAhy926 
EAhy926 cells (2 x 104 cells per well) were serum starved for 24 hours before 
incubation in either 10% serum (as a positive control), serum free media or with 
25μg/ml – 100μg/ml PMPs in serum free medium, (with prior RNAse or control 
treatment), for 18 hours. Conditioned media was removed and the presence of 
cytokines assessed. Treatment of EAhy926 cells with PMPs caused a significant 
increase in the releases of Interleukin-8 (IL-8), C-C motif chemokine 2 (MCP-1), 
Platelet-derived growth factor- subunit-A (PDGF-AA), Platelet Factor 4 (PF4), 
Placental growth factor (PIGF), Metalloproteinase inhibitor 1 (TIMP-1) and 
Urokinase-type plasminogen activator (uPA) compared to cells cultured in serum 
free medium (p<0.05) (Figure 3.11). Furthermore, PMPs caused a significant 
reduction in the release of Endothelin-1 (p<0.05) compared to negative controls 
(Figure 3.11). The data also suggests that there could be a concentration 
dependent effect, because treatment with 25μg/ml of PMPs caused a significant 
increase in the release of cytokines highly increased in 100μg/ml of PMPs 
treatment, including significant increase in the release of PF4, PIGF, and uPA 
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when compared to basal levels (Figure 3.11). RNAse treatment of PMPs caused 
a significant decrease in their ability to stimulate the release of MCP-1, PDGF-
AA, PF4, PIGF, TIMP-1 and uPA by EAhy926 cells compared to control PMPs 
(p<0.05) (Figure 3.11B). The 100μg/ml of PMPs treated with RNAse also 
caused a significant increase in the release of Serpin F1 and Thrombospodin-1 
(p<0.05) compared to 100μg/ml of PMPs treatment (Figure 3.11). 
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Figure 3.11: PMPs causes differential release of angiogenic cytokines by 
EAhy926 through RNA dependent mechanims. Protein array images showing 
binding of proteins present in EAhy926 cell culture supernatents in: A-I) absent 
of serum (A-II) 100μg/ml of PMPs, and (A-III) in the presence of 100μg/ml of 
PMPs with RNAse. Quantitative data of pixel density expressed in pixels (B). 
Data shown are mean ± standard error of mean, n=3 in each group. *P<0.05 
Tukey SD individual protein expressions between basal levels and 100μg/ml of 
PMPs, between PMPs and PMPs with RNAse. The arrow head indicate the 
direction of the comparison. The green highlights represent the postive control 
spots, while the red highlights shows the negative control spots.  
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3.7 Effect of platelet micro-particles on EAhy926 cell proliferation   
Our data demonstrate that PMPs increase angiogenesis and modulate cytokine 
release from EAhy926, partly through transfer of RNA (potentially miRNA). We 
next investigated the effect of PMPs on EAhy926 cell proliferation because 
proliferation is a further step in angiogenesis.  
3.7.1 Optimisation of proliferation assay  
CellTiter-Glo was used to measure EC proliferation (Thoreen et al. 2009). In the 
first instance, we confirmed the sensitivity of the reagent by measuring 
increasing numbers of cells (1000, 2000, 4000, 8000 cells per well). The 
luminescence values showed a linear relationship with cell number. A 
concentration of 2000 cells/well seems to have optimal luminescence value 
(Figure 3.12) whilst not being so confluent that further growth would not occur. 
Hence, 2000 cells were used for subsequent experiments.  
 
 
 
 
 
Figure 3.12: Cell number correlates with luminescent values. 
Representative graph of CellTiter-Glo specificity test for EAhy926 cells. Cells 
were plated in 96 well plates at (1000, 2000, 4000, 8000 cells per well) and 
incubated with CellTiter-Glo reagent. Luminescence signal was measured using 
plate reader and plotted aginst cell number. 
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3.7.2 Optimisation of serum concentration   
Initial attempts to use serum free medium for the proliferation assay resulted in 
cell death (data not shown). Hence, we performed optimization experiments to 
determine the concentration of serum that will allow EAhy926 cells to remain 
viable without inducing robust proliferation. This control experiment allowed us 
to determine if PMPs can induce proliferation. EAhy926 cells (2000 cells/well) 
were cultured in different concentrations of serum (0-, 10%) for 72 hours and 
proliferation was measured by CellTiter-Glo kit. EAhy926 cells cultured in less 
than 0.5% serum did not survive to 72 hours (luminescence values of 100) 
(Figure 3.13), but EAhy926 cells cultured in 1% to 10% serum survived for 72 
hours, with luminescence values of 20000, 18300 and 30000, respectively 
compared to 10000 at time 0 (Figure 3.14). EAhy926 cells cultured in 1% serum 
had proliferation rates that were lower than EAhy926 cells cultured in 10% 
serum, which were 17232 in 1% serum and 22000 in 10% serum at 48 hours 
(Figure 3.13). The data suggests that further experiments using 1% would allow 
cells to grow within the range that is suitable to detect any change caused by 
PMP treatment. 
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Figure 3.13: Optimization of CellTiter-Glo assays using different 
concentration of serum. EAhy926 cells (2000 cells/well) were incubated in 
different concentrations of serum (0.5%, 1%, 5% and 10%) or serum free 
medium for 72 hours and cell numbers was quantified every 24 hours. Data 
shown are mean luminescence ± standard error of mean, n=1 for no serum, 
0.5% serum and 5% serum, and n=2 for 1% serum and 10% serum.  
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3.7.3 Effect of platelet micro-particles on EAhy926 proliferation  
Optimisation experiments showed that 1% serum could sustain EAhy926 cell 
survival, without inducing strong proliferation. To determine if PMPs can induce 
long-term EC proliferation, EAhy926 cells (2000 cells per well) were incubated 
with either 10% serum (positive control), 1% serum (as basal level) or with 
25μg/ml - 100μg/ml PMPs in 1% serum, and proliferation was quantified 
luminescently. The result show no significant effect on luminescence signals. 
After 48-hours incubation, treatment with 25μg/ml or 100μg/ml PMPs seems to 
increase EAhy926 proliferation with luminescence values of 13300 and 12340, 
respectively compared to the basal level with luminescence value of 8201 
(Figure 3.14). However, treatment with 25μg/μl or 100μg/ml PMPs seems to 
reduce EAhy926 cell proliferation after 24 hours at 20000 and 18560, 
respectively, compared to the basal level at 23129 (Figure 3.14). Generally, 
there seems to be no difference in EAhy926 proliferation before 24 hours, while 
PMPs seems to sustain cell survival after 24 hours (Figure 3.14).  
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Figure 3.14: Effect of PMPs on EAhy926 proliferation. Proliferation of 
EAhy926 cells in the presences of 1% serum (negative control), presence of 
10% serum (positive control), and in the presence of 25μg/ml or 100μg/ml of 
PMPs were incubated with CellTiter-Glo reagent and Luminescence measured 
with a plate reader. Data shown are mean luminescence ± standard error of 
mean, n=3 in each group. 
 
To confirm these proliferation results, viability assay was conducted with the 
trypan blue assay. EAhy926 cells were incubated in 10% serum (positive 
control), 1% serum (basal level) or with 25μg/ml – 100μg/ml PMPs in 1% serum 
and cell number counted. The result show no significant effect on cell number. 
After 24-hours incubation, treatment with 25μg/ml or 100μg/ml PMPs seems to 
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decrease proliferation with cell numbers of 3432 and 2100, respectively (Figure 
3.15) compared to negative control (3123). Furthermore, after 48 hours and 72 
hours the cell number reduced even further to (48 hours; 25μg/ml: 3310, 
100μg/ml: 2231 compared to basal level: 6821, 72 hours; 25μg/ml: 4210, 
100μg/ml: 2612 compared to basal level (7129). PMPs seem to fairly reduce cell 
number in a time dependent manner (Figure 3.15), but the results were not 
significant within the same time point.  
 
 
Figure 3.15: Effect of PMPs on Eahy926 cell number. Proliferation of 
Eahy926 cells in the presences of 1% serum (negative control), presence of 
10% serum (positive control), and in the presence of 25μg/ml or 100μg/ml of 
PMPs trypsinised and counted using haemocytometer. Data shown are mean 
cell number ± standard error of mean, n=3 in each group. 
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3.8 Effect of platelet micro-particles on HUVEC angiogenesis  
Having optimised the angiogenic effects of PMPs using Eahy926, we wished to 
assess these responses in primary HUVECS. The differences between 
immortalised cell lines and primary cells including genetic and signalling 
differences are well documented. Indeed, the transformation of cell lines to 
achieve sustained and increased growth requires significant modifications to 
several molecular profile and function (Lidington et al. 1999). A study showed 
differences in signalling mechanisms between different types of endothelial 
cells, which suggests that EAhy926 cells might respond differently to PMP 
treatment compared to primary HUVEC cells (Boerma et al. 2006). Moreover, 
genome wide analysis of HUVEC and EAhy926 cells treated with similar amount 
of atorvastatin showed 103 differential expressed genes in HUVEC compared to 
466 genes in EAhy926. Therefore, we determined the effect of PMPs on 
HUVEC angiogenesis and mapped the extent of the differences between the 
two cell types.  
 
3.8.1 PMP induced angiogenesis response by HUVEC 
The effect of PMP and RNAse treated PMPs on angiogenesis was measured 
using Matrigel assays. HUVEC (3 X104 cells/well) were cultured with Medium 
200 supplemented with 1% serum, 100μg/ml PMPs or RNAse treated PMP in 
1% serum, for 18 hours. The angiogenesis potential was assessed by 
measuring tube length and the number of branch points (Jung et al. 2015, Lee et 
al. 2015, Wilson et al. 2015), and fluorescent images were quantified with 
Angiotool. Incubation of HUVEC with PMPs caused a significant increase in 
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angiogenesis (Figure 3.16) compared to basal level. Treatment with PMPs 
increased tube length to 29000μm (p<0.05) (Figure 3.16A) and branching to 150 
(p<0.05) compared to basal level at 18000μm tube length and 98 branching. 
Pre-treatment of PMPs with RNAse significantly decreased their ability to induce 
tube formation and tube length compared to the effect of untreated PMP, 
19000μm tube length and 99 branching. However, HUVEC treated with RNAse 
degraded PMP showed both reduced tube length and branching (Figure 3.16B) 
compared to only reduced branching observed following treatment of EAhy926 
cells with RNAse treated PMPs (Figure 3.10). This result suggests a potential 
role for the differences in signalling mechanisms between both types of EC. 
 
 
 122 
 
 
 
Figure 3.16: PMP mediated angiogenesis in HUVEC is associated with 
PMP-RNAs. HUVEC cells (2 x 104 cells per well) seeded on ECM matrix were 
treated with 1% serum, 100μg/ml PMPs or PMPs treated with RNAse in 
Medium-200 supplemented with 1% serum for 18 hours. Angiogenesis was 
measured using an in-vitro Tube formation assay kit and data quantified with 
AngioTool. (A) Representative images (×40 magnification) showing extracellular 
matrix gel-based capillary-like tube formation of HUVEC cells incubated in: 
supplemented 1% serum (EC), in the presence of 100μg/ml PMPs (EC+PMP), 
in the presence 100μg/ml PMPs pre-treated with RNAse in 1% serum 
(EC+PMP+RNAse). (C) Quantitative data of total tube length expressed in μm 
and (B) Quantitative data of total number of branching. Data shown are mean ± 
standard error of mean, n=3 in each group. * P<0.05 ANOVA, total tube length 
and branch point between treatment group. 
 123 
3.9 PMPs modulate the production of angiogenic cytokines by HUVECS 
Having demonstrated that treatment with PMPs increased HUVEC angiogenesis 
and cell sprouting, the underlying molecular mechanisms was investigated. 
Similar to the initial experiments on EAhy926, the effect of PMPs and RNAse 
treated PMPs on HUVEC’s release of cytokines and growth factors known to 
modulate angiogenesis was investigated by the human angiogenesis proteome 
profiler array kit (Santhekadur et al. 2012).  
 
3.9.1 PMP induces differential release of angiogenic cytokines by HUVEC 
HUVEC cells (3 x 104 cells per well) were incubated in 1% serum for 24 hours. 
Cells were then treated for 18 hours in Medium-200 with 1% serum, or 100μg/ml 
PMPs (plus/minus prior RNAse treatment). Conditioned media was collected 
and analysed for the presence of cytokines using angiogenesis proteome array 
(R&D). The data was quantified with ImageStudioLite and ImageJ (Version 
5.2.5, by LI-COR Biosciences: National Institute of cancer). Treatment of 
HUVEC with PMPs caused a significant increase in the release of C-C motif 
chemokine 2 (MCP-1), Platelet Factor 4 (PF4), Placental growth factor (PIGF), 
Metalloproteinase inhibitor 1 (TIMP-1), Pentraxin 3, Endothelin-1, Endoglin, 
Angiogenin, Angiopoietin-2, Insulin-like growth factor binding protein 3 (IGFBP-
3) and Serpin F1 protein compared to 1% serum treatment (p<0.05) (Figure 
3.17). Furthermore, PMPs caused a significant reduction in the release of 
Thrombospondin-1 and Serpin E1 (p<0.05) compared to basal level (Figure 
3.18). Pre-treatment of PMPs with RNAse reduced the ability of PMPs to 
stimulate HUVEC release of MCP-1, PF4, PIGF, TIMP-1, Endothelin-1, 
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Endoglin, Angiogenin and IGFBP-3 (p<0.05) (Figure 3.17). HUVEC treated with 
RNAse degraded PMPs significantly released higher levels of Thrombospodin-1, 
EGF and IGFBP-2 (p<0.05) compared to HUVEC incubated with untreated 
PMPs (Figure 3.17). Combined with the tube formation results, the differences in 
the profile of angiogenic proteins between HUVEC and EAhy926 resulted in the 
use of HUVEC for the remaining part of the project. Moreover, HUVEC is 
physiologically relevant in cardiovascular diseases compared to Eahy926. 
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Figure 3.17: PMPs induce cytokine release by HUVEC through RNA 
dependent mechanism. Protein array images showing binding of proteins 
present in HUVEC cell culture supernatants in: A-I) 1% serum, (A-II) 100μg/ml 
PMPs, and (A-II) 100μg/ml PMPs treated with RNAse. Quantitative data of pixel 
density expressed in pixels. Data shown are mean ± standard error of mean, 
n=4 technical measures of pixel density in each group and n=4 biological 
samples of PMPs. *P<0.05 Tukey SD individual protein expressions between 
untreated HUVEC and HUVEC treated with 100μg/ml PMPs, between HUVEC 
treated with 100μg/ml PMPs and 100μg/ml PMPs pre-treated with RNAs.The 
green highlights represent the postive control spots, while the red highlights 
shows the negative control spots. 
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3.10: Discussion 
The endothelium plays an important role in maintaining vascular tone (Moncada 
et al. 1988) and haemostasis (Rubanyi 1993), as well as providing barrier 
functions (Verma and Anderson 2002). The healthy endothelium is quiescent 
(Rubanyi 1993), but once activated by pathological conditions, endothelial cells 
(ECs) express inflammatory mediators, adhesion receptors and release a range 
of cytokines and growth factors (Dzau and Gibbons 1991). Such changes 
causes an increase in angiogenesis and proliferation (Pober and Sessa 2007). 
Increased angiogenesis combined with increased supply of nutrient to plaques 
can cause destabilisation of arteriosclerotic lesions, which is a common 
pathological features of CVD (Carmeliet 2003). 
 
Upon activation by agonists produced at sites of vascular injury such as 
thrombin, which is often increased in CVD patients (Juhan-Vague et al. 2000, 
Tregouet et al. 2009), platelets release large quantities of PMPs (Kahn et al. 
1998). Consistently PMPs are elevated in the blood of patients with 
cardiovascular complications (VanWijk et al. 2003, Willis 2015). PMPs play a 
role in vascular damage through the modulation of pathogenic pathways in ECs 
(Adrover and Hidalgo 2015, Coughlin 2000, George et al. 1986a, Undas et al. 
2009) such as downregulating protective nitric oxide synthase expression and 
inducing inflammatory mediators such as interleukin-6, MCP-1, intercellular 
adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin, which 
promote signalling causing dysfunction (Barry et al. 1997). Co-incubation of ECs 
with PMPs in-vitro causes ECs proliferation and migration (Boilard et al. 2010a), 
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induces inflammation and promotes angiogenesis (Barry et al. 1997, Brill et al. 
2005). These responses are all upregulated in CVD. However, the molecular 
mechanisms by which PMPs induce these changes, leading to the development 
and progression of athero-thrombosis, remain to be fully determined (Laffont et 
al. 2013).  
 
We tested our hypothesis that the diverse miRNAs already identified within 
PMPs, which can be transferred to ECs (Laffont et al. 2013) underpin this 
process. We show that treatment of EAhy926 and primary HUVEC cells with 
PMPs caused increased tube formation and EC sprouting (Figure 3.6 and 3.8), 
confirming that PMPs can induce angiogenesis as previously shown  (Kim et al. 
2003). The observed angiogenesis in our experiments was equally comparable 
to levels induced by just whole platelets in-vitro (Brill et al. 2005), demonstrating 
a  robust response, relevant to pathological conditions. The levels of MP in the 
circulation of healthy individuals ranges from 5μg/ml – 50μg/ml (Antwi-Baffour et 
al. 2010), which increases by more than 2-folds in CVD including hypertension, 
thrombosis and diabetes (Nomura et al. 2000, Nomura et al. 1995, Tan and Lip 
2005). Therefore, PMP released during CVD is comparable to the concentration 
used in this study. The induction of angiogenesis by PMPs was significantly 
blocked by degrading the RNA content of the PMPs with RNase. Degrading of 
the RNA in PMPs increased PMPs induced tube formation but significantly 
reduced PMP induced sprouting in EAhy926 cells (Figure 3.11). However, in 
HUVEC, the primary cells, both tube formation and branching was reduced by 
degrading RNA content of PMP (Figure 3.17). Because RNase treatment has 
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previously been shown to blunt the ability of PMPs to transfer miRNAs (Laffont 
et al. 2013), these data thus suggest a potential role for PMP-miRNA in the 
induction of angiogenesis and may contribute in the development of CVD. The 
differences in the responses elicited by PMP treatment of the EC line EAhy926 
and primary HUVECs is likely due to the different cytokine and signalling 
signatures of these cell types, as described in the results section. We further 
investigated this response and the underpinning mechanisms by assaying the 
released angiogenic cytokine profile of both cell types before and after PMP 
treatment. 
 
Our results show that PMPs caused the release of a distinct angiogenic protein 
signature from ECs. We found increased release of PIGF, TIMP-1, MCP-1, PF4, 
IL-8, angiopoietin-2, Endoglin, IGFBP-2 and uPA in both EAhy293 and HUVEC 
(Figure 3.9). Interestingly, PIGF, MCP-1, IL-8, uPA and angiopoietin-2 are pro-
angiogenic in nature, but both TIMP-1 and PF4 have anti-angiogenic functions 
(Gomez et al. 1997, Maione et al. 1990). THBS-1, a key anti-angiogenic protein, 
was reduced in HUVEC but remained largely undetected in EAhy926 cells. 
Conversely, anti-angiogenic endothelin-1 was increased in HUVEC but reduced 
in EAhy926 cells. EAhy296 cells have undergone genetic transformation 
combining EC and fibroblast function to improve growth and survival (Edgell et 
al., 1990; Gifford et al., 2004; Unger et al., 2002). The genetic differences arising 
from this hybridization could result in different response to PMP treatment 
(Edgell et al., 1990; Gifford et al., 2004; Unger et al., 2002). 
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Given the critical role played by cytokines in angiogenesis (Senger 1996), the 
induction of angiogenesis seen in our study is likely due to modulation of these 
released modulators by PMPs. IL-8 and MCP-1 both stimulate endothelial cell 
migration (Bhadada et al. 2011, Distler et al. 2003) by directly binding to the 
CXCR1, and CXCR2 and CCR2 receptors, respectively to induce direct cell 
response (Salcedo et al. 2000). Migration is a key early step for angiogenesis. 
MCP-1, a member of the chemokine superfamily, is additionally implicated in 
several cellular responses linked to CVD development, including inflammation, 
angiogenesis, atherosclerosis, and tissue remodelling (Deshmane et al. 2009). 
The functions and the implications of increased MCP-1 release are discussed in 
Chapter 5.  
 
 IL-8 belongs to the CXC family of chemokine, which has been shown to 
mediate angiogenic activity through CXCR2 binding (Addison et al. 2000). 
Moreover, IL-8 is a potent mediator of inflammatory responses and a growth 
factor for ECs  (Schraufstatter et al. 2001). Schraufstatter et al (2001) also 
showed that IL-8 activates the small G protein Rho and Rac signalling pathways 
through ECs CXCR receptor 1 and receptor 2 (Schraufstatter et al. 2001), 
enabling adhesion and leucocyte rolling. IL-8 also has been shown to increase 
endothelial MMP-2 and MMP-9 mRNA (Li et al. 2003), which once translated 
into protein, will increase the degradation of the extracellular matrix, promoting 
angiogenesis.  
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The increase in PIGF release is important because it is a member of the VEGF 
tyrosine kinase family, the archetypical angiogenesis regulators. There are 
different isoforms including  PIGF-1, -2, -3 and -4, which all mediate their effect 
through VEGFR-1 (Ylä-Herttuala and Alitalo 2003). Data on the angiogenic 
effects of PIGF remains inconsistent however. Roy et al (2005) showed PIGF - 
VEGFR-1 ligation had no effect on EC growth and angiogenesis (Roy et al. 
2005), but Autiero et al reported that PIGF/VEGFR-1 signalling facilitates 
angiogenesis and promotes EC viability (Autiero et al. 2003). It is thought that 
PIGF modulates EC activity by eliciting its signalling or amplifying VEGF –driven 
angiogenesis (Autiero et al. 2003). Indeed, overexpression of PIGF-2 has been 
found to cause significant increase in angiogenesis in tissues (Ahmed et al. 
2000, Luttun et al. 2002). The regulation of PIGF by PMPs therefore warrants 
further investigation.  
 
The high levels of the MMP inhibitor TIMP-1 detected is surprising considering 
that angiogenesis is characterised by MMP degradation of the extracellular 
matrix (Rundhaug 2005), which allows EC migration and formation of new blood 
vessels (Rundhaug 2005). TIMP-1 can inhibit this function and ultimately 
angiogenesis. The finding that PMPs caused tube formation and sprouting 
despite elevated TIMP-1, suggests that TIMP-1 levels could not completely 
inhibit the angiogenic effects of MMPs or possible feed-forward mechanism, 
where increased MMP causes upregulation of TIMP but not enough to 
overcome the effect of the MMPs.  The fact that TIMP-1 is detected in 
atherosclerotic plaques (Crisby et al. 2001) also suggests potential pathological 
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functions independent of angiogenesis, maybe through regulation of 
inflammatory mediators (Crisby et al. 2001). Additionally, MCP-1 and IL-8 are 
both capable of inhibiting TIMP-1 (Friedman 2000), both of which we also found 
to be released by ECs treated with PMP, suggesting that the high levels of 
TIMP-1 could be remedied by MCP-1 and IL-8. 
 
Our proliferation data seem to show that PMP inhibited EAhy293 and HUVEC 
cell proliferation, this result is contrary to the reported PMP-induced increase in 
proliferation by another study (Kim et al. 2003). The Kim study used HUVEC 
from commercial sources, which have often been selectively sorted for 
proliferation capacity, compared to the cell line and primary HUVECs isolated 
from donors used in this PhD study. Unfortunately, the study by Kim et al., 2003 
did not measure the release of angiogenic proteins, which made it difficult to 
determine if the protein response between the cells in both studies were 
different. Another likely explanation is the known negative effect of PF4 and 
TIMP-1 on EC proliferation (Gomez et al. 1997, Maione et al. 1990), where 
increased in our study. TIMP-1 has been shown to inhibit human EC 
proliferation through mechanisms independent of its proteinase activity on MMP. 
In addition, PF4 has been demonstrated to inhibit EC entry into the S phase, 
inhibiting cell proliferation independent of the type and concentration of stimuli 
used to induce angiogenesis (Gupta and Singh 1994). 
 
Degrading PMP RNA before EC co-incubation blunted the ability of PMPS to 
alter the angiogenic profile of ECs. We show for the first time that RNA 
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degradation of PMPs from healthy donors reduced MCP-1, PIGF, PF4, TIMP-1 
and uPA release, whilst increasing THBS-1 production compared to treatment 
with non-RNase incubated PMPs. Of particular interest is THBS-1, a matrix-
cellular glycoprotein that binds to extracellular matrix proteins, such as 
fibronectin (Bale et al. 1985) strongly inhibit angiogenesis. The protein has high 
affinity for heparin sulphate proteoglycans and some integrins, which enables it 
to modulate angiogenesis, chemotaxis, and adhesion (Bornstein 1995). Given 
the profound anti-angiogenic role of THBS-1, and that its production from ECs 
fitted a miRNA regulated pattern (a reduction after PMP treatment but not after 
RNase-PMP treatment), we investigated its role in PMP mediated angiogenesis 
in Chapter 4.  
 
We confirmed the existence of miRNAs in PMPs and revealed the potential 
complex molecular, cellular and biological functions of these miRNAs using RNA 
sequencing and computational, functional analysis. Platelets are key elements 
of the cardiovascular system and contain a diverse transcriptome of miRNA 
(Landry et al. 2009) that can be packaged into PMPs to target many protein 
coding genes in recipient cells, including ECs (Laffont et al. 2013). In support of 
this functional role, predictive functional analysis of some of the mRNAs targeted 
by highly-expressed miRNAs in PMP including many members of the Let-7 
miRNA family, revealed many pathways and cellular processes associated with 
angiogenesis. Considering that angiogenesis plays a critical role in athero-
thrombosis, targeting of its components pathways like Ras signalling pathway 
and cytokine-cytokine signalling, and cellular processes like cell adhesion and 
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migration by PMP-miRNA suggests they may promote the development and 
progression of CVD and associated comorbidities like renal and neurological 
complications. This hypothesis was strengthened by the observation that the 
predicted mRNAs targets of the top highly expressed PMP-miRNA are linked to 
cardiovascular, metabolic, renal and neurological diseases. These diseases 
have been shown to strongly correlate with the events preceeding the rupture of 
atherosclerotic plaques (Kuzemczak et al. 2016, Yusuf et al. 2001).  
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CHAPTER 4: PMP-MIRNA REGULATE THSB-1 MRNA TO INDUCE 
ANGIOGENESIS  
4.1 Introduction 
This part of the study was based on the hypothesis that miRNAs played a role in 
PMP induction of angiogenesis. Chapter 3 highlighted the important role of PMP 
transferred RNAs in modulating the release of angiogenic cytokines by ECs with 
corresponding induction of tube formation. PMP induced reduction in THBS-1 
protein level was reversed by pre-treatment of PMP with RNAse, and this 
correlates with the observed angiogenesis profile. miRNAs primarily target 
mRNAs to inhibit protein production, the reduction of THBS-1 protein release by 
PMP correlates with this regulation process. THBS-1 is a potent endogenous 
inhibitor of angiogenesis, which acts by reducing EC migration and survival, as 
well as antagonising the angiogenic activity of some growth factors like VEGF 
(BenEzra et al. 1993, Kazerounian et al. 2008, Lawler 2002). Thus, the inhibition 
of THBS-1 release will reverse these inhibitory effects to allow a robust 
angiogenesis response. Therefore, we investigated the mechanisms of PMP 
inhibition of THBS-1 protein release.  
 
Initially, miRNAs that target THBS-1 were identified in silico using TargetScan, a 
prediction tool for miRNA targets. The potential targets were probed against the 
published list of miRNAs in PMPs (Diehl et al. 2012b). The target identification 
process revealed that Let-7a and miR-221 can target THBS-1 (Figure 4.1). This 
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computational result is supported by a recent study that reported several 
chemically synthesised miRNAs, including Let-7a and miR-221 that inhibit 
THBS-1 expression (Dogar et al. 2014).  
 
 
Figure 4.1: Predicted target sites of Let-7a and miR-221 on the THBS-1 
3’UTR (TargetScan). 
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4.2 PMP express the microRNA Let-7a and miR-221 
To confirm the microarray/computational search results (Figure 4.1), we 
determined the expression of Let-7a and miR-221 in our PMPs by stem-loop 
qRT-PCR. PMP pellets were lysed and RNA extracted as described in section 
2.10.1. Specific stem-loop primers for Let-7a, miR-221 and U6s, a small non-
coding nuclear RNA reference gene (Koch et al. 2011), were used to generate 
stem-loop cDNA and expression levels analysed by qRT-PCR using specific 
forward primers and universal reverse primers. PMPs treated with RNAse were 
used to confirm efficiency. The results show that PMPs contain both miRNA Let-
7a and miR-221 compared to RNAse treated PMP (Figure 4.2). Moreover, the 
analysis of RNAse treated PMPs revealed total degradation of Let-7a and miR-
221 (Figure 4.2).  
 
 
 
 
 
Figure 4.2: PMPs contain Let-7a and miR-221, which are degraded by 
RNAase treatment. Levels of miRNAs Let-7a and miR-221 in PMP were 
measured by stem-loop qRT-PCR. Bar represents relative expression of 
microRNA Let-7a and miR-221 in PMPs treated with RNAse 0.1 Units/ml or 
control buffer. Data shown are mean ± standard error of mean, n=3. 
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4.2.1 PMP express all the subtypes of the microRNA Let-7a and miR-221 
Three subtypes of Let-7a including Let-7a-1, Let-7a-2 and Let-7a-3 have been 
identified in the human genome, and published data on miRNA contents of PMP 
show they contain different subtypes of Let-7a members. Therefore, we 
investigated if the different members of Let-7a miRNA family were in our PMPs. 
Total RNA samples from PMPs were analysed by Ilumina RNA sequencing. The 
normalised transcript counts showed that the PMP contain large amounts of Let-
7a subtypes (Figure 4.2a). The analysis showed that members of the Let-7a 
family are amongst the most highly-expressed miRNAs in PMPs.  
 
Figure 4.2a: PMPs express high levels of members of the Let-7 miRNA 
family. Total RNA was isolated from healthy PMPs and analysed by Ilumina 
RNA sequencing.  Data represents normalised transcript counts, n=3 biological 
replicates.  
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4.3 PMP increased the levels of Let-7a in HUVEC 
Let-7a has been shown to target THBS-1 mRNA and repress its protein 
expression in Hela cells, and our data demonstrate that PMPs inhibit THBS-1 
protein release. We next investigated the transfer of Let-7a to HUVEC. HUVEC 
(3 x105) were cultured in Medium 200 supplemented with 1% serum or 100μg/ml 
PMPs (with and without prior RNAse treatment) in 1% serum for 24 hours. Total 
RNA was extracted and the expression of Let-7a and miR-221 measured with 
stem-loop qRT-PCR. Treatment of HUVEC with 100μg/ml PMPs caused a 
significant increase in Let-7a levels (2-fold ± SEM, p<0.05) compared to basal 
levels, which was blocked by pre-treating PMPs with RNAse (Figure 4.3). 
 
 
 
 
 
 
 
Figure 4.3: PMPs deliver the microRNA Let-7a to HUVEC. Relative miRNA 
expression of Let-7a miRNA in HUVEC cultured in: (EC) 1% serum, (EC+PMP) 
100μg/ml PMPs, or (EC+PMP+RNAse) in the presence of 100μg/ml PMPs 
treated with RNAse for 24 hours. Data shown are mean ± standard error of 
mean, n=3 independent biological samples of PMPs. *P<0.05 Tukey SD 
individual miRNA expression level between EC and EC+PMP, or between 
EC+PMP and EC+PMP+RNAse. 
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Surprisingly, treatment of HUVEC with 100μg/ml PMPs caused a significant 
decrease in miR-221 levels (0.63-fold) compared to the basal level (Figure 4.4). 
This was further decreased by treatment with 100μg/ml PMPs pre-treated with 
RNAse (0.25-fold) (p<0.05) (Figure 4.4) compared to the complete PMP 
treatment or basal level. The results suggest that PMPs could inhibit the 
endogenous expression of miR-221, even though the PMP miRNA is actively 
delivered to the endothelial cells. Though this result limited our selection to Let-
7a for further analysis, further investigation to confirm this result and the 
potential implications will be insightful.  
 
 
 
 
 
 
 
 
Figure 4.4: PMPs deliver and downregulate the microRNAs miR-221 in 
HUVEC. Relative miRNA expression of miRNA-221 in HUVEC cultured in (EC) 
1% serum, (EC+PMP) 100μg/ml PMPs, or (EC+PMP+RNAse) in the presence 
of 100μg/ml PMPs treated with RNAse for 24 hours. Data shown are mean ± 
standard error of mean, n=3 independent biological samples of PMPs. *P<0.05 
Tukey SD individual miRNA expression level between EC and EC+PMP, or 
between EC+PMP and EC+PMP+RNAse. 
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4.4 PMP transfer is required to elicit endogenous expression of Let-7a in 
treated HUVEC. 
To confirm that the observed increase in Let-7a levels in PMP-treated HUVEC is 
dependent on active transfer rather than increased EC endogenous production 
of Let-7a, we inhibited active transcription with actinomycin D (actD). The 
binding of actD to DNA and inhibition of transcription is associated with cell 
death. Therefore, initial cell viability assessment was performed by manual 
counting. The result show that 4-hours pre-treatment with 0.25ng/µl of actD 
before 24-hours cell culture caused cell death, but allowed enough cells to 
survive for subsequent PMP treatment and RNA analysis by stem-loop qRT-
PCR.  
 
 
 
 
 
 
 
 
Figure 4.5: Actinomycin D induce marginal HUVEC cell death. Cell number 
of HUVEC cultured in 1% serum (EC) or pre-treated with (0.25ng/µl) of 
actinomycin D in 1% serum for 4-hours before culture for 24-hours. Data shown 
are mean ± standard error of mean, n=3 independent experiments.  
 
 141 
HUVEC were cultured either in 1% serum, pre-treated with 0.25ng/µl of actD in 
1% serum, treated with 100μg/ml PMPs in 1% serum or pre-treated with 
0.25ng/ul of actD in 1% serum for 4-hours before treatment with 100μg/ml PMPs 
in 1% serum, for 24-hours. Total RNA was extracted, converted to stem-loop 
cDNA and Let-7a levels assessed by stem-loop qRT-PCR. Treatment with 
100μg/ml PMPs caused a significant increase in Let-7a levels (184.129-folds) 
compared to basal level (Figure 4.6), which was consistent with the results in 
Figure 4.3. Moreover, treatment of actD treated cells with 100μg/ml PMPs also 
caused a significant increase in Let-7a levels (64.64-fold) compared to basal 
levels, which suggest that PMP transferred this Let-7a. However, Let-7a levels 
after consecutive actD and 100μg/ml PMPs treatment had significantly reduced 
level of Let-7a compared to 100μg/ml PMPs treatment (Figure 4.6). Hence, the 
increased level of Let-7a is in part because of endogenous increase in 
expression but is predominantly mediated by PMP transfer. 
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Figure 4.6: PMPs deliver and increase the expression Let-7a in HUVEC. 
Relative miRNA expression of Let-7a in HUVEC cultured in 1% serum (EC), pre-
treated with 0.25ng/ul of actinomycin D for 4-hours before 24-hours culture in 
1% serum (EC+actD), treated with 100μg/ml PMPs in 1% serum (EC+PMP) or 
pre-treated with 0.25ng/ul of actinomycin D for 4-hours in 1% serum before 
treatment with 100μg/ml PMPs in 1% serum, for 24-hours (EC+actD+PMP). 
Data shown are mean ± standard error of mean, n=3 pooled biological samples 
of healthy PMPs. *P<0.05 Tukey SEM individual miRNA expression level 
between EC and EC+PMP, EC+actD+PMP and EC+PMP and EC+actD+PMP 
and EC.  
 
 
 
 
 
 143 
4.4.1 PMP is internalised by HUVEC in time dependent manner 
To further confirm the transfer of PMP content, HUVEC cells 1 x 105 cells were 
treated with DiOC6 dye stained PMP for 6, 12 or 18 hours and visualised with a 
fluorescent microscope. The results showed that HUVEC internalise PMP in a 
time dependent manner (Figure 4.6a). 
 
Figure 4.6a: PMP is internalised by HUVEC in a time dependent manner. 
HUVEC cells (1 x 105 cells per well) seeded on a cover slip were treated with 
100μg/ml of DiOC6 stained PMPs for 6, 12 or 18 hours. PMP internalisation was 
capture with a florescent microscope. Images show representative treatments of 
three biological replicates. 
4.5 PMPs express THBS-1 mRNA 
To exclude the contribution of transcription level effect on THBS-1 on the 
reduced THBS-1 protein shown before in Figure 3.19, we used a standard qRT-
PCR to measure the mRNA transcripts of THBS-1 in primary HUVEC treated 
with PMP. Because of the reported presence of THBS-1 mRNA in PMP, we 
initially investigated the presence of THBS-1 mRNA in PMP. Though transfer of 
THBS-1 mRNA transcript from PMP would cause high expression value in qRT-
PCR analysis of PMP treated HUVEC, these transcripts are unlikely to be 
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translated to functional THBS-1 protein because of pre-binding of miRNAs 
contained in PMPs (Probst et al. 2007). Total RNA extracted from PMPs or 
RNAse treated PMPs were converted to cDNA and analysed for the presence of 
THBS-1 mRNA by qRT-PCR. The data show that PMPs do contain THBS-1 
mRNA (1-fold), which was degraded by RNAse treatment (Figure 4.7).  
 
 
 
 
 
 
 
 
 
Figure 4.7: RNAse treatment of PMPs degrades THBS-1 mRNA content. 
Relative expression of THBS-1 in (PMP) untreated PMPs and (PMP+RNAse) 
PMP treated with RNAse. Data shown are mean ± standard error of mean, n=3. 
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4.5.1 PMP express three subtypes of THBS mRNA 
There are currently four identified human subtypes of THBS including THBS-1, 
THBS-2, THBS-3 and THBS-4, but the levels of these subtypes in PMP has not 
been previously described. Therefore, we measured the levels of the four types 
of THBS mRNA in PMPs to support the transfer of THBS-1 mRNA transcripts to 
treated HUVEC. Total RNA samples from PMPs were analysed by Ilumina RNA 
sequencing. The normalised transcript counts showed that PMP contain large 
amounts of THBS transcripts (Figure 4.3). The analysis showed that THBS-1 
was highly-expressed compared to THBS-3 and THBS-4, while THBS-2 is 
absent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7a: PMP express three subtypes of THBS mRNA. Total RNA was 
isolated from PMP and analysed by Ilumina RNA sequencing. Data represents 
normalised transcript counts, n=3 biological replicates (Figure 4.3). 
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4.8 PMPs elicit positive feedback transcription of THBS-1 
Having shown that PMPs induce angiogenesis, which was associated with 
reduced THBS-1 protein levels, we investigated the potential contribution of 
altered mRNA levels of THBS-1 mRNA. HUVEC (3 x 105 cells/well) were 
cultured with either 1% serum, 100μg/ml PMPs or RNAse treated PMP in 1% 
serum, for 24-hours. Extracted total RNA was converted to cDNA and mRNA 
expression of THBS-1 quantified by qRT-PCR. The results showed that 24-
hours treatment with 100μg/ml PMPs, or PMPs pre-treated with RNAse caused 
a significant increase in THBS-1 mRNA levels (1.9-fold) (Figure 4.8) compared 
to basal level (1-fold). THBS-1 mRNA in treatment with 100μg/ml PMPs pre-
treated with RNAse (1.5-folds) was significantly lower than levels in cells treated 
with 100μg/ml PMPs (Figure 4.8). Thus, treatment with PMPs induce increased 
transcription of THBS-1 in HUVECS, independent of transferred mRNA 
transcript, whilst transferring its THBS-1 mRNA content.  
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Figure 4.8: PMPs elicit positive feedback transcription of THBS-1. Relative 
mRNA expression of THBS-1 in HUVEC cultured in (EC) 1% serum, (EC+PMP) 
100μg/ml PMPs, or (EC+PMP+RNAse) in the presence of 100μg/ml PMPs 
treated with RNAse for either. Data shown are mean ± standard error of mean, 
n=3 independent biological samples of PMPs. *P<0.05 Tukey SD individual 
miRNA expression level between EC and EC+PMP, or between EC+PMP and 
EC+PMP+RNAse. 
 
4.9 PMP inhibit translation of THBS-1 protein 
Previous sections showed that PMPs transfer Let-7a miRNA to HUVECS, and 
that increased angiogenesis corresponds to reduced THBS-1 protein release. 
mRNA levels of THBS-1 were increased, likely due to exogenous transfer. 
Binding of miRNA to target mRNA can inhibit protein production without altering 
mRNA levels. Therefore, we transfected HUVEC with a selective Let-7a inhibitor 
using Lipofectamine 3000 before treating the cells with PMPs to investigate the 
contribution of Let-7a in PMP mediated regulation of THBS-1 protein level. 
HUVEC (3 X105 cells/well) were cultured in 1% serum overnight before 
 148 
transfection of Let-7a inhibitor or non-targeting miRNA inhibitor. 24 hours after 
incubation untransfected or transfected cells were treated with PMP or control 
and THBS-1 levels analysed by ELISA. 
4.9.1 THBS-1 protein level in HUVEC is not affected by transfection reagent 
The effect of Lipofectamine reagent on endothelial cell production and release of 
THBS-1 has not been investigated. Therefore, we performed additional control 
experiments to ensure that the effect of Let-7a inhibitor on PMP mediated 
regulation of THBS-1 protein is specific and independent of the transfection 
reagent. Cell culture media collected after transfection before PMP treatments 
as described above was analysed by THBS-1 ELISA. The result showed that 
24-hours transfection of Let-7a or non-targeting inhibitor had no effect on the 
release of THBS-1 protein (Let-7a:1544ng/ml) and (non-targeting 
inhibitor:1571ng/ml) compared to un-transfected cells (EC: 1426ng/ml) (Figure 
4.9). Therefore, the effect of Let-7a inhibitor on the ability of PMP to inhibit 
THBS-1 protein level can be interpreted independent of the effect of transfection 
reagents.  
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Figure 4.9: THBS-1 is not affected by transfection reagent. THBS-1 protein 
concentration released in the growth medium of HUVEC cultured in 1% serum 
(EC), transfected with Let-7a inhibitor for 24-hours (EC+7aI) or transfected with 
non-targeting inhibitor for 24-hours (EC+SC). Data shown are mean ± standard 
error of mean, n=15 pooled experimental samples. *P<0.05 Tukey SD protein 
concentration comparisons between EC, EC+7aI and EC+SC. 
4.9.2 PMP inhibition of THBS-1 protein expression in HUVEC is dependent on its 
Let-7a content 
The data showed that 24-hours PMPs treatment of untransfected ECs, caused a 
significant reduction in the release of THBS-1 protein (134.4ng/ml) compared to 
untreated HUVEC (221.5ng/ml), transfected with Let-7a inhibitor (241.7ng/ml) or 
EC transfected with non-targeting inhibitor (235.4ng/ml) (p<0.05) (Figure 4.10). 
Transfecting scrambled control was unable to block the effect of PMP treatment 
(150.2ng/ml) compared to untreated and EC at 1191ng/ml (p<0.005) (Figure 
4.11A), confirming a Let-7a specific effect. The transfection reagent had no 
effect on the release of THBS-1 protein in untransfected HUVEC, transfected 
with Let-7a or transfected with non-targeting inhibitor because no significant 
difference was observed. These data show that 24-hours treatment with PMPs 
reduces THBS-1 from HUVEC through transferring Let-7a. 
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Figure 4.10: PMP inhibition of THBS-1 protein release is dependent on its 
Let-7a. Absolute thrombospodin-1 protein concentration released 24hours post 
treatment in the growth medium of HUVEC cultured in 1% serum (EC), 
100μg/ml PMPs in 1% serum (EC+PMP), 1% serum after 24-hours transfection 
of Let-7a inhibitor (EC+7aI), 100μg/ml PMPs after 24-hours transfection of Let-
7a inhibitor in 1% serum (EC+7aI+PMP), 1% serum after 24-hours transfection 
of scrambled inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of 
scrambled inhibitor in 1% serum (EC+SC+PMP). Data shown are mean ± 
standard error of mean, n=3 independent biological samples of healthy PMPs. 
*P<0.05 Tukey SD relative protein expression of all shown comparisons 
between EC+PMP, EC+7aI, EC+7aI+PMP, EC+SC and EC+SC+PMP. 
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4.10 PMP-Let-7a inhibition of THBS-1 is necessary and sufficient to 
promote angiogenesis in HUVEC 
Following the observation that the inhibition of THBS-1 release was dependent 
on post-translation regulation by Let-7a, we then investigated the functional 
implications by in-vitro angiogenesis assay. HUVEC (3 X105 cells/well) were 
cultured in 1% serum overnight before transfection with the Let-7a inhibitor or 
non-targeting miRNA inhibitor. An additional 24 hours after incubation (3x104 
cells/well) untransfected or transfected cells were treated with PMP (100μg/ml) 
or left untreated as a negative control. Angiogenesis was measured by Matrigel 
and quantified by measuring tube length and the number of branch points. 
Treatment of HUVEC with PMP caused a significant increase in tube length 
(12494uM) and branch point (86.33) compared to untreated HUVEC: tube length 
3599uM and branching 86.33 (Figure 4.11) as reported in chapter 4. In HUVEC 
transfected with the Let-7a inhibitor, PMPS had a significantly weaker effect on 
tube length (8005uM) and branching (55.50) compared to HUVEC treated with 
PMP alone: tube length (13505uM) and branching (93.17) (Figure 4.11). 
Scrambled inhibitor had no effect on PMP mediated angiogenesis. Similarly, 
transfection alone did not change the angiogenic response. The result show that 
PMP mediated angiogenesis is through Let-7a inhibition of THBS-1 protein 
release. However, let-7a inhibition did not fully blunt the angiogenic effects of 
PMPs, suggesting that additional mechanisms contribute to PMP induced 
angiogenesis.  
 
 152 
 
Figure 4.11: PMP-Let-7a inhibition of THBS-1 is necessary and sufficient to 
promote angiogenesis in HUVEC. Representative images (×40 magnification) 
showing extracellular matrix gel-based, capillary-like tube formation of HUVEC 
cells incubated in 1% serum (EC), 100μg/ml PMPs in 1% serum (EC+PMP), 1% 
serum after 24hours transfection of Let-7a inhibitor (EC+7aI), 100μg/ml PMPs 
after 24-hours transfection of Let-7a inhibitor in 1% serum (EC+7aI+PMP), 1% 
serum after 24-hours transfection of scrambled inhibitor (EC+SC) or 100μg/ml 
PMPs after 24-hours transfection of scrambled inhibitor in 1% serum 
(EC+SC+PMP). Data shown are mean ± standard error of mean, n=3 
independent biological samples of PMPs. *P<0.05 Tukey SD total tube length or 
branch points of all shown comparisons between EC+PMP, EC+7aI, 
EC+7aI+PMP, EC+SC and EC+SC+PMP.  
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4.11 Functional Integrin b1 (CD29) and Integrin associated protein (CD47) 
is indispensable in PMP induced angiogenesis  
Our data show that the inhibition of Let-7a blocks PMP mediated downregulation 
of EC’s THBS-1 release, and inhibits PMP induced angiogenesis. Therefore, we 
assessed if the reduction in THBS-1 release from HUVECS was directly 
responsible for promoting the observed angiogenesis. The activity of THBS-1 
has been linked to its binding to the surface receptors, integrin subunit beta1 
(CD29) and integrin associated protein (CD47) (Nör et al. 2000). Therefore, we 
used blocking antibodies against both receptors in an in-vitro angiogenesis 
assay to see if the functional effect of THBS-1 inhibition could be rescued. 
HUVEC (3 X105 cells/well) were cultured in 1% serum overnight before 
transfection of Let-7a inhibitor or the control, non-targeting miRNA inhibitor for 
24 hours, followed by subsequent 1 hour treatment with combinations of 
blocking antibodies for CD29 and CD47 at 2µg/ml. PMP treatment was then 
applied to HUVEC on Matrigel for 18 hours and tube formation measured as 
described before. Unfortunately, both antibodies ablated angiogenesis 
regardless of PMP treatment or Let-7a inhibition, so could not be used as tools 
to interrogate if Let-7a inhibition of THBS-1 release drives angiogenesis (Figure 
4.12). However, the results suggest that both functional CD29 and CD47 are 
vital for HUVEC angiogenesis.  
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Figure 4.12: Functional Integrin b1 (CD29) and Integrin associated protein 
(CD47) are indispensable in PMP induced angiogenesis. A) Representative 
images (×40 magnification) showing extracellular matrix gel-based, capillary-like 
tube formation of HUVEC cells, (B and C) quantitative tube length and branch 
point, respectively. Transfected or untransfected HUVEC cells 2 x 104 cells per 
well on ECM matrix were treated with a combination of anti-CD29 and anti-CD47 
before treatment with PMP, for 18-hours. Data shown are mean ± standard error 
of mean, n=3 independent biological samples of PMPs. 
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4.12 Targeting of THBS-1 by transferred Let-7a is critical in PMP induced 
angiogenesis 
Next, we used a blocking antibody against THBS-1 (Clone A.4.1) in the Matrigel 
angiogenesis assay to see if altered THBS-1 levels in our system were 
responsible for angiogenesis. PMP treatment of HUVECs reduced THBS-1 
levels (Figure 3.18) and at the same time increased angiogenesis (Figure 3.17). 
This was blocked by pre-transfection with a targeted Let-7a inhibitor (Figure 4.10 
and Figure 4.11), where THBS-1 levels remained high and angiogenesis 
remained low. If the decreased THBS-1 levels after PMP treatment were 
responsible for inducing angiogenesis, and inhibiting Let-7a blocked the 
induction of angiogenesis through stopping the decrease in THBS-1, then 
antibody inhibition of THBS-1 followed by PMP treatment would induce 
angiogenesis in both Let-7a inhibitor and non-targeting inhibitor transfected 
HUVECs. HUVECs (3 X105 cells/well) were cultured with 1% serum, then 
transfected for 24 hours with the Let-7a inhibitor or non-targeting inhibitor. 
HUVEC were then incubated with a THBS-1 blocking Ab (Clone A4.1 at 2ug/ml) 
or control for incubation time, followed by treatment with PMPs as before. The 
results showed that HUVEC treatment with PMP caused a significant increase in 
tube length (12494uM) and branch point (86.33) compared to untreated HUVEC: 
tube length 3599uM and branching 86.33 (p<0.05) (Figure 4.13). In HUVEC 
transfected with Let-7a inhibitor, PMPs had a significantly weaker effect on tube 
length (8005uM) and branching (55.50) compared to HUVEC treated with PMP 
alone: tube length (13505uM) and branching (93.17) (Figure 4.13).  
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Treatment of Let-7a transfected HUVEC with THBS-1 blocking antibody before 
PMP caused a significant increase in tube length (14237uM) and branching (46) 
compared to transfection controls and untreated HUVEC (Figure 4.13). PMP 
treatment of HUVEC in the presence of THBS-1 neutralising antibody caused 
significant increase in angiogenesis independent of the transfection of Let-7a or 
non-targeting inhibitors. However, tube length (14237uM) and branch point (73) 
were significantly higher in untransfected HUVEC treated with neutralising 
THBS-1 antibody and PMPs compared to treatment of HUVEC transfected with 
let-7a inhibitor or non-targeting inhibitor with THBS-1 and PMPs. However, there 
were no difference between HUVEC transfected with let-7a inhibitor or non-
targeting inhibitor treated with neutralising THBS-1 antibody and PMPs. The 
result show that imbibition of THBS-1 protein allowed PMP to induce 
angiogenesis independent of Let-7a inhibition. 
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Figure 4.13: Targeting of THBS-1 by transferred Let-7a is critical in PMP 
induced angiogenesis. Representative images (×40 magnification) showing 
extracellular matrix gel-based, capillary-like tube formation of HUVEC cells, (B 
and C) quantitative tube length and branch point, respectively. HUVEC cells 2 x 
104 cells per well on ECM matrix were treated with 1% serum (EC), pre-treated 
with THBS-1 antibody (EC+THBS-1) or treated with 100μg/ml PMPs after pre-
treatment with THBS-1 (EC+THBS-1+PMP), treated with: THBS-1 after 24-
hours transfection of Let-7a inhibitor (EC+7AI+THBS-1), THBS-1 after 24-hours 
transfection of non-targeting inhibitor (EC+SC+THBS-1), 100μg/ml PMPs after 
24-hours transfection of Let-7a inhibitor followed by pre-treatment with THBS-1 
(EC+7aI+THBS-1+PMP) or 100μg/ml PMPs after 24-hours transfection of non-
targeting inhibitor followed by pre-treatment with THBS-1 (EC+SC+THBS-
1+PMP)  Data shown are mean ± standard error of mean, n=3 independent 
biological samples of PMPs. *P<0.05 Tukey SD total tube length or branch 
points for all shown comparisons between. 
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4.13 PMP inhibited caspase 3 activation in HUVEC through a Let-7a 
dependent mechanism 
One of the key mechanism of THBS-1 regulation of angiogenesis is the 
induction of apoptosis through the activation of caspase pathway (Nör et al. 
2000). Specifically, caspase 3 is a reliable marker of apoptosis, an executioner 
which acts in coordination, downstream of other caspases to induce programed 
cell death. Therefore, we investigated the effect of PMP treatment on the level of 
activated caspase 3 in HUVEC by western blot to see if PMP mediated changes 
in THBS-1 protein through Let-7a correlated with reduced caspase 3 activation. 
HUVEC (3 X105) were cultured in 1% serum overnight before transfection of Let-
7a inhibitor (EC+7aI) or non-targeting miRNA inhibitor. Additional 24 hours after 
transfection cells were treated with PMP or left untreated as negative 
transfection controls. Whole protein sample was isolated and used for 
immunoblotting. Treatment of HUVEC with PMP caused a significant reduction 
in activated caspase 3 (2050) compared to untreated HUVEC (4200) (Figure 
4.14A). In HUVEC transfected with Let-7a inhibitor, PMPs significantly induced 
caspase 3 activation (4000) compared to HUVEC treated with PMP. The results 
showed that PMP mediated inhibition of caspase 3 activation is a Let-7a 
dependent mechanism, potentially through inhibition of THBS-1 protein release. 
Let-7a inhibition completely reversed the anti-caspase activation effect of PMPs, 
suggesting that Let-7a mechanism might be the sole mechanism involved. 
Transfection with non-targeting inhibitor or Let7a inhibitor alone did not largely 
alter caspase 3 activation. 
 
 159 
 
Figure 4.14: PMP inhibits caspase 3 activation through a Let-7a dependent 
mechanism. (A) Representative blots (B) Relative quantification of cleaved 
caspase 3 by western blot of whole cell lysate of HUVEC cultured in 1% serum 
(EC), 100μg/ml PMPs in 1% serum (EC+PMP), 1% serum after 24-hours 
transfection of Let-7a inhibitor (EC+7aI), 100μg/ml PMPs after 24-hours 
transfection of Let-7a inhibitor in 1% serum (EC+7aI+PMP), 1% serum after 24-
hours transfection of scrambled inhibitor (EC+SC) or 100μg/ml PMPs after 24-
hours transfection of scrambled inhibitor in 1% serum (EC+SC+PMP). Data 
shown are mean ± standard error of mean, n=3 independent biological samples 
of healthy PMPs. *P<0.05 Tukey SEM relative protein expression of all shown 
comparisons between EC+PMP, EC+7aI, EC+7aI+PMP, EC+SC and 
EC+SC+PMP. 
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4.14 Let-7a directly target the 3’UTR of THBS-1 mRNA to inhibit its protein 
expression 
Our data show that PMPs transfer Let-7a to HUVEC to inhibit THBS-1 protein 
release and induce angiogenesis. Therefore, we assessed if direct Let-7a 
targeting of THBS-1 mRNA was responsible for reducing THBS-1 protein levels. 
The activity of Let-7a on THBS-1 protein levels has been linked to its binding to 
the 3’UTR of THBS-1 mRNA (Nör et al. 2000). Therefore, we used a reporter 
plasmid expressing the THBS-1 3’UTR in a Luciferase assay to see if the 
reporter signal of THBS-1 3’UTR construct can be reduced by overexpressing 
Let-7a miRNA through an expression plasmid. HEK 293T cells (1.3 X104) were 
cultured in 10% serum overnight, before the co-transfection of the reporter 
plasmid for THBS-1 3’UTR or empty reporter plasmid and Let-7a expression 
plasmid or empty miRNA expression plasmid. After 12 hours, transfected HEK 
293T cells were further treated with PMP. Reporter signal was measure by 
LightSwitch luciferase assay reagent. The results showed that expression of Let-
7a completely reduced the reporter signal of THBS-1 mRNA 3’UTR (4% 
targeting to non-targeting ratio) compared to (1100% targeting to non-targeting 
ratio) (P<0.05) (Figure 4.15). Inhibition of Let-7a by transfection with the Let-7a 
inhibitor significantly rescued the effect of Let-7a expression on the reporter 
signal of THBS-1 3’UTR construct (430% targeting to non-targeting ratio) (Figure 
4.15). This confirms that Let-7a directly target THBS-1 by binding to its 3’UTR. It 
is likely we did not get full reversal due to the large levels of Let-7a produced by 
the transfected plasmid. 
 161 
 
Figure 4.15: Let-7a directly targets the 3’UTR of THBS-1 mRNA to inhibit its 
protein expression. HEK 293T cells transfected with THBS-1 3’UTR where 
transfected with Let-7a pmiR plasmid or empty pmiR plasmid and Let-7a miRNA 
inhibitor or non-targeting miRNA inhibitor. Luciferase signal for the 3’UTR was 
measured by Lightswitch luciferase reagent. Data represents mean ratio of 
treatment signal to non-specific control signal in percentages, n = 6 +- SEM. 
*P<0.05 Tukey SEM relative luminesces signal of all shown comparisons. 
 
4.15 PMP delivered RNA content target the 3’UTR of THBS-1 to inhibit its 
protein expression 
Next, we explored the ability of PMP to inhibit the reporter signal of THBS-1 
3’UTR, which would confirm the mechanism of PMP mediated reduction in 
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THBS-1. HEK 293T cells (1.3 X104) were cultured in 10% serum overnight 
before transfection of reporter plasmid for THBS-1 3’UTR or empty reporter 
plasmid. After 12 hours, transfected HEK 293T cells were treated with PMPs 
and luciferase signal measured by Lightswitch luciferase assay reagent. The 
results showed that treatment with PMP completely reduced the reporter signal 
of THBS-1 3’UTR (8% targeting to non-targeting ratio) compared to (1120% 
targeting to non-targeting ratio) (Figure 4.16). Therefore, the results confirm that 
PMP delivered contents directly target THBS-1 3’ UTR.  
 
 
Figure 4.16: THBS-1 3’ UTR is a target of PMP delivered microRNA. HEK 
293T cells transfected with THBS-1 3’UTR were treated PMP. Data represents 
mean ratio of treatment signal to non-specific control signal in percentages, n = 
6 +- standard error of mean. *P<0.05 T-test. 
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4.16 Let-7a is a pro-angiogenic miRNA that regulate angiogenesis through 
THBS-1  
Having shown that Let-7a miRNA plays an important role in PMP mediated 
angiogenesis by inhibiting the production of THBS-1, we assessed the direct 
ability of Let-7a to induce angiogenesis independent of other biological 
components of PMPs. The direct angiogenic effect of Let-7a has not previously 
been investigated. HUVEC (3 X104) cultured with Medium 200 supplemented 
with 1% serum were transfected with a Let-7a expression plasmid or empty 
miRNA expression plasmid for 12 hours. The angiogenesis potential was 
assessed by measuring tube length and the number of branch points in Matrigel 
assays, and fluorescent images were quantified with Angiotool. Overexpression 
of Let-7a in HUVEC caused a robust significant increase in angiogenesis, where 
tube length increased to 20000μm (p<0.05) (Figure 3.14A) and branching to 97 
(p<0.05) compared to basal levels of 11000μm and a mean 48 branch point 
(p<0.05) (Figure 4.17). This data show for the first time that Let-7a is a pro-
angiogenic miRNA and further confirm our hypothesis that PMP delivered LET-
7a is responsible for angiogenesis.  
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Figure 4.17: Overexpression of Let-7a microRNA mediated tube formation 
and micro vascular sprouting in vitro. HUVEC 2 x 104 cells untransfected, 
pre-transfected with Let-7a expression vector or empty expression vector per 
well were seeded on ECM matrix coated plates for 16 hours. Angiogenesis was 
measured using an in-vitro Tube formation assay kit and data quantified with 
AngioTool software. A) Representative photomicrographs (×40 magnification) 
showing extracellular matrix gel-based, capillary-like tube formation by human 
HUVEC cells. B) Quantitative data of total tube length expressed in μm and C) 
Quantitative data of total number of branching. Data shown are mean ± standard 
error of mean, n=4 in each group. *P<0.05 ANOVA, for PMP treatment 
compared with basal or empty plasmid. 
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4.17: Discussion 
Angiogenesis is a clear feature of atherosclerotic plaques (Khurana et al. 2005, 
O'Brien et al. 1994) but the role it plays in destabilisation hence CVD 
progression is debated. However, the number of leaky and immature neo-blood 
vessels are significantly increased in unstable atherosclerotic plaques (Jain et 
al. 2007). Angiogenesis in plaques increases the infiltration of inflammatory cells 
and promotes bleeding, which further destabilises plaques (Jain et al. 2007). 
Weakening of plaques is critical to adverse cardiovascular events as rupture 
allows athero-thrombosis, which contributes to the increased morbidity and 
mortality among patients with CVD (Yusuf et al. 2001). A common feature of 
patients at high risk of cardiovascular disease is platelet activation, which is 
known to cause enhanced release of PMPs (Minuz et al. 2002, Rückerl et al. 
2007, VanWijk et al. 2003). PMPs induce endothelial cell activation and 
angiogenesis (Diamant et al. 2004). However, the full molecular mechanisms by 
which PMPs regulate angiogenesis are poorly understood.  
 
This chapter provides several lines of evidence showing that the PMP delivered 
miRNA Let-7a, and subsequent reduction of THBS-1 release, help drive this 
phenotype. These results presented are strongly supported by published studies 
that inhibited angiogenesis by directly increasing the levels of THBS-1 through 
exogenous THBS-1 protein treatment or endogenous overexpression of THBS-1 
(Isenberg et al. 2005, Short et al. 2005). Correspondingly, the pro-survival and 
migratory effects of a different miR (miR-200a) on HUVEC is linked to the 
inhibition of THBS-1 protein release (Li et al. 2011). THBS-1 inhibit EC migration 
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through the binding of its TSRs to the surface receptors CD36 and integrin β1 
(CD29) (Dawson et al. 1997, Short et al. 2005). Moreover, the inhibition of nitric 
oxide activity through CD36 and CD47 dependent mechanisms allow THBS-1 to 
directly inhibit angiogenesis (Isenberg et al. 2009, Roberts et al. 2007). We 
confirm that PMPs induce angiogenesis and alter the angiogenic secretome of 
ECs, including down regulating THBS-1. TargetScan analysis show THBS-1 is 
targeted by Let-7a, which has been reported to be present in platelets. We show 
with RNA-Seq, validated by qRT-PCR, that Let-7a is in PMPs, and show it is 
delivered to primary ECS. Functional luciferase experiments confirmed that Let-
7a directly target THBS-1. Let-7a inhibition strongly reversed the downregulation 
of THBS-1 release and angiogenesis induced by PMPS. Antibody neutralisation 
of THBS-1 reversed the negative effect of inhibiting Let-7a on PMP induced 
angiogenesis. Finally, overexpression of Let-7a alone induced robust 
angiogenesis. However, functional CD29 and CD47 are required for PMP 
induced angiogenesis. 
 
Let-7a was one of the first miRNAs described (Roush and Slack 2008), and can 
target several mRNA 3’UTRs including THBS-1, MYC transcription factor, type 1 
collagen and integrin β3 (Makino et al. 2013, Müller and Bosserhoff 2008, 
Sampson et al. 2007). Synthetic Let-7a and miR-221 have been reported to 
directly target the 3’ UTR of THBS-1 mRNA using dual luciferase assay and 
western blot in Hela cells (Dogar et al. 2014). Let-7a plays a role in a range of 
cellular process including proliferation (Johnson et al. 2007), differentiation of 
cardiovascular system and migration (Bao et al. 2013), through a coordinated 
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and complex regulation of translation and potential indirect regulation of 
transcription (Roush and Slack 2008). These potential functions can be related 
to the data in this project because of the importance of proliferation and 
migration in angiogenesis. Concerning the increased levels of Let-7a shown in 
this thesis, published work on different miRNA (223) demonstrated in a series of 
morphological and molecular techniques showed that PMP contained (miR-223) 
can be effectively transferred to ECs and incorporated into the endogenous 
RISC complex within these cells (Pan et al. 2014). Moreover, our result showed 
that PMP is internalised by HUVEC in a time dependent manner. Thus, the 
increase in Let-7a in HUVEC following PMP treatment in our experiments is 
consistent with the results reported by Pan et al. 2014.  
 
Target prediction by TargetScan algorithm revealed the miRNAs Let-7a and 
miR-221 as potential modulators of THBS-1. Both miRNAs have been reported 
by microarray analysis to be present in platelets (Gidlof et al. 2013) and our 
RNA-Seq data confirmed that they are transferred to PMPs in large amounts 
(Laffont et al. 2013). We validated this data with stem-loop qRT-PCR, but failed 
to observe increase in miR-221 in ECs treated with PMP. Though miR-221 was 
excluded from further analysis because of cost limitations, the implications of 
this downregulation require further investigation. miRNA-221 is implicated in the 
effect of hyperglycaemia on ECs, where it inhibits C-kit the receptor for stem cell 
factor in HUVECs to inhibit EC migration (Li et al. 2009). In ECs, miR-221 
inhibits proliferation and migration, while promoting apoptosis, but causes the 
opposite effect on vascular smooth muscle cells (Xiaojun Liu et al. 2012). Thus, 
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the reduced miR-221 in our study correlates with increased angiogenesis we 
observed. This highlights the tight control of the effects of PMP-miRNA on ECs, 
which leads to increased migration and angiogenesis. Mechanisms 
underpinning this process could be miRNA directed downregulation of 
endogenous miR-221 or selective degradation of delivered PMP-miRNA. 
However, the mechanisms for this tight control require investigation. 
 Actinomycin D inhibition of transcription in HUVEC before PMP treatment 
showed some of the Let-7a increase in PMP treated HUVEC was due to EC 
production of Let-7a rather than direct PMP transfer. Indeed, miRNAs can target 
transcription factors to regulate endogenous expression of itself or other 
miRNAs (Caporali and Emanueli 2011). Moreover, these effects will have 
influence on multiple signalling pathways by the altered release of angiogenic 
modulators induced by PMP treatment. For instance, increased levels of VEGF 
can increase the expression of miR-191 by increasing its transcription (Suarez 
et al. 2007, Suárez et al. 2008). Though reported in B-cells, the transcription 
factor MYC that is targeted by Let-7 family members can also regulate Let-7a-1 
by binding at the promoter of the Let-7a-1, 7f and 7d cluster (Chang et al. 2008, 
Zifeng Wang et al. 2011). However, these mechanisms remain to be explored in 
our model and would require RNA-Seq of ECs treated with PMP to identify the 
global changes in transcription factors.  
 
The results in this chapter revealed the presence of THBS-1 mRNA in PMP and 
corresponding increases in the treated ECs. PMPs have been shown to contain 
different classes of RNA and RNA sequencing of PMP revealed the expression 
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of THBS-1, THBS-3 and THBS-4 in our study. However, some reports suggest 
that the functional effect of transferred mRNA by platelets is significantly blunted 
by the activity of the massive amount of miRNA they contain. The regulatory 
effects of miRNAs are dependent on the number of complementary binding sites 
occupied by miRNAs on their target mRNA and their bioavailability, therefore it 
is unlikely that the THBS-1 mRNA transferred is not complexed with miRNA 
RISC complex. The proposed interactions will inhibit the translation of PMP 
derived THBS-1 by the ECs (Landry et al. 2009, Pan et al. 2014). Moreover, the 
sequencing results showed high levels of Let-7 miRNA family members that can 
potentially target THBS-1 due to the similarities in their mature RNA sequence. 
The idea that transferred THBS-1 mRNAs is redundant is supported by the 
evidence that PMP miRNA are distributed between pre-miRNA that require 
further processing and mature miRNA that are complexed with RISC (Landry et 
al. 2009, Pan et al. 2014). Moreover, PMP treatment can induce a negative 
feedback effect by increasing the transcription of THBS-1 gene in ECs to control 
angiogenesis. This idea is in-line with numerous lines of evidence supporting the 
homeostatic functions of ECs in vascular function through differential expression 
of angiogenic genes. However, the function of miRNA is exacted through 
inhibition of translation or degradation of mRNA transcripts, thus the targeting of 
THBS-1 by Let-7a will ensure that transcription increase does not correlate to 
increased THBS-1 protein.  
 
Inhibiting the binding of THBS-1 to its receptors CD47 and CD29 with 
neutralising antibodies fully blocked angiogenesis regardless of PMP treatment 
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or Let-7a inhibition. These data show functional CD47 and CD29 are 
indispensable in the induction of angiogenesis by PMPs. CD47 and CD29 
strengthen the attachment and interaction of ECs with the extracellular matrix 
(Albelda and Buck 1990, Eliceiri and Cheresh 2001, Schwartz and DeSimone 
2008). Moreover, CD29 has been shown to activate several signalling molecules 
including focal adhesion kinase (FAK) and Ras/ERK pathways that are known to 
play an important role in the interaction between extracellular proteins and 
integrins (Schober and Fuchs 2011, Qin Wang et al. 2011). This interaction is 
central to cell migration, matrix remodelling and angiogenesis (Mettouchi and 
Meneguzzi 2006). Embryonic deletion of CD29 from ECs in a mouse model 
resulted in lethal blood vessel defects (Tanjore et al. 2008). Therefore, it can be 
concluded that CD29 is indispensable in the induction of angiogenesis by PMP. 
Likewise, CD47 interacts with numerous integrin subunits particularly α2β1 
integrins to mediate spreading, cytokine synthesis, migration and proliferation 
(Wang and Frazier 1998). Thus, while the inhibition of CD29 and CD47 in this 
study would effectively inhibit THBS-1 activity, the critical processes required for 
ECs migration and spreading will also be inhibited. Concerning reduced protein 
levels of activated caspase 3, THBS-1 has been shown to regulate the p38 
kinase signalling pathway through CD36 to activate caspases-3 (Nör et al. 2000, 
Volpert 2000). This result suggests that inhibition of THBS-1 by PMP delivered 
Let-7a modulates the signalling mechanism targeted by THBS-1 to inhibit 
angiogenesis. The enhanced understanding of how PMPs induce angiogenesis 
through the THBS-1 pathway identified in this thesis highlight this as potential 
therapeutic target for the management of athero-thrombosis.  
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CHAPTER 5: PMP MEDIATED ANGIOGENESIS REQUIRE TRANSCRIPTION 
LEVEL REGULATION OF PRO-ANGIOGENIC PROTEINS MCP-1 
5.1 Introduction  
One of the key phenotypes driving angiogenesis is increased migration, which 
has been shown to be mediated by chemokines including members of the C-C 
family, characterised by two adjacent cysteines near their amino terminus. They 
can increase angiogenesis by increasing ECs migration. In addition to the 
alterations in THBS-1 identified in this thesis, protein array analysis of released 
angiogenesis modulators revealed that PMPs increased the release of PIGF and 
MCP-1 as shown in Figure 3.18. The effect on MCP-1 was particularly strong, 
and MCP-1 has been shown to positively regulate angiogenesis through 
increased migration of endothelial cells (Salcedo et al. 2000). Importantly, 
RNAse treatment of PMPs blocked their ability to induce the release of MCP-1. 
This does not fit with the common direct action of miRNAs, where the central 
dogma is inhibition of protein production rather than promotion. Thus, potential 
miRNA targeting of transcription factors that directly or indirectly inhibit the 
expression of the target proteins described above, could explain the increased 
protein release. Some transcription factors have both negative and positive 
effect on gene transcription (Latchman 1996) depending on context.  
 
Members of the activating transcription factor group of proteins are those that 
bind the CAMP responsive element (CRE) and share a Leucine zipper DNA-
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binding motif (Hai and Curran 1991). These ATF proteins are majorly associated 
with stress responses because they are activated by stress related stimuli like 
cytokines and toxic compounds (Hai et al. 1989, Zhou et al. 2003). However, 
signals that induce ATF gene expression and their cellular function are not 
limited to the stress response because they serve as adaptive molecules for 
alterations in the extracellular and intracellular space (Hai and Hartman 2001). 
Thus, ATF proteins are crucial regulators of cellular functions including 
migration, proliferation and angiogenesis (Hai and Hartman 2001). Some of the 
proteins increased by PMP treatment have are associated with members of the 
ATF protein family, acting through angiogenesis related transcription factors. Of 
note the activating transcription factor -4 (ATF-4) reduced the transcription of 
PIGF in endothelial cells in response to placental endoplasmic reticulum stress 
(Mizuuchi et al. 2016), whilst its overexpression in endothelial cells increased 
MCP-1 (Huang et al. 2015). Therefore, the potential targeting of ATF-4 or dimer 
members of the ATF-4 proteins by the miRNAs delivered by the PMP would 
result in the upregulation of PIGF, MCP-1 and angiogenin expression and 
release, which could explain their increase in EC following treatment with PMP 
and reduction after RNAse pre-treatment of the PMP. However, the potential 
mechanisms involved in such response require investigation.  
 
5.2 PMP increased the transcription of ATF-4 mRNA through Let-7a 
dependent mechanism 
Due to the potential role for ATF-4 described above, we first investigated the 
transcription of ATF-4 protein in HUVEC treated with PMP, for 24-hours. PMP 
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(100µg/ml) treatment caused a significant increase in ATF-4 mRNA (1.376 fold) 
in HUVECs. Next, we assessed if PMP delivered Let-7a was responsible for the 
change in ATF-4 mRNA. Transfection with the let-7a inhibitor prior to PMP 
treatment reduced the ATF-4 mRNA levels back to basal level. Suggesting 
potential Let-7a mediated degradation of ATF-4 mRNA. Pre-treatment with a 
non-targeting inhibitor did not reduce the effect of PMP co-incubation, but non-
targeting inhibitor potentiated the effect of PMP on ATF-4 levels (Figure 5.1). 
The data also suggest a potential role of endogenous Let-7a in the regulation of 
ATF-4 transcription, as transfection with the let-7a inhibitor caused a significant 
increase in ATF-4 mRNA compared to untreated cells (Figure 5.1). This 
increase was consistent with the level in PMP treated HUVEC, which showed 
the extent of the role of Let-7a in ATF-4 maintenance, but also highlighted the 
important control of ATF-4 transcription factor by PMP-let-7a.  
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Figure 5.1: PMPs increase the transcription of ATF-4 mRNA through a Let-
7a dependent mechanism. Relative quantification of ATF-4 mRNA expression 
in HUVEC cultured in 1% serum only (EC) or with addition of 100μg/ml PMPs in 
1% serum (EC+PMP), or 1% serum after 24hours transfection of Let-7a inhibitor 
(EC+7aI), 100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor in 1% 
serum (EC+7aI+PMP), 1% serum after 24hours transfection of non-targeting 
inhibitor (EC+SC) or 100μg/ml PMPs after 24hours transfection of scrambled 
inhibitor in 1% serum (EC+SC+PMP). Data shown are mean ± standard error of 
mean, n=3 independent biological samples of PMPs. *P<0.05 Tukey SD relative 
mRNA expression of all shown comparisons between EC+PMP, EC+7aI, 
EC+7aI+PMP, EC+SC and EC+SC+PMP. 
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5.3 PMP treatment did not regulate ATF-4 protein level in HUVEC  
We explored if the altered mRNA level of ATF-4 after PMP treatment translated 
to altered protein level. HUVEC (3 X105) were cultured in 1% serum overnight 
before transfection with the Let-7a inhibitor or non-targeting miRNA inhibitor. An 
additional 24 hours after transfection, cells were treated with PMP or control. 
Cells were lysed and lysate used for immunoblotting of ATF-4 protein. The 
results showed that HUVEC expressed consistent level of ATF-4 protein 
regardless of PMP treatment or Let-7a inhibition (Figure 5.2). The immunoblot 
also revealed multiple reactive bands, which could point to extensive post-
translational modifications of ATF-4 protein or varying strength of ATF-4 
interaction with other proteins (Ameri and Harris 2008). As the observation of 
multiple bands is consistent with the results by other studies (Watson and 
Andley 2010).  
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Figure 5.2: ATF-4 protein is tightly controlled in HUVEC irrespective of 
PMP treatment. (A) Representative blots (B) Relative quantification of cleaved 
ATF-4 protein by western blot of whole cell lysate of HUVEC cultured in 1% 
serum (EC), 100μg/ml PMPs in 1% serum (EC+PMP), 1% serum after 24-hours 
transfection of Let-7a inhibitor (EC+7aI), 100μg/ml PMPs after 24-hours 
transfection of Let-7a inhibitor in 1% serum (EC+7aI+PMP), 1% serum after 24-
hours transfection of scrambled inhibitor (EC+SC) or 100μg/ml PMPs after 24-
hours transfection of scrambled inhibitor in 1% serum (EC+SC+PMP). Data 
shown are mean ± standard error of mean, n=3 independent biological samples 
of healthy PMPs. *P<0.05 Tukey, SEM relative protein expression of all shown 
comparisons. 
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5.4 PMP mediate differential enrichment of ATF-4 proteins at promoter 
regions of pro-angiogenic proteins in HUVEC 
Since ATF-4 protein level was unchanged following PMP treatment (section 
5.3), we investigated if PMPs induced differential recruitment of ATF-4 to the 
promoter regions of MCP-1 and PIGF, which are pro-angiogenic modulators 
shown by our protein array data (Figure 3.18) to be upregulated by PMP 
treatment. Physiologically, transcription factors act by binding to the promoter 
region of a gene directly or as a complex with other factors to activate or inhibit 
its transcription. Therefore, the alterations of these binding events could explain 
our protein array data showing increased release of pro-angiogenic proteins. 
Chromatin immunoprecipitation (CHIP) and subsequent qRT-PCR analysis 
using primers to the promoter regions of both genes were used to achieve this 
objective. HUVEC (1 X 106 cells/well) either transfected with Let-7a inhibitor or 
non-targeting inhibitor were treated with PMPs for 24-hours, then chromatin was 
crosslinked, fragmented, precipitated with ATF-4 antibody and analysed by qRT-
PCR as discussed in the methods section.  
 
5.4.1 PMPs mediate ATF-4 enrichment at the MCP-1 promoter in HUVEC through 
a Let-7a dependent mechanism 
CHIP- qRT-PCR analysis showed that PMP treatment caused a significant 
21.3% increase in ATF-4 enrichment at the MCP-1 promoter compared to basal 
levels. Consistently, PMP treatment of HUVEC transfected with non-targeting 
inhibitor caused a significant 102% increase in ATF-4 enrichment at MCP-1 
promoter compared to untreated HUVEC transfected with non-targeting inhibitor 
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(Figure 5.3). Conversely, PMP treatment of HUVEC transfected with Let-7a 
inhibitor significantly reduced the ATF-4 enrichment at MCP-1 promoter by 56% 
compared to untreated HUVEC transfected with Let-7a inhibitor (Figure 5.3). 
The comparison of each PMP treatment with the corresponding basal level 
enabled us to control for the growth condition mediated differences. Moreover, 
the matched conditions are derived from equal number of cells, thus ideal for 
comparison and derivation of relative differences.  
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Figure 5.3: PMP mediates ATF-4 enrichment at the MCP-1 promoter 
through a Let-7a dependent mechanism. Percentage enrichment of ATF-4 
protein at MCP-1 promoter in (A) 1% serum (EC) or 100μg/ml PMPs in 1% 
serum (EC+PMP), (B) 1% serum after 24-hours transfection of Let-7a inhibitor 
(EC+7aI) or 100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor in 1% 
serum (EC+7aI+PMP), (C) 1% serum after 24-hours transfection of scrambled 
inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of scrambled 
inhibitor in 1% serum (EC+SC+PMP), and (D) Precipitated with Histone H3 
(positive control) antibody or normal IgG (negative control) antibody. Data 
shown are mean ± standard error of mean, n=9 independent biological samples 
of PMPs, pooled to in equal n=3. *P<0.05 Tukey SD percentage enrichment 
between EC+PMP and EC, EC+7aI+PMP and EC+7aI, or EC+SC+PMP and 
EC+SC. 
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5.4.2 PMPs mediate ATF-4 enrichment at the placental growth factor (PIGF) 
promoter in HUVEC through a Let-7a dependent mechanism 
The CHIP- qRT-PCR analysis of the PIGF promoter for ATF-4 enrichment 
showed that PMP treatment caused a significant 129.4% increase in ATF-4 
enrichment at PIGF promoter compared to basal levels (Figure 5.4). PMP 
treatment of HUVEC transfected with non-targeting inhibitor caused a significant 
173% increase in ATF-4 enrichment at PIGF promoter compared to untreated 
HUVEC transfected with non-targeting inhibitor (Figure 5.4). Conversely, PMP 
treatment of HUVEC transfected with Let-7a inhibitor showed no difference in 
the ATF-4 enrichment at PIGF promoter compared to untreated HUVEC 
transfected with Let-7a inhibitor (Figure 5.4). The basal ATF-4 enrichment at 
PIGF promoter varied between the control.  
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Figure 5.4: PMP mediates ATF-4 enrichment at the PIGF promoter through 
a Let-7a dependent mechanism. Percentage enrichment of ATF-4 protein at 
PIGF promoter in (A) 1% serum (EC) or 100μg/ml PMPs in 1% serum 
(EC+PMP), (B) 1% serum after 24-hours transfection of Let-7a inhibitor 
(EC+7aI) or 100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor in 1% 
serum (EC+7aI+PMP), (C) 1% serum after 24-hours transfection of scrambled 
inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of scrambled 
inhibitor in 1% serum (EC+SC+PMP), and (D) Precipitated with Histone H3 
(positive control) antibody or normal IgG (negative control) antibody. Data 
shown are mean ± standard error of mean, n=9 independent biological samples 
of PMPs, pooled to in equal n=3. *P<0.05 Tukey SD percentage enrichment 
between EC+PMP and EC, EC+7aI+PMP and EC+7aI, or EC+SC+PMP and 
EC+SC. 
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5.7 PMPs increases HUVEC mRNA levels of MCP-1 and PIGF in RNA 
dependent mechanism 
 
ATF-4 recruitment to the promoter regions of MCP-1 and PIGF may inhibit or 
activate transcription of both genes depending on the interaction with other 
proteins expressed by HUVEC. We initially investigated if PMP treatment 
regulated MCP-1 and PIGF transcription in HUVEC using qRT-PCR analysis. 
HUVEC were cultured with 1% serum before treatment with 100μg/ml PMPs or 
RNAse treated PMP in 1% serum, for 24-hours. Then, total RNA was isolated 
and mRNA levels of MCP-1 and PIGF analysed by qRT-PCR. Treatment with 
100μg/ml PMPs caused a significant increase in MCP-1 mRNA levels (13.812-
fold) (Figure 5.5) compared to basal levels. This effect was blocked by RNAse 
treatment (reduction to 4.56-fold above basal) (Figure 5.5). Similarly, treatment 
with 100μg/ml PMPs caused a significant increase in PIGF mRNA levels (1.64-
fold) compared to basal level, which was significantly decreased by RNAse 
treatment (0.89-fold compared to basal.) (Figure 5.5). Thus, these data show 
that PMP-RNA dependent mechanism regulate the transcription of MCP-1 and 
PIGF. 
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Figure 5.5: PMPs mediate transcription of MCP-1 and PIGF through an 
RNA dependent mechanism. Relative mRNA expression of (A) MCP-1 and (B) 
PIGF in HUVEC cultured in (EC) 1% serum, (EC+PMP) 100μg/ml PMPs, or 
(EC+PMP+RNAse) in the presence of 100μg/ml PMPs treated with RNAse. 
Data shown are mean ± standard error of mean, n=3 independent biological 
samples of PMPs. *P<0.05 Tukey SD individual miRNA expression level 
between EC and EC+PMP, or between EC+PMP and EC+PMP+RNAse. 
 
5.9 PMPs induce the transcription of MCP-1 and PIGF in HUVEC through 
Let-7a dependent mechanism 
we investigated if PMP-Let-7a increased the transcription of PIGF and MCP-1 to 
explain the observed protein array results showing that PMP treatment increase 
MCP-1 and PIGF release from HUVECS. HUVEC (3 X105) were cultured in 1% 
serum overnight before transfection of the Let-7a inhibitor (EC+7aI) or non-
targeting miRNA inhibitor. 24 hours after incubation, cells were treated with PMP 
or buffer controls before isolation of total RNA used for qRT-PCR analysis of 
MCP-1 and PIGF mRNAs. The result showed that 24-hour treatment with PMPs 
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caused a significant increase in the mRNA level of MCP-1 (3.971-fold) 
compared to basal (p<0.05). Transfection with non-targeting inhibitor (0.398-
fold) or Let-7a inhibitor (0.399-fold) had no significant effect on MCP-1 
transcription. Treatment with PMPs in Let-7a transfected HUVEC significantly 
reduced MCP-1 mRNA levels (0.56-fold compared to control) (Figure 5.6A) 
showing PMPs induced HUVEC MCP-1 mRNA production in a Let-7a 
dependent manner.  
 
24-hour treatment with PMPs caused a significant increase in the mRNA level of 
PIGF (1.45-fold) compared to basal (p<0.05). Transfection with non-targeting 
inhibitor (0.953-fold) or Let7a inhibitor (0.99-fold) had no significant effect alone. 
Treatment with PMPs in Let-7a transfected HUVEC importantly resulted in 
significant reduction in PIGF mRNA levels (0.967-fold) compared to control 
(Figure 5.6A). These results show that PMPs induced HUVEC PIGF mRNA 
production in a Let-7a dependent manner. In these experiments, treatment with 
PMPs in non-targeting transfected HUVECs increased PIGF mRNA levels 
above PMP treatment alone (4.681-fold) the reasons for this are unclear (Figure 
5.6A). 
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Figure 5.6: PMPs mediates transcription of MCP-1 and PIGF through Let-7a 
dependent mechanism. Relative quantification of mRNA (A) MCP-1 and (B) 
PIGF in HUVEC cultured in 1% serum (EC), 100μg/ml PMPs in 1% serum 
(EC+PMP), 1% serum after 24-hours transfection of Let-7a inhibitor (EC+7aI), 
100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor in 1% serum 
(EC+7aI+PMP), 1% serum after 24-hours transfection of scrambled inhibitor 
(EC+SC) or 100μg/ml PMPs after 24-hours transfection of scrambled inhibitor in 
1% serum (EC+SC+PMP). Data shown are mean ± standard error of mean, n=3 
independent biological samples of PMPs. *P<0.05 Tukey SD relative mRNA 
expression of all shown. 
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5.10 PMP-Let-7a related transcription of MCP-1 correlates with increased 
MCP-1 protein expression. 
Having shown that PMP treatment, via transferring Let-7a, increased MCP-1 
mRNA levels, we then investigated changes in protein level. HUVEC (3 X105) 
were cultured in 1% serum overnight before transfection of Let-7a inhibitor 
(EC+7aI) or non-targeting miRNA inhibitor. 24 hours after incubation, cells were 
treated with PMP or buffer controls, for 24 hours. Cell culture media was 
collected and analysed by MCP-1 ELISA. 
 
PMP treatment caused a significant increase in MCP-1 protein release 
(1160pg/ml compared to 818.3pg/ml, p<0.05). This was partly reversed by pre-
transfection with the Let-7a inhibitor, where MCP-1 levels significantly reduced 
to 984.5pg/ml compared to PMP treatment (p<0.05) (Figure 5.7). These data 
suggest that PMPs induce MCP-1 protein expression and release from HUVECs 
via a Let-7a dependent mechanism, but Let-7a insensitive pathways also exist. 
The proteins directly or indirectly targeted by Let-7a to mediate increased 
recruitment of ATF-4 to MCP-1 promoter requires further investigation. 
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Figure 5.7: PMP-Let-7a related transcription of MCP-1 correlates with 
increased protein expression. Protein concentration of MCP-1 after 24-hours 
treatment of HUVEC cultured in 1% serum (EC), 100μg/ml PMPs in 1% serum 
(EC+PMP), 1% serum after 24-hours transfection of Let-7a inhibitor (EC+7aI), 
100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor in 1% serum 
(EC+7aI+PMP), 1% serum after 24-hours transfection of scrambled inhibitor 
(EC+SC) or 100μg/ml PMPs after 24-hours transfection of scrambled inhibitor in 
1% serum (EC+SC+PMP). Data shown are mean ± standard error of mean, n=3 
independent biological samples of PMPs. *P<0.05 Tukey SD protein 
concentration of all shown comparisons between EC+PMP, EC+7aI, 
EC+7aI+PMP, EC+SC and EC+SC+PMP.  
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5.11 PMP enhance HUVEC migration is dependent on transferred Let-7a  
Following the observation that the increased MCP-1 release is potentially 
dependent on indirect transcription regulation by Let-7a, as MCP-1 is a known 
inducer of EC migration (Ma et al. 2007, Weber et al. 1999), we then 
investigated the functional implications by the in vitro scratch assay. HUVEC (3 
X 105) were cultured in 1% serum overnight before transfection of Let-7a 
inhibitor or non-targeting miRNA inhibitor. Confluent cells were scratch after 24 
hours and immediately treated with PMP or left untreated as negative controls. 
Migration was assessed at 12-hours and 24-hours post scratching by measuring 
percentage gap closure (GC). Within 12-hours of treatment, PMPs caused a 
significant increase in migration (24.6% compared to 15.7% GC). Transfection of 
HUVECs with the Let-7a inhibitor fully reversed the migratory effects of PMPs 
(16.33% vs.15.7% basal and 24.6% in the presence of PMPs) (Figure 5.8A). 
The same pattern was apparent after 24hours, where basal gap closure was 
24.91% compared to 34.01% in the presence of PMPs (Figure 5.8B). 
Transfection with the Let-7a inhibitor significantly blocked the ability of PMPs to 
induce migration (16.41% GC) (p<0.05) (Figure 5.8B). The results suggest PMP, 
through a Let-7a dependent mechanism, has a modest but significant effect on 
HUVEC migration. Further experiments are required to determine if this is 
dependent on the ability of PMPs to modulate MCP-1 levels through an ATF-4 
dependent mechanism. 
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Figure 5.8: PMP induction of MCP-1 protein is Let-7a dependent. 
Percentage gap closure, after 12-hours or 24-hours treatment of HUVEC 
cultured in 1% serum (EC), 100μg/ml PMPs in 1% serum (EC+PMP), 1% serum 
after 24-hours transfection of Let-7a inhibitor (EC+7aI), 100μg/ml PMPs after 24-
hours transfection of Let-7a inhibitor in 1% serum (EC+7aI+PMP), 1% serum 
after 24-hours transfection of scrambled inhibitor (EC+SC) or 100μg/ml PMPs 
after 24-hours transfection of scrambled inhibitor in 1% serum (EC+SC+PMP). 
Data shown are mean ± standard error of mean, n=3 independent biological 
samples of PMPs. *P<0.05 Tukey SD percentage gap closure of all shown 
comparisons between EC+PMP, EC+7aI, EC+7aI+PMP, EC+SC and 
EC+SC+PMP.  
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5.12 Discussion 
miRNA targeting of mRNAs encoding transcription factors can mediate indirect 
effects on protein release through reduced or increased transcription (Gosline et 
al. 2016, Lewis et al. 2003). A range of studies have shown that miRNA regulate 
protein expression by targeting transcription factors (Gosline et al. 2016, Kong et 
al. 2008). Global inhibition of miRNAs in microvascular EC due to Dicer 
knockdown increases the expression of high mobility group box transcription 
factor (HBP1). HBP1 is a suppressor transcription factor that negatively 
regulates the expression of p47phox (Dinauer and Newburger 1993), a promoter 
of oxidative stress. Indeed, increased expression of HBP1 by dicer knockdown 
reduced the expression of p47phox, which in turn inhibited ROS-dependent 
angiogenic signalling (El-Benna et al. 2009). In an animal model, miR-134 
regulated the differentiation of mouse embryonic stem cells by targeting 
transcription factors Nanog and LRH1 to increase the levels of pro-differentiation 
proteins like fibroblast growth factor-5 and the tyrosine protein kinase (KDR) 
(Tay et al. 2008). KDR is a receptor that interacts with VEGFA, VEGFB and 
VEGFC to regulate angiogenesis, proliferation, and vascular permeability (Tay 
et al. 2008). We show that PMP treatment of HUVEC increased the transcription 
of MCP-1 and PIGF genes, which could be associated with a pro-inflammatory 
phenotype and was reversed by transfection of the Let-7a inhibitor. Given that 
miRNAs bind and inhibit the translation of target mRNA, the increase in the 
release of MCP-1 and PIGF indicated a secondary regulation by other 
transcription mechanisms which may have being induced by transfer of Let-7a. 
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The targeting of transcription related proteins through a Let-7a dependent 
mechanism may be important in PMP mediated angiogenesis. Let-7a can target 
a wide range of genes, including transcription factors c-Myc (Yongchao Liu et al. 
2012) and NF kB (Iliopoulos et al. 2009) that could mediate the observed 
angiogenic effects. In renal cell carcinoma, Let-7a inhibits proliferation by 
directly inhibiting c-Myc to block proliferating cell nuclear antigen (PCNA) and 
cyclin D1 (CCND1) (Yongchao Liu et al. 2012). Conversely, Let-7a has been 
shown to inhibit the expression of IL-6 through indirect inhibition of NF kB 
(Iliopoulos et al. 2009, Persico et al. 1999). Changes in transcription factor 
activity control the function of many pro-angiogenic proteins including MCP-1 
(Miceli et al. 2016) and PIGF (Cao et al. 1996), which we showed are increased 
by PMP treatment and corresponded to pro-angiogenic phenotype. 
 
There are four key mechanisms by which miRNAs could indirectly regulate 
transcription of genes.  
1. miRNA targeting of transcription factors that physiologically inhibit the 
expression of MCP-1 and PIGF would allow their transcription to occur and 
cause increased protein release (Latchman 1996). Indeed, overexpression of 
the miR-200c in A549 cells inhibits the transcription factor 8 (TCF8), which in 
turn increases the expression of E-cadherin to promote cell invasion (Hurteau et 
al. 2007). Because TCF8 negatively regulates the expression of E-cadherin in 
epithelial cells and plays an important role in epithelial-to mesenchymal 
transition, miR-200c can indirectly control this process by targeting inhibitory 
transcription factor TCF8 (Hurteau et al. 2007).  
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2. Alternatively, miRNA targeting of protein kinases that direct a transcription 
factor to the promoter regions of MCP-1 and PIGF would inhibit the promoter 
enrichment of such transcription factor and subsequently cause reduced protein 
release. For instance, Let-7a directly targets the Ras protein kinase leading to 
the inhibition of the Ras protein kinase signalling that reduces NF kB activity and 
inhibits IL-6 expression (Iliopoulos et al. 2009).  
3. Likewise, miRNA targeting of proteins that form transcription activation or 
inhibition dimers with a transcription factor that binds to MCP-1 and PIGF 
promoter regions would allow the formation of alternative dimers, which would 
reduce or increase their protein expression. For instance, miR-122 was shown 
to inhibit the transcription of c-Myc by targeting TFDP2 transcription factor and 
reducing the binding specificity of E2F1 (Wang et al. 2014). The interaction 
between TFDP2 and E2F1 enhances the transactivation function of the 
heterodimer in hepatocellular cancer, which allows miR-122 to function as a 
tumour suppressor (Wang et al. 2014).  
4. miRNA targeting of chromatin remodelling proteins associated with changes 
in the chromatin states of MCP-1 and PIGF genes could modulate their 
transcription. In breast cancer, miR-22 inhibits the activity of the Ten elven 
translocation enzymes (TET), thereby remodelling chromatin toward miR-200 
silencing and inhibiting its anti-metastatic function (Song et al. 2013). TETs are 
family of methylcytosine dioxygenases that play an important role in cytosine 
demethylation and regulation of gene expression through differential chromatin 
remodelling (Ito et al. 2011). 
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Interestingly, we showed that PMP treatment increased the recruitment of ATF-4 
transcription factor to the promoter regions of MCP-1 and PIGF through a Let-7a 
dependent mechanism. ATF-4 is a member of the activating transcription factors 
that bind the cAMP responsive element (CRE) and share a Leucine zipper DNA-
binding motif with CREBS and CREBs-like proteins (Hai and Curran 1991). ATF-
4 protein can function as either transcriptional activator or inhibitor depending on 
the interaction with other transcription factors through the Leucine Zipper motif 
(Ahn et al. 1998, Lemaigre et al. 1993). ATF-4 protein is implicated in many 
biological processes, including metabolism and differentiation (Ameri and Harris 
2008), and various cancers and vascular diseases, reviewed by Ameri and 
Harris (2008). In the vascular system, ATF-4 is induced by injuries and fibroblast 
growth factor-2, and can serve as conduit for growth factor – growth factor cross 
talk in atherosclerosis (Malabanan and Khachigian 2010). PMP also increased 
the transcription of ATF-4 mRNA but did not increase proteins levels in HUVEC 
suggesting a tight regulation of translation by EC. The tight control of protein 
levels within HUVEC suggest that the enrichment of ATF-4 protein at the 
promoter regions of MCP-1 and PIGF is dependent on its interaction with other 
factors. 
 
miRNA targeting of ATF-4 can regulate gene expression potentially through the 
mechanism described above. For instance, miR-214 inhibits gluconeogenesis by 
inhibiting ATF-4 production and ATF-4 – FOXO1 dimer formation (Li et al. 2015). 
Moreover, miR-1283 plays a key role in endothelial cells injury through inhibition 
of ATF-4 by the regulation of the PERK-eIF2α-ATF-4 signalling (He et al. 2016). 
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Let-7a targeting of ATF-4 could modulate other processes through the 
interaction with other transcription factors like c-Jun, Fos, Fra-1 and CREB, as 
well as kinases NF kB and P38 (Hai and Curran 1991, Huang et al. 2015), but 
the implications in angiogenesis, cell migration and proliferation remains poorly 
described. It is known that the interaction between ATF-4 and these transcription 
factors described above exhibit variable DNA-binding specificities (CRE or AP-1 
consensus), which could facilitate differential regulation of angiogenic genes 
(Ameri and Harris 2008). We showed that ATF-4 induces EC migration 
potentially through increase in MCP-1 release mediated by dimerization with NF 
kB, P38 or JNK MAP kinases inducing transcription (Huang et al. 2015). 
Conversely, ATF-4 inhibits PIGF to regulate placental endoplasmic reticulum 
through interaction with ATF6a (Mizuuchi et al. 2016). The PMP-Let-7a 
mediated enrichment of ATF-4 at the promoter regions of MCP-1 and PIGF in 
HUVEC correlated with increased migration of ECs treated with PMP. This 
suggests a potential functional link between ATF-4 enrichment, and increased 
MCP-1 and PIGF release by PMP treatment through the effect of delivered Let-
7a on the activity of ATF-4 dimerisation with other transcription factors. 
However, the potential interacting factors mediating such pro-angiogenic effects 
requires further investigation. Such investigation should include inhibition of 
ATF-4 and MCP-1 before PMP treatment and assessment of migration. 
Potential dimer members involved in this process could be identified by stable 
isotope labelling in culture before PMP treatment to identify the interacting 
members through chromatin immuno-precipitation assay.  
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CHAPTER 6: GENERAL DISCUSSION AND FUTURE WORK 
6.1 Discussion 
The contribution of platelets to the development of CVD is a multifactorial 
process that heavily depends on cross-talk between platelets and endothelial 
cells (ECs). Platelets exert influence on ECs through multiple mechanisms, 
including direct interaction and indirect interactions through soluble proteins and 
cellular contents. Activated platelets can release large amounts of functional 
PMP, which enter the circulation and regulate the function of targets cells by 
releasing their biomolecules (Hunter et al. 2008). It is known that in response to 
arterial thrombosis, platelets release significantly more PMP (Mallat et al. 2000). 
PMP play important role in the pathogenesis of atherosclerosis and exert 
angiogenic control through miRNA transfer (Hunter et al. 2008, Janowska-
Wieczorek et al. 2005). Moreover, PMP levels are viewed as a prognostic 
marker for atherosclerotic vascular disease and inflammation (Pearson et al. 
2003, Puddu et al. 2010). Underlying this prognostic potential is the ability of 
PMPs to cause angiogenesis. Angiogenesis underlines the progression of 
cardiovascular diseases (CVD) including arthritis, thrombosis (Armstrong et al. 
2011, Glass and Witztum 2001, Järvilehto and Tuohimaa 2009), and cancer 
(Folkman 1995). Pathogenic features of angiogenesis such as bleeding, leaky 
immature blood vessels, infiltration of inflammatory cells and mechanical stress 
can rupture atherosclerotic plaques. Angiogenesis mediated plaque rupture 
causes athero-thrombosis and increases CVD morbidity (Folkman 1995). We 
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showed that THBS-1 is a key regulator of this pathological mechanism in-vitro 
through PMP delivered Let-7a. However, further studies are needed to confirm 
the in-vivo implication of this signalling pathway in the development of athero-
thrombosis. Rodent models of athero-thrombosis that mimic the increased 
platelet activation seen in human athero-thrombosis have been used extensively 
(Furie and Furie 2007, Narayanaswamy et al. 2000, Sachs and Nieswandt 
2007). Thus, the athero-thrombotic implications of THBS-1 modulation by PMP 
delivered Let-7a in those models can easily be studied and should add weight to 
the evidence of the research in this thesis. 
 
Moreover, the molecular and angiogenic implications of the array of miRNAs in 
PMP in this important pathologic control has been unknown until now. We 
showed that PMPs contains a wide range of miRNAs, potentially contributing to 
the cumulative pro-angiogenic response of EC. Thus, these miRNAs need 
further investigations. Such investigations are important because of the 
evidence that miRNAs can have profound effects when acting within a larger 
regulatory network that involves other miRNAs, transcription factors and kinases 
(Gurtan and Sharp 2013, Schmiedel et al. 2015). The supporting evidence for 
this can be found in the Let-7 regulation of HMGA2 (Mayr et al. 2007) and the 
miR-134 regulation of Nanog and LRH1 transcription factors (Tay et al. 2008). 
Moreover, there is emerging evidence that miRNAs selectively target 
transcription factors (Gurtan and Sharp 2013) and are found within network 
motifs (Gerstein et al. 2012). This evidence suggests that miRNAs act alongside 
other factors to cause wide spread changes in gene expression associated with 
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a pathogenic phenotype in vascular cells. Thus, initial in-vitro analysis of the 
miRNAs found in PMP using loss and gain of function analysis will provide much 
needed evidence of roles in endothelial dysfunction, followed by investigation of 
the overall effect in-vivo, which will confirm the pathogenic role in 
atherosclerosis. 
 
Furthermore, angiogenesis is also driven by matrix remodelling/migration, 
proliferation, and other cytokines. However, we did not fully investigate the 
mechanisms linking PMP delivered miRNAs to these processes. Cell invasion 
and migration is an essential process during angiogenesis, both of which are 
modulated by degradation of the extracellular matrix. We showed increased 
release of Endoglin, a pro-angiogenic type I integral membrane protein that has 
been shown to play an important role in TGF-b dependent vascular remodelling 
during angiogenesis (Guerrero-Esteo et al. 2002, Lebrin and Mummery 2008). 
The cytosolic domain of endoglin promotes EC migration and focal adhesion 
(Conley et al. 2004, Lebrin and Mummery 2008). Both endoglin and MCP-1 are 
involved in the pathogenesis of many CVD through their regulation of cell 
migration and angiogenesis (Ikemoto et al. 2012, Niu and Kolattukudy 2009). 
Similarly, cell proliferation is a critical process in maturation of EC’s sprouts and 
can be regulated by some of the cytokines increased by PMP treatments. 
However, PMPs seems to inhibit proliferation in the in-vitro model used in this 
thesis, thus the actual effects of these proteins in-vivo require investigation. It is 
important to note that new blood vessels in atherosclerotic plaques are 
immature and leaky in part due to incomplete EC junctions (Sluimer et al. 2009). 
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While compromised structural integrity will increase leakage, impaired 
proliferation can also inhibit maturation leading to further leakage and increased 
risk of rupture (Le Dall et al. 2010).  
 
Let-7a is one of the most investigated miRNAs to date (Roush and Slack 2008), 
and can target a range of human genes including transcription factor MYC, 
integrin b3 and THBS-1 (Dogar et al. 2014, Müller and Bosserhoff 2008, Park et 
al. 2007, Peter 2009, Sampson et al. 2007), hence regulating apoptosis, cell 
migration and proliferation. Despite the work previously published, it’s effects are 
not fully explained. The targeting of THBS-1 mRNA in HUVEC by PMP 
transferred Let-7a chiefly modulate the functional effect of PMP on EC. The 
inhibition of THBS-1 translation enabled PMP to increase angiogenesis and 
migration in the presence of functional CD29 and CD47 surface receptors and 
reduced cleaving of caspase-3, an apoptotic marker. The multi-functional role of 
Let-7a was clear in the increased transcription of the key migration mediator 
(MCP-1) and potentially key growth factor (PIGF), which is further supported by 
Let-7a’s ability to induce angiogenesis independent of other PMP miRNAs 
(Summarised in Figure 6.1). These results suggest that Let-7a is a master 
regulator of PMP induced angiogenesis, which is supported by its ability to 
induce angiogenesis independent of other biomolecules contained in PMP.  
 
Let-7 miRNA family members are expressed in many cardiovascular systems 
including the recent evidence that PMP contain significant amounts of this family 
of miRNAs. Besides cardiovascular pathologies, Let-7 family is important in 
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heart development and embryonic differentiation (Bao et al. 2013), so it has 
multiple roles. In addition to targeting THBS-1 and MCP-1 (indirectly), Let-7 
family members directly target toll-like receptor 4 and cyclin D2 and indirectly 
target angiopoietin II, reviewed extensively in (Bao et al. 2013), emphasising 
their importance in health and disease. Let-7 family members are highly 
expressed in many CVD and contribute in the pathogenesis of heart 
hypertrophy, atherosclerosis, myocardial infarction and hypertension (Bao et al. 
2013). For instance, the levels of circulating Let-7b and Let-7i potentially derived 
from platelets and PMP are predicted biomarkers of myocardial infarction and 
dilated cardiomyopathy respectively (Bao et al. 2013). Functionally, reduction of 
Let-7f and Let-7b inhibit EC sprouting that is associated with angiogenesis 
(Kuehbacher et al. 2007, Otsuka et al. 2008). Though the knockdown of Dicer in 
EC inhibited angiogenesis and impaired migration with reduced levels of these 
miRNAs including Let-7a, the effect of Let-7a on angiogenesis have not been 
independently investigated (Suarez et al. 2007). However, many published 
studies validate mRNA targets of Let-7 miRNA members like THBS-1, THBS-2, 
TIMP-1, Tie-1 and Tie-2 all of which are important players in angiogenesis (Bao 
et al. 2013). Therefore, characterisation of the sources and roles of these multi-
functional miRNA family members in the development and progression of CVD 
through angiogenesis require further investigation. 
6.2 Conclusion 
We show that platelet micro-particles regulate endothelial cell function through a 
complex biological, cellular, and molecular effects mediated by transferred 
microRNA (summarised in Figure 6.1). 
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Specifically, we showed that;  
1. A unique profile of cytokines stays bound on the surface of platelet 
microparticles, including CD40L, ICAM-1, RANTES, C5/C5a, which are 
known mediates of inflammatory response, cell-cell adhesion, platelet 
activation, migration, and chemotaxis.  
2. Platelet microparticles contain more than 500 diverse miRNA species and 
a high amount of Let-7a family members. 
3. Platelets microparticles have more than 2000 mRNA species, with a high 
number of thrombospodin-1 transcript. 
4. Platelet microparticles are internalised by endothelial cells in a time 
dependent manner. 
5. Platelet micro-particles induce angiogenesis and migration, while 
inhibiting proliferation. 
6. Platelet micro-particles induce the release of novel pro-angiogenic 
cytokine subsets specific to platelet micro-particle’s RNA content. 
7. The targeting of thrombospondin-1 mRNA by platelet micro-particles’ 
transferred Let-7a chiefly modulate the angiogenic effect on endothelial 
cells. 
8. The ability to increase angiogenesis through Let-7a inhibition of 
thrombospondin-1 translation needs functional integrin beta-1 and 
integrin associated protein. 
9. Platelet microparticles reduces the cleaving of caspase-3, a pro-apoptotic 
protein and downstream of thrombospodin-1 through integrin associated 
protein. 
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10.  Platelet micro-particle modulate the transcription of monocyte 
chemoattractant protein-1 and placental growth factor in a Let-7a 
dependent manner.  
11. Platelet micro-particles increases the enrichment of activating 
transcription factor-4 at the promoter regions of monocyte 
chemoattractant protein-1 and placental growth factor in a Let-7a 
dependent manner.  
12. Finally, Let-7a induces angiogenesis independent of other platelet micro-
particle’s microRNAs. 
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Figure 6.1: Proposed model for the action of PMP transferred Let-7a on 
endothelial THBS-1 protein level. PMPs transfer Let-7a that inhibit THBS-1 
translation, the resultant reduced THBS-1 concentration reduces the 
bioavailability of THBS-1 to bind CD47 and CD29, and inhibits the cleaving of 
caspase-3. The events that reduce the inhibition of migration/ induction of 
apoptosis and angiogenesis by THBS-1. PMP through Let-7a mechanism 
increase ATF-4 recruitment to the promoter region of MCP-1 and PIGF, with 
increased transcription. 
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6.3 Future Work 
1. As elaborated in chapter 6, the in-vitro evidence showing that PMP delivered 
Let-7a inhibits THBS-1 protein release to induce angiogenesis requires 
investigation in-vivo in animal models of athero-thrombosis, inflammation and 
CVD. The investigations presented in this thesis will help confirm the athero-
thrombotic and CVD implications of PMP induced angiogenesis through THBS-
1-Let-7a pathway.  
 
2. There is evidence of pathological development of immature blood vessels in 
CVD, which are leaky and promote plaque rupture (Jain et al. 2007). Therefore, 
the observed reduction in EC proliferation might be playing a pathological role 
and requires further investigation. The in-vivo confirmation of the role of PMP-
Let-7a in CVD (described in 1) needs to incorporate this aspect. 
 
3. Literature evidence shows that MCP-1 contributes in the pathogenesis of 
CVD through increased recruitment of inflammatory cells and induction of 
vascular permeability (Sprague and Khalil 2009). Therefore, future in-vitro 
studies and potentially in-vivo studies need to investigate if the Let-7a mediated 
increase in MCP-1 modulates recruitment of inflammatory cells and increases 
vascular permeability. The in-vitro investigations should involve siRNA inhibition 
of ATF-4 before the treatment with PMP in the presence of Let-7a inhibitor to 
see if MCP-1 protein release is reversed to basal levels. 
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4. Published evidence seems to show that miR-221 is preferentially degraded to 
enhance angiogenesis, future studies using miRNA inhibitors can investigate the 
mechanisms underlying this process. Again, the proposed in-vivo investigation 
(described in 1 and 2) might need to incorporate this goal. 
 
5. The array of proteins modulated by PMP cannot only be linked to direct 
targeting by miRNA, or the activity of Let-7a miRNA. As PMPs contain a diverse 
species of miRNA, the observed angiogenic phenotype following PMP treatment 
and reversal in RNAse treatment suggest that PMP-miRNA species act in a 
coordinated manner to regulate angiogenesis. These proteins can regulate EC 
migration, survival, extracellular matrix remodelling and proliferation in 
angiogenesis (Ahmed and Bicknell 2009). Experimental validation of the 
predicated functional targets of the PMP-miRNA content should be conducted to 
guide the investigation into their effects on cytokine release. Initial approaches 
should also include the inhibition of individual miRNAs (in addition to Let-7a) to 
study their mechanisms. Moreover, the findings of such validation and functional 
analysis should be extended to animal models to confirm any potential role in 
athero-thrombosis and CVD.  
 
6. Other pathological conditions such as psoriasis, diabetes, renal diseases and 
neurological diseases directly or indirectly linked to athero-thrombosis should be 
the target of long-term investigations. This is very important because of the array 
of signalling pathways like the mitogenic Ras signalling, cytokine-cytokine 
receptor signalling and growth factor pathways revealed by the computational 
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target prediction analysis. Beyond the involvement in angiogenesis and CVD, 
potential renal and neurological roles of PMP delivered miRNAs could be 
explored based on the results of the computational prediction.  
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APPENDIX  
Appendix 1 
Table 3.4: Relative group biological process association of predicted 
mRNA targets of top 25 highly expressed miRNAs in PMP.  
Term Genes Fold 
Enrichment 
MAPK cascade FGF18, FGF7, IL18, FGF16, 
FGF10, TGFB1, CAMKK2, MEN1 
1.879519151 
Positive regulation of 
transcription from RNA 
polymerase II promoter 
HMGN3, THRA, IL18, ARNT2, 
EDN1, ATP1B4, FGF10, FOXO1, 
FOXO4 
1.346956793 
Angiogenesis FGF18, ATP5B, IL18, FGF10, 
CXCR3, TNFSF12, MMP2, 
TSPAN12, SERPINE1 
1.803383174 
Aging LITAF, TACR3, NPY2R, SNCA, 
MMP7, PAX5, ITGB2, 
1.890150775 
Negative regulation of 
transcription from RNA 
polymerase II promoter 
JDP2, EDN1, SNCA, FOXO1, 
AURKB, CBX7, TGFB1, CBX6 
1.367872271 
Positive regulation of natural 
killer cell chemotaxis 
CCL3, CXCL14, CCL4L1, CCL5, 
XCL1, CCL7 
7.03477168 
Positive regulation of release 
of sequestered calcium ion 
into cytosol 
F2RL3, PDPK1, BAX, SNCA, 
CXCL9, IL13, CXCR3, CXCL11, 
XCL1, CXCL10, F2R 
3.343687774 
Cell-cell adhesion RTN4, ABCF3, RANGAP1, 
LARP1, PAK6, BZW2, EFHD2, 
BZW1 
1.574819736 
Cell proliferation COPS2, RETNLB, PPARD, 
CDC14A, ELF5, NR6A1, CLK1 
1.457568813 
Phosphatidylinositol-mediated 
signalling 
FGF18, FGF7, ERBB4, ERBB2, 
FGF16, NCS1, KITLG, FGF10 
1.935668308 
Negative regulation of neuron 
apoptotic process 
SNCA, CNTFR, BCL2L1, PDPK1, 
BDNF, CLCF1, BCL2, PIK3CA, 
POU4F1 
1.803104357 
Neural crest cell development EDNRA, ALDH1A2, TAPT1, 
EDN1, FOXC2, NRG1, SOX9 
4.419279645 
Protein autophosphorylation ERBB4, STK10, ERBB2, MKNK2, 
KIT, AURKB, MAPKAPK2, CLK1 
1.67007661 
Anterior/posterior pattern 
specification 
ARC, RARG, HOXA11, YY1, 
EMX2, VANGL2, ZBTB16, GLI2, 
HOXD10 
2.051808407 
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Appendix 2 
Table 3.6: Relative group molecular functions associated with the 
predicted mRNA targets of top 25 highly expressed miRNAs in PMP.  
Term Genes Fold 
Enrichment 
Calcium-dependent 
protein kinase C activity 
PRKCA, CCL3, PRKCG 6.128146176 
BH3 domain binding BAX, BCL2, BCL2L1 6.128146176 
Sequence-specific mRNA 
binding 
SRSF3, FMR1, LIN28A 6.128146176 
ATPase inhibitor activity PLN, ATPIF1, FNIP2 6.128146176 
Aldehyde dehydrogenase 
[NAD(P)+] activity 
ALDH1A3, ALDH3B2, ALDH3A2 5.447241045 
3-chloroallyl aldehyde 
dehydrogenase activity 
FAR1, ALDH1A2, ALDH3B2, 
ALDH3A2 
5.10678848 
CCR5 chemokine 
receptor binding 
CCL3, CCL4L1, CCL5, STAT1, 
STAT3 
5.10678848 
MAP kinase activity MAPK6, MAPK13, MAPK4, NLK, 
MAPK3 
4.669063753 
CCR1 chemokine 
receptor binding 
CCL3, CCL4L1, CCL5, CCL7 4.669063753 
Phosphate ion binding MTHFD2, G6PC, RELA, GNG12, 
RPH3A, SLC34A2 
4.085430784 
Receptor signalling 
protein tyrosine kinase 
activity 
TYRO3, ERBB4, ERBB2, KIT, KDR 4.085430784 
RNA stem-loop binding CPEB3, FMR1, ZC3H12A, DAZAP1 4.085430784 
Peptide alpha-N-
acetyltransferase activity 
NAA20, NAA11, NAA10, NAA60, 
NAA16 
3.714027986 
pre-mRNA binding SRSF2, TARBP2, SRSF6, TRA2B 3.63149403 
Retinoic acid receptor 
binding 
PRMT2, LRIF1, SNW1, HMGA1, 
NSD1 
3.404525653 
Glycine binding GSS, GRIN2B, GLRA3, GLRA2, 
GRIN1 
3.268344627 
MAP kinase 
tyrosine/serine/threonine 
phosphatase activity 
DUSP5, DUSP2, DUSP10, DUSP8, 
DUSP6 
3.142639065 
miRNA binding TARBP2, POU5F1, FMR1, AGO1, 
ZC3H12A, LIN28A 
3.064073088 
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Appendix 3: THBS-1 3’ UTR 
 
TTGAAAGCCTTTGGAAAGCATAATATATGTTCTGGAAGGTTCACGCTGTGTC
GGTCTCCTAGCATCAATGTCAGCTAATAAAATTAAATGCTAATGTGCTTGAA
CAACCTTAAAATTAGGCTTTTGTCATTAGAAAAGTAGAGCTATTCCTATGTG
GTTAACTTATTAACTAAGATGTCTATGCTTTTATGAATTAGTTTTCATTTGTAT
ATTTATTTATATTTGTTTATTTAACAGATCCCTAATCATCAAATTGTTGATTGA
AAGACTGATCATAAACCAATGCTGGTATTGCACCTTCTGGAACTATGGGCT
TGAGAAAACCCCCAGGATCACTTCTCCTTGGCTTCCTTCTTTTCTGTGCTTG
CATCAGTGTGGACTCCTAGAACGTGCGACCTGCCTCAAGAAAATGCAGTTT
TCAAAAACAGACTCAGCATTCAGCCTCCAATGAATAAGACATCTTCCAAGCA
TATAAACAATTGCTTTGGTTTCCTTTTGAAAAAGCATCTACTTGCTTCAGTTG
GGAAGGTGCCCATTCCACTCTGCCTTTGTCACAGAGCAGGGTGCTATTGTG
AGGCCATCTCTGAGCAGTGGACTCAAAAGCATTTTCAGGCATGTCAGAGAA
GGGAGGACTCACTAGAATTAGCAAACAAAACCACC 
CTGACATCCTCCTTCAGGAACACGGGGAGCAGAGGCCAAAGCACTAAGGG
GAGGGCGCATACCCGAGACGATTGTATGAAGAAAATATGGAGGAACTGTTA
CATGTTCGGTACTAAGTCATTTTCAGGGGATTGAAAGACTATTGCTGGATTT
CATGATGCTGACTGGCGTTAGCTGATTAACCCATGTAAATAGGCACTTAAAT
AGAAGCAGGAAAGGGAGACAAAGACTGGCTTCTGGACTTCCTCCCTGATC
CCCACCCTTACTCATCACCTGCAGTGGCCAGAATTAGGGAATCAGAATCAA
ACCAGTGTAAGGCAGTGCTGGCTGCCATTGCCTGGTCACATTGAAATTGGT
GGCTTCATTCTAGATGTAGCTTGTGCAGATGTAGCAGGAAAATAGGAAAAC
CTACCATCTCAGTGAGCACCAGCTGCCTCCCAAAGGAGGGGCAGCCGTGC
TTATATTTTTATGGTTACAATGGCACAAAATTATTATCAACCTAACTAAAACA
TTCCTTTTCTCTTTTTTCCTGAATTATCATGGAGTTTTCTAATTCTCTCTTTTG
GAATGTAGATTTTTTTTAAATGCTTTACGATGTAA 
AATATTTATTTTTTACTTATTCTGGAAGATCTGGCTGAAGGATTATTCATGGA
ACAGGAAGAAGCGTAAAGACTATCCATGTCATCTTTGTTGAGAGTCTTCGT
GACTGTAAGATTGTAAATACAGATTATTTATTAACTCTGTTCTGCCTGGAAAT
TTAGGCTTCATACGGAAAGTGTTTGAGAGCAAGTAGTTGACATTTATCAGCA
AATCTCTTGCAAGAACAGCACAAGGAAAATCAGTCTAATAAGCTGCTCTGC
CCCTTGTGCTCAGAGTGGATGTTATGGGATTCTTTTTTTCTCTGTTTTATCTT
TTCAAGTGGAATTAGTTGGTTATCCATTTGCAAATGTTTTAAATTGCAAAGAA
AGCCATGAGGTCTTCAATACTGTTTTACCCCATCCCTTGTGCATATTTCCAG
GGAGAAGGAAAGCATATACACTTTTTTCTTTCATTTTTCCAAAAGAGAAAAA
AATGACAAAAGGTGAAACTTACATACAAATATTACCTCATTTGTTGTGTGAC
TGAGTAAAGAATTTTTGGATCAAGCGGAAAGAGTTTAAGTGTCTAACAAACT
TAAAGCTACTGTAGTACCTAAAAAGTCAGTGTTGTACATAGCATAAAAACTC
TGCAGAGAAGTATTCCCAATAAGGAAATAGCATT 
GAAATGTTAAATACAATTTCTGAAAGTTATGTTTTTTTTCTATCATCTGGTAT
ACCATTGCTTTATTTTTATAAATTATTTTCTCATTGCCATTGGAATAGATATCT
CAGATTGTGTAGATATGCTATTTAAATAATTTATCAGGAAATACTGCCTGTA
GAGTTAGTATTTCTATTTTTATATAATGTTTGCACACTGAATTGAAGAATTGT
TGGTTTTTTCTTTTTTTTGTTTTGTTTTTTTTTTTTTTTTTTTTTGCTTTTGACC
TCCCATTTTTACTATTTGCCAATACCTTTTTCTAGGAATGTGCTTTTTTTTGT
ACACATTTTTATCCATTTTACATTCTAAAGCAGTGTAAGTTGTATATTACTGT
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TTCTTATGTACAAGGAACAACAATAAATCATATGGAAATTTATATTTATACTT
ACTGTATCCATGCTTATTTGTTCTCTACTGGC 
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Appendix 4: Further Results  
 
PMP mediates ATF-4 enrichment at ET-1 promoter  
 
 
PMP mediates ATF-4 enrichment at ET-1 promoter. Percentage enrichment 
of ATF-4 protein at ET-1 promoter in (A) 1% serum (EC) or 100μg/ml PMPs in 
1% serum (EC+PMP), (B) 1% serum after 24-hours transfection of Let-7a 
inhibitor (EC+7aI) or 100μg/ml PMPs after 24-hours transfection of Let-7a 
inhibitor in 1% serum (EC+7aI+PMP), (C) 1% serum after 24-hours transfection 
of scrambled inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of 
scrambled inhibitor in 1% serum (EC+SC+PMP), and (D) Precipitated with 
Histone H3 (positive control) antibody or normal IgG (negative control) antibody. 
(E) Relative enrichment to corresponding basal levels of ATF-4 protein at ET-1 
in EC+PMP, EC+SC+PMP, EC+7aI+PMP or Histone H3 precipitation. Data 
shown are mean ± standard error of mean, n=9 independent biological samples 
of PMPs, pooled to in equal n=3. *P<0.05 Tukey SD percentage enrichment 
between EC+PMP and EC, EC+7aI+PMP and EC+7aI, or EC+SC+PMP and 
EC+SC.  
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PMP mediates ATF-4 enrichment at ANG promoter  
 
 
PMP mediates ATF-4 enrichment at ANG promoter. Percentage enrichment 
of ATF-4 protein at ANG promoter in (A) 1% serum (EC) or 100μg/ml PMPs in 
1% serum (EC+PMP), (B) 1% serum after 24-hours transfection of Let-7a 
inhibitor (EC+7aI) or 100μg/ml PMPs after 24-hours transfection of Let-7a 
inhibitor in 1% serum (EC+7aI+PMP), (C) 1% serum after 24-hours transfection 
of scrambled inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of 
scrambled inhibitor in 1% serum (EC+SC+PMP), and (D) Precipitated with 
Histone H3 (positive control) antibody or normal IgG (negative control) antibody. 
(E) Relative enrichment to corresponding basal levels of ATF-4 protein at ANG 
in EC+PMP, EC+SC+PMP, EC+7aI+PMP or Histone H3 precipitation. Data 
shown are mean ± standard error of mean, n=9 independent biological samples 
of PMPs, pooled to in equal n=3. *P<0.05 Tukey SD percentage enrichment 
between EC+PMP and EC, EC+7aI+PMP and EC+7aI, or EC+SC+PMP and 
EC+SC. 
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PMP mediated changes in ET-1 is independent of transcription activity 
 
 
 
PMPs elicit early transcription of ET-1. Relative mRNA expression of ET-1 in 
HUVEC cultured in (EC) 1% serum, (EC+PMP) 100μg/ml PMPs, or 
(EC+PMP+RNAse) in the presence of 100μg/ml PMPs treated with RNAse for 
either (A) 12-hours or (B) 24-hours. Data shown are mean ± standard error of 
mean, n=3 independent biological samples of PMPs. *P<0.05 Tukey SD 
individual miRNA expression level between EC and EC+PMP, or between 
EC+PMP and EC+PMP+RNAse. 
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Transfection reagent effects the expression of MCP-1 protein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transfection reagent increased MCP-1 release by HUVEC. MCP-1 protein 
concentration released in the growth medium of HUVEC cultured in 1% serum 
(EC), transfected with Let-7a inhibitor for 24-hours (EC+7aI) or transfected with 
scrambled inhibitor for 24-hours (EC+SC). Data shown are mean ± standard 
error of mean, n=15 pooled experimental samples. *P<0.05 Tukey SD protein 
concentration comparisons between EC, EC+7aI and EC+SC. 
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PMP induce slow cell death through a late Let-7a dependent mechanism 
 
 
 
 
PMP induce slow cell death through a late Let-7a dependent mechanism. 
Luminescence values from HUVEC cultured in 1% serum (EC), 100μg/ml PMPs 
in 1% serum (EC+PMP), 1% serum after 24-hours transfection of Let-7a 
inhibitor (EC+7aI), 100μg/ml PMPs after 24-hours transfection of Let-7a inhibitor 
in 1% serum (EC+7aI+PMP), 1% serum after 24-hours transfection of scrambled 
inhibitor (EC+SC) or 100μg/ml PMPs after 24-hours transfection of scrambled 
inhibitor in 1% serum (EC+SC+PMP). Data shown are mean luminescence ± 
standard error of mean, n=3 independent biological samples of healthy PMPs. 
*P<0.05 Tukey SD relative mRNA expression of all shown comparisons 
between EC+PMP, EC+7aI, EC+7aI+PMP, EC+SC and EC+SC+PMP. 
 
 
